,NCT#,phase,condition,sponsor,start_date,mesh_list,criterion,Ground_Truth
0,NCT01650441,Phase 2,Asthma,"University Hospital, Antwerp",10-Feb-15,Asthma,Inability to carry out pulmonary function testing,0.0
1,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Inability to carry out pulmonary function testing;,0.0
2,NCT02740543,Phase 2,Asthma,NYU Langone Health,10-Feb-15,Asthma,Inability to perform lung function or other maneuvers,0.0
3,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,Patient unable to perform pulmonary function testing,0.0
4,NCT00465413,Phase 2,Asthma,Mackay Memorial Hospital,10-Feb-15,,poor performance of pulmonary function testing. ,0.0
5,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Acute illnesses or evidence of clinically significant active infection, such as fever ³",1.0
6,NCT00983658,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Acute infection (including viral infection) within the 6 weeks preceding dosing (8 weeks for respiratory infections) or any ongoing chronic infection,1.0
7,NCT01563029,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Culture-documented or suspected bacterial or viral infection,1.0
8,NCT01573767,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Culture-documented or suspected bacterial or viral infection,1.0
9,NCT00634036,Phase 2,Asthma,Fernando Holguin,10-Feb-15,Asthma,"Current/active upper respiratory infection (if active URI, wait until asymptomatic for 1 week to enroll)",1.0
10,NCT00787644,Phase 2,Asthma;Obesity,University of Vermont,10-Feb-15,Asthma,"Current/active upper respiratory infection (if active URI, wait until asymptomatic for 1 week to enroll)",1.0
11,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Diagnosis of / suspected COVID-19 infection with associated pneumonia / pneumonitis.,1.0
12,NCT01123252,Phase 2,Seasonal Affective Rhinitis;Asthma;Grass Allergy,University of East Anglia,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Documented evidence of acute or significant chronic sinusitis,1.0
13,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Evidence of clinically significant non-respiratory active infection, including ongoing chronic infection",1.0
14,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,Have a chronic or recurrent infectious disease,1.0
15,NCT04150341,Phase 2,Asthma,Theravance Biopharma,10-Feb-15,Asthma,"Have a current bacterial, parasitic, fungal or viral infection",1.0
16,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,"Have a history of chronic cough, haemoptysis, weight loss, or pyrexia considered suggestive of possible current tuberculosis infection",1.0
17,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,Have a history of opportunistic infections,1.0
18,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"History of active bacterial, viral or fungal infection (including SARS-CoV-2) within 6 weeks of first treatment visit (Day 1)",1.0
19,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,History of recurrent bacterial infection as an adult or history or presence of any chronic infectious condition,1.0
20,NCT00983658,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,"History of recurrent bacterial infection as an adult or history or presence of any chronic infectious condition, including (but not limited to), tuberculosis, parasitic infection, etc.",1.0
21,NCT00697801,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,History suggestive (or diagnosis) of other concomitant lung disease. ,1.0
22,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Ongoing or recurrent infections requiring systemic antibiotics. ,1.0
23,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,Patients with current active tuberculosis (TB) or atypical mycobacterial infection or a previous history of these infections,1.0
24,NCT01704495,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Patients with recurrent, latent, or chronic infections",1.0
25,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Presence of active infectious disease as judged by the investigator,1.0
26,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,> 0 time use of cannabis in the past 12 months,2.0
27,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,> 0 time use of illicit drugs in the past 12 months,2.0
28,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,1 use of marijuana per day for 1 year,2.0
29,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,a history of regular alcohol consumption within 6 months of the screening visit,2.0
30,NCT00452400,Phase 2,"Pulmonary Disease, Chronic Obstructive;Asthma",Boehringer Ingelheim,10-Feb-15,"Pulmonary Disease, Chronic Obstructive",a history of significant alcohol or drug abuse,2.0
31,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A history of substance abuse including alcohol.,2.0
32,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive pre-study drug/alcohol screen,2.0
33,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive pre-study drug/alcohol test at screening.,2.0
34,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,Abuse of alcohol or drugs,2.0
35,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,Alcohol or drug abuse,2.0
36,NCT00557700,Phase 2,Asthma,"University Hospital, Ghent",10-Feb-15,Asthma,Alcohol or drug abuse.,2.0
37,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,Alcohol or recreational drug abuse,2.0
38,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Alcohol or substance abuse history,2.0
39,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any subject with a history of alcohol or substance abuse,2.0
40,NCT01650441,Phase 2,Asthma,"University Hospital, Antwerp",10-Feb-15,Asthma,Current alcohol or drug abuse,2.0
41,NCT00995800,Phase 2,Asthma,Mundipharma Research Limited,10-Feb-15,Asthma;Inflammation,Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit,2.0
42,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Current history of suicidal ideation or a past history of suicide attempt.,2.0
43,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,current regular use or a recent past abuse (within past 5 years) of alcohol (>14 drinks/week) or illicit drugs;,2.0
44,NCT01582503,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Current substance abuse,2.0
45,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,current suspected drug and/or alcohol abuse ,2.0
46,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,Drug and/or alcohol abuse for ≥1 year,2.0
47,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Drug or alcohol abuse which would interfere with the patient's proper completion of the protocol assignment. Administrative reasons:,2.0
48,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,H/O alcohol or drug abuse,2.0
49,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day) within the past 1 year prior to the Screening visit,2.0
50,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,Have had substance abuse (drug or alcohol) problem within the previous 10 years,2.0
51,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Have history or evidence of drug or alcohol abuse within 2 years of study entry;,2.0
52,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,"History of, drug or alcohol abuse within the past 2 years prior to Screening.",2.0
53,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,History of a diagnosis of drug or alcohol dependency or abuse within approximately the last 3 years.,2.0
54,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"History of alcohol, drug or chemical abuse",2.0
55,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"History of alcohol, drug or chemical abuse",2.0
56,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening.,2.0
57,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening.,2.0
58,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of alcohol abuse or drug abuse that required treatment <1 year prior to randomization into the study,2.0
59,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,History of alcohol abuse within 6 months of screening,2.0
60,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,history of alcohol abuse within the past 5 years,2.0
61,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of alcohol misuse or substance abuse,2.0
62,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,History of alcohol or drug abuse;,2.0
63,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,History of alcohol or drug abuse in the 6 month period prior to enrollment,2.0
64,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of alcohol or drug abuse within 12 months prior to screening,2.0
65,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,History of alcohol or drug abuse within two years preceding the Screening Visit,2.0
66,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,History of alcohol or drug abuse within two years preceding the Screening Visit,2.0
67,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of alcohol or drug abuse: Likely to interfere with the study,2.0
68,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of alcohol or illegal substance abuse consumption within 2 years of the study start.,2.0
69,NCT03393806,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of alcohol or illegal substance abuse within 2 years prior to Screening (Visit1).,2.0
70,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,History of alcohol/drug abuse,2.0
71,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of alcohol/drug abuse or dependence within 12 months of the study,2.0
72,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of alcohol/drug abuse or dependence within 12 months of the study. Abuse of alcohol defined as an average weekly intake of >14 drinks/week for men or >7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or,2.0
73,NCT01348139,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,History of alcohol/drug abuse or excessive intake of alcohol as judged by the Investigator,2.0
74,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,History of and/or active alcohol or drug abuse,2.0
75,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,History of chronic alcohol or drug abuse,2.0
76,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,"History of drug abuse including marijuana, PCP, cocaine, crack, LSD or other identified street drugs",2.0
77,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,History of drug or alcohol abuse,2.0
78,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,History of drug or alcohol abuse within 12 months prior to enrolment,2.0
79,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,"History of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.",2.0
80,NCT01424124,Phase 2,Asthma,Yuhan Corporation,10-Feb-15,Asthma,History of drug/chemical/alcohol abuse,2.0
81,NCT01516073,Phase 2,Asthma,Dey,10-Feb-15,Asthma,History of illegal drug or alcohol abuse within the past 5 years,2.0
82,NCT01516086,Phase 2,Asthma,Dey,10-Feb-15,Asthma,History of illegal drug or alcohol abuse within the past 5 years,2.0
83,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,History of illicit drug abuse within 6 months of screening,2.0
84,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,History of illicit drug use or alcohol abuse within 12 months before Screening.,2.0
85,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of regular alcohol consumption within 6 months of the study.,2.0
86,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,History of regular alcohol consumption within 6 months of the study.,2.0
87,NCT00322686,Phase 2,Asthma,Forest Laboratories,10-Feb-15,Asthma,History of substance abuse,2.0
88,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of treatment for alcohol or drug abuse within the past year,2.0
89,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of treatment for alcohol or drug abuse within the past year,2.0
90,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of treatment for alcohol or drug abuse within the past year,2.0
91,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,History of treatment for alcohol or drug abuse within the past year,2.0
92,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,History of treatment for alcohol or drug abuse within the past year.,2.0
93,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,History or evidence of drug or alcohol abuse,2.0
94,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,History or evidence of drug or alcohol abuse,2.0
95,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,History within past 6 months of alcohol abuse or illicit drug abuse,2.0
96,NCT00614874,Phase 2,Asthma,Creighton University,10-Feb-15,Asthma,History within the past year of excessive alcohol intake or drug addiction,2.0
97,NCT00634036,Phase 2,Asthma,Fernando Holguin,10-Feb-15,Asthma,Illicit drug use within the past year,2.0
98,NCT00787644,Phase 2,Asthma;Obesity,University of Vermont,10-Feb-15,Asthma,Illicit drug use within the past year,2.0
99,NCT01848769,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Known hypersensitivity to the active treatments,2.0
100,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,Known or suspected history of alcohol drug or drug/solvent abuse ,2.0
101,NCT01332292,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Parent/guardian has history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g., inability to read, comprehend and write) which will limit the validity of consent to participate in this study.",2.0
102,NCT00801853,Phase 2,Asthma,"Aerovance, Inc.",10-Feb-15,Asthma,Patient has a history of alcohol or substance abuse within 2 years of Screening (Visit 1),2.0
103,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Patients with any history of abuse of alcohol or other recreational drugs,2.0
104,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Patients with documented or suspected or current history of alcohol and drug abuse,2.0
105,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,positive result for the alcohol and/or drug tests at screening or check-in,2.0
106,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,Previous intravenous drug use,2.0
107,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Recent (less than 1 year) history of alcohol dependency,2.0
108,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Recent history of alcohol dependency,2.0
109,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Recent history of drug or alcohol abuse (within 3 years prior to Visit 1),2.0
110,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Significant alcohol or drug abuse within past 2 years (see exclusion criteria No. 1),2.0
111,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject had a history of substance abuse or drug abuse within 12 months prior to screening.,2.0
112,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,Subject has a history of physician diagnosed panic disorder or other anxiety disorders,2.0
113,NCT00512863,Phase 2,Asthma,Abbott,10-Feb-15,Asthma,Subject with a history of clinically significant drug or alcohol abuse in the last year,2.0
114,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with a history of substance abuse or drug abuse within 12 months preceding study start.,2.0
115,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with a history of substance abuse or drug abuse within 12 months preceding study start.,2.0
116,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with a history of substance abuse or drug abuse within 12 months preceding study start.,2.0
117,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Subject with a history of substance abuse or drug abuse within 12 months preceding study start.,2.0
118,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with a history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to Screening (Visit 1).,2.0
119,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years. This includes marijuana, which is considered an abused drug.",2.0
120,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with recent history (within two years prior to screening) of alcohol misuse or substance abuse prior screening.,2.0
121,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Substance abuse within the last year,2.0
122,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,Substance Abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2-year period prior to Screening (Visit 1a),2.0
123,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,The participant has a history of chronic alcohol or drug abuse within the previous 2 years.,2.0
124,NCT00407524,Phase 2,Asthma,University of Aberdeen,10-Feb-15,Asthma,The patient has a history of known alcohol or substance abuse within the one-year prior to Visit 1,2.0
125,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has a positive pre-study drug/alcohol screen unless a positive can be explained by the patients' medication.,2.0
126,NCT00815347,Phase 2,Asthma,UConn Health,10-Feb-15,Asthma,Use of any illegal drugs or alcohol abuse. ,2.0
127,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Any subject with a known allergy to other beta agonists;,3.0
128,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Any treatment with ß2-antagonists (including eye drops),3.0
129,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Current use of any β-adrenergic antagonist (e.g., propranolol);",3.0
130,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Current use of any β-adrenergic antagonist (e.g. propranolol).,3.0
131,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Current use of any β-adrenergic antagonist (eg, propranolol);",3.0
132,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Current use of any β-adrenergic antagonist (eg, propranolol);",3.0
133,NCT01484197,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Excessive use of short acting beta agonists ,3.0
134,NCT01951222,Phase 2,Asthma,Pierre Fabre Medicament,10-Feb-15,Asthma,Intolerance to tiotropium (or any other atropine-derived compound).,3.0
135,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Long acting Beta-2-agonists within 24 hours;,3.0
136,NCT02382510,Phase 2,Asthma,"Theron Pharmaceuticals, Inc.",10-Feb-15,Asthma,Long-acting muscarinic receptor antagonist (LAMA),3.0
137,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,Patients unable to withhold bronchodilator treatment for 12 hours prior to dosing,3.0
138,NCT00436670,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,"Received long-acting beta agonist, theophylline, inhaled anticholinergics, oral beta 2 agonists, or cromolyn therapeutics within 1 week of first run-in visit.",3.0
139,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,"regular long-acting ß2-agonists at least 3 weeks,",3.0
140,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,"short-acting ß2-agonists and short-acting anticholinergics at least 6 hours,",3.0
141,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Short acting Beta-2-agonists within 8 hours;,3.0
142,NCT01772368,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Taking long-acting β-agonists within 2 weeks of the SV,3.0
143,NCT00407524,Phase 2,Asthma,University of Aberdeen,10-Feb-15,Asthma,The patient is unable to discontinue short-acting beta-2-adrenergic agonists for at least 4 hours prior to the Screening Visit,3.0
144,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Theophylline, long-acting bronchodilators, and anti-cholinergics for 2 weeks prior to the first study visit",3.0
145,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Treatment with inhaled tiotropium within 4 weeks of Visit 2,3.0
146,NCT01128569,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unable to abstain from short acting beta agonists,3.0
147,NCT01128595,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unable to abstain from short acting beta agonists,3.0
148,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unable to abstain from short acting beta agonists as described in the restrictions section,3.0
149,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Unable to abstain from short acting beta agonists within 8 hours prior to an allergen challenge, dosing with study drug or any lung function assessment.",3.0
150,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,unable to abstain from short acting β2-agonists as described in the restriction section of the protocol,3.0
151,NCT00150397,Phase 2,Asthma,Pfizer,10-Feb-15,Asthma,Use of any maintenance therapy except short acting bronchodilators,3.0
152,NCT00697801,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,Use of inhaled long acting bronchodilators.,3.0
153,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Use of long-acting ß2-agonists in last 3 weeks before the first methacholine challenge or during the study,3.0
154,NCT00530166,Phase 2,Asthma,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",10-Feb-15,Asthma,Use of long-acting beta-2 agonists or montelukast within 2 weeks,3.0
155,NCT00330070,Phase 2,Asthma,Inflazyme Pharmaceuticals Ltd,10-Feb-15,Asthma,use of long-acting beta-2-agonists within 5 weeks prior to randomization,3.0
156,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Use of oral beta-adrenergic agents within 4 weeks prior to screening,3.0
157,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Use of short-acting ß2-agonists more than thrice a week in the previous month,3.0
158,NCT00054964,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Requires beta-blockers, MAO inhibitors, tricyclic antidepressants, long-acting beta-blockers, steroids other than those inhaled",4.0
159,NCT02251379,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Taking a beta-blocker,4.0
160,NCT00501527,Phase 2,"Rhinitis, Allergic, Seasonal;Conjunctivitis, Allergic;Asthma","Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal;Conjunctivitis;Conjunctivitis, Allergic",Treatment with ß-blockers,4.0
161,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Diagnosis of depression, psychosis, bipolar disorder, or schizoaffective disorder.",5.0
162,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Has severe neuropsychiatric or neurological disorders (eg, history of depression associated with suicidal thinking, suicidal ideation or behavior)",5.0
163,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"history of a clinically significant psychiatric disorder, other than stable depression, within past ≤12 weeks",5.0
164,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"history of a psychiatric disorder, other than stable depression, within 3 months prior to Screening Visit;",5.0
165,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of suicidal behavior in the previous 3 years as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) at Day -28,5.0
166,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,Hospitalized for psychiatric disorder in the previous 12 months or has a history of attempted suicide within 5 years prior to the Screening Visit,5.0
167,NCT03364608,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Hospitalized for psychiatric disorder or attempted suicide within 1 year,5.0
168,NCT03371459,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Hospitalized for psychiatric disorder or attempted suicide within 1 year,5.0
169,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,"Patients who have been hospitalized for any psychiatric illness in the past year, or are diagnosed with major depression",5.0
170,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Severe depression as measured by a depression score > 15 on the Hospital Anxiety and Depression Scale (HADS) at either Day-28 or Day 1,5.0
171,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,"Significant history of depressive disorder or suicidal ideation. Specifically; individuals with current severe depression (ie, a low mood, which pervades all aspects of life and an inability to experience pleasure in activities that formerly were enjoyed); individuals with a past history of depression that required hospitalization or referral to psychiatric services in the past 5 years; individuals who currently feel suicidal or have attempted suicide in the past",5.0
172,NCT01902290,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS),5.0
173,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,Suicidal ideation (a score of greater than 0 on Question 9 on the PHQ-9),5.0
174,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness,5.0
175,NCT02293499,Phase 2,Asthma,University of Rochester,10-Feb-15,Asthma,"Those who have serious health (other than asthma) and emotional preconditions (e.g., severe depression, anxiety disorders, schizophrenia). ",5.0
176,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Treated for or diagnosed with clinical depression within six months of screening or has a history of significant psychiatric illness.,5.0
177,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,Uncontrolled depression as defined by a score of 15 or greater on the depression questions of the PHQ-9,5.0
178,NCT00554970,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,A history of acute or severe asthma attack requiring ICU admission or ventilatory support. ,6.0
179,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,A history of asthma-related respiratory failure requiring intubation.,6.0
180,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"A history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years.",6.0
181,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"A history of life-threatening asthma, which is defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years",6.0
182,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,"A history of life-threatening asthma defined as any history of significant asthma episodes(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)",6.0
183,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,A history of life-threatening asthma within the last 5 years.,6.0
184,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,"A life-threatening asthma episode within the last six months or > 2 within the past year. A life-threatening asthma episode is defined as an asthma exacerbation which required hospitalization and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures",6.0
185,NCT00697801,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,Any history of acute or severe asthma attack requiring ICU admission or ventilatory support.,6.0
186,NCT02427165,Phase 2,Asthma,Verona Pharma plc,10-Feb-15,Asthma,Any prior life threatening episode of asthma (intensive care admission),6.0
187,NCT00443482,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Asthma is not stable: patients were admitted to hospital or received emergency room treatment,6.0
188,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,ever required ventilator support for respiratory failure secondary to asthma,6.0
189,NCT01823016,Phase 2,Asthma,"Janssen Research & Development, LLC",10-Feb-15,Asthma,"Has ever had a life-threatening asthma attack including respiratory arrest, intubation, or intensive care unit (ICU) admission due to asthma",6.0
190,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,"Has had a life threatening asthma exacerbation in the last 2 years requiring intubation, mechanical ventilation or resulting in a hypoxic seizure. ",6.0
191,NCT01258803,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Has required ventilator support for respiratory failure secondary to asthma,6.0
192,NCT00400855,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Have a history of life-threatening asthma, defined as an asthma episode, which required intubation and/or was associated with either hypercapnea, respiratory arrest or hypoxia seizures.",6.0
193,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,History of hypoxic seizures during a wheezing episode,6.0
194,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,History of ICU admission/intubation due to asthma in the past 1 year,6.0
195,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,History of ICU admission/intubation due to asthma in the past year;,6.0
196,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,History of ICU admission/intubation due to asthma in the past year,6.0
197,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,History of intubation for asthma,6.0
198,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,History of intubation or mechanical ventilation for respiratory illness,6.0
199,NCT00980200,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of Life-Threatening Asthma,6.0
200,NCT01128569,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of life-threatening asthma,6.0
201,NCT01128595,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of life-threatening asthma,6.0
202,NCT01225315,Phase 2,Asthma,Idorsia Pharmaceuticals Ltd.,10-Feb-15,Asthma,History of life-threatening asthma,6.0
203,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,history of life-threatening asthma,6.0
204,NCT01563029,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,history of life-threatening asthma,6.0
205,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of Life threatening asthma,6.0
206,NCT01573767,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,history of life-threatening asthma,6.0
207,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of life threatening asthma,6.0
208,NCT04150341,Phase 2,Asthma,Theravance Biopharma,10-Feb-15,Asthma,History of life-threatening asthma,6.0
209,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"History of life-threatening asthma, clinically significant uncontrolled disease or respiratory infection.",6.0
210,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"History of life-threatening asthma, clinically significant uncontrolled disease or respiratory infection.",6.0
211,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 10 years",6.0
212,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest and/or hypoxic seizures",6.0
213,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 10 years.",6.0
214,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures",6.0
215,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.",6.0
216,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.",6.0
217,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.",6.0
218,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.",6.0
219,NCT01499446,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxia seizures.",6.0
220,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubation or was associated with hypercapnoea, respiratory arrest or hypoxic seizures.",6.0
221,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubations and/or was associated with hypercapnia, respiratory arrest and/or hypoxic seizures.",6.0
222,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of life-threatening asthma, defined as an asthma episode that required intubations and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.",6.0
223,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"History of life-threatening asthma, deﬁned as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest and/or hypoxic seizures. History of asthma exacerbations that required ward hospitalization or an emergency room stay greater than 48 hours within 5 years prior to Visit",6.0
224,NCT01437735,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"History of life-threatening asthma, including a history of significant hypercarbia (pCO2>45mmHg), prior intubation, respiratory arrest, or seizures as a result of asthma.",6.0
225,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,History of life-threatening asthma attack,6.0
226,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,History of life-threatening asthma attack or asthma attack requiring ventilation.,6.0
227,NCT00530166,Phase 2,Asthma,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",10-Feb-15,Asthma,History of life-threatening asthma attack within 3 months,6.0
228,NCT03944707,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"History of life-threatening asthma event such as significant hypercarbia (pCO2 > 45 mmHg), endotracheal intubation, non-invasive positive pressure ventilation (NIPPV), respiratory arrest, or seizure as a result of asthma.",6.0
229,NCT02382510,Phase 2,Asthma,"Theron Pharmaceuticals, Inc.",10-Feb-15,Asthma,"History of life-threatening asthma exacerbation requiring ICU admission, mechanical ventilation, or tracheostomy ",6.0
230,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,History of life-threatening asthma in the last three years,6.0
231,NCT00174746,Phase 2,Asthma,Sanofi,10-Feb-15,Asthma,"History of life-threatening asthma; other pulmonary diseases; URI within 4 weeks before screening; Use of systemic steroids within 1 month before screening or more than 3 times in previous 6 months; beta-adrenergic blocking agent use; More than 2 in-patient hospitalizations or ER visits due to asthma exacerbations in the prior year before screening; Pregnant or breast-feeding females; Females of child-bearing potential not using adequate means of birth control; Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease; Abnormal clinical laboratory parameters that would limit participation in the study or interfere with interpretation of study results; History of drug or alcohol abuse; Treatment with any investigational product within 30 days prior to study entry ",6.0
232,NCT01899144,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures",6.0
233,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures",6.0
234,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures",6.0
235,NCT01772368,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.,6.0
236,NCT02061670,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",History of life-threatening asthma.,6.0
237,NCT02161107,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",History of life-threatening asthma.,6.0
238,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.",6.0
239,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of Life-threatening asthma: Within previous 5 years,6.0
240,NCT01650441,Phase 2,Asthma,"University Hospital, Antwerp",10-Feb-15,Asthma,History of near fatal asthma,6.0
241,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,"History of near fatal asthma, brittle asthma, accident and Emergency treatment or hospitalisation for asthma exacerbation in Intensive Care Unit within 1 year before screening;",6.0
242,NCT01651650,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in Intensive Care Unit)",6.0
243,NCT01584492,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in Intensive Care Unit).",6.0
244,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,"History of near fatal asthma (e.g. brittle asthma, hospitalization for asthma exacerbation in Intensive Care Unit)",6.0
245,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,History of near-fatal asthma and/or admission intensive care unit because of asthma;,6.0
246,NCT01502371,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,History of ventilator support for respiratory failure secondary to asthma.,6.0
247,NCT02910401,Phase 2,Asthma;Allergic Rhinitis,University of Virginia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",Intubation or management in the intensive care unit (ICU) for an asthma exacerbation ever,6.0
248,NCT02388997,Phase 2,Asthma,University of Virginia,10-Feb-15,Infections;Asthma,Intubation or management in the intensive care unit for an asthma exacerbation,6.0
249,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Life threatening asthma, defined as a history of asthma episode(s) requiring intubation and/or associated hypercapnea, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).",6.0
250,NCT03364608,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)",6.0
251,NCT03371459,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)",6.0
252,NCT00207740,Phase 2,Asthma,"Centocor, Inc.",10-Feb-15,Asthma,"Life-threatening asthma attack requiring cardiopulmonary support (eg, intubation) in the 6-month period prior to screening",6.0
253,NCT00675649,Phase 2,Asthma,"Centocor, Inc.",10-Feb-15,Asthma,Life-threatening asthma attack requiring intubation in the 6-month period prior to screening,6.0
254,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Life-Threatening Asthma: A subject must not have life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s) within the 12 months prior to screening",6.0
255,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Life-Threatening Asthma: A subject must not have life-threatening asthma. Lifethreatening asthma is defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within the 12 months prior to Visit 1a (Screening)",6.0
256,NCT00995800,Phase 2,Asthma,Mundipharma Research Limited,10-Feb-15,Asthma;Inflammation,Near fatal or life-threatening (including intubation) asthma within the past year,6.0
257,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Need for immediate intubation, mechanical ventilation, or non-invasive positive pressure ventilation as determined by the Investigator;",6.0
258,NCT02148796,Phase 2,Asthma;Wheezing,University of Arizona,10-Feb-15,Respiratory Sounds,Participants may not have a history of any life-threatening respiratory illness that required intubation and mechanical ventilation.,6.0
259,NCT00941798,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who had ever required ventilator support for respiratory failure,6.0
260,NCT03108027,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have had previous intubation for a severe asthma ttack/exacerbation.,6.0
261,NCT02271334,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Previous history of asthma or COPD;,6.0
262,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,"Previous life-threatening asthma, such as asthma requiring intubation or ICU admission for asthma",6.0
263,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,Prolonged hospitalization for asthma within the past year (emergency room treatments using nebulized beta-agonists is permitted),6.0
264,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject was currently diagnosed with life-threatening asthma, defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to screening..",6.0
265,NCT00583947,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject with any history of life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures.",6.0
266,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.",6.0
267,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.",6.0
268,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 3 months prior to study start.",6.0
269,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,"Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 3 months prior to study start.",6.0
270,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects with a history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with either respiratory arrest or hypoxic seizures",6.0
271,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,"Subjects with a history of life-threatening asthma attacks (i.e. requiring ICU admission, orotracheal intubation).",6.0
272,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Subjects with a history of life-threatening asthma attacks (i.e. requiring intensive care unit (ICU) admission, orotracheal intubation)",6.0
273,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,"Subjects with frequent emergency room visits for asthma, with prior ICU admission or those with prior intubation",6.0
274,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,The presence of hypercapnic ventilatory failure and/or the requirement of nocturnal non-invasive ventilation therapy.,6.0
275,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,Type 2 respiratory failure necessitating non-invasive or invasive ventilation,6.0
276,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Concurrent enrollment in another clinical study,7.0
277,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,Current or recent (within 30 days) in an investigational treatment study.,7.0
278,NCT00995800,Phase 2,Asthma,Mundipharma Research Limited,10-Feb-15,Asthma;Inflammation,Current participation in a clinical study. ,7.0
279,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Current participation in an interventional trial (e.g. drugs, diets, etc.)",7.0
280,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,Current participation or participation in an experimental drug study within 30 days. ,7.0
281,NCT00133666,Phase 2,Asthma,National Institute of Nursing Research (NINR),10-Feb-15,Asthma,Enrolled in another asthma study ,7.0
282,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Enrollment in a clinical trial where the study medication was administered within the past 60 days or within 5 half-lives (whichever is greater),7.0
283,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Have participated in a clinical study with an investigational drug, other than an MN-221 study, within 30 days;",7.0
284,NCT01174732,Phase 2,Asthma;Bronchospasm,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma;Bronchial Spasm,Having been on other clinical drug/device studies in the last 30 days;,7.0
285,NCT01189396,Phase 2,Asthma;Bronchospasm;Chronic Obstructive Pulmonary Disease (COPD),"Amphastar Pharmaceuticals, Inc.",10-Feb-15,"Asthma;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive;Bronchial Spasm",Having been on other clinical drug/device studies in the last 30 days;,7.0
286,NCT02210806,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Having been on other clinical drug/device studies in the last 30 days prior to Screening. ,7.0
287,NCT00688467,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Is presently participating in any other clinical study.,7.0
288,NCT02148796,Phase 2,Asthma;Wheezing,University of Arizona,10-Feb-15,Respiratory Sounds,Participant has previously been randomized in this study. Participants who failed run-in and were not randomized may have study participation terminated and then be re-enrolled for a second run-in period.,7.0
289,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Participated in another clinical study with an investigational drug within 30 days of randomization;,7.0
290,NCT00346398,Phase 2,Asthma;Allergic Sensitization,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Participated in another clinical study within the 3 months prior to study entry ,7.0
291,NCT00557700,Phase 2,Asthma,"University Hospital, Ghent",10-Feb-15,Asthma,Participating in another clinical trial.,7.0
292,NCT00096616,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,participating in another interventional trial ,7.0
293,NCT00394914,Phase 2,Asthma;Common Cold;Picornavirus Infection;Rhinovirus,Merck Sharp & Dohme Corp.,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,Participating in any other clinical study.,7.0
294,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Participation in a clinical trial involving an investigational drug within 4 weeks of screening visit,7.0
295,NCT00987064,Phase 2,Asthma;Perennial Allergy,Airsonett AB,10-Feb-15,Asthma,Participation in a drug trial ,7.0
296,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,Participation in an investigational study within the past 4 weeks,7.0
297,NCT01478152,Phase 2,Asthma,Bitop AG,10-Feb-15,Asthma,Participation in another clinical study in the previous month,7.0
298,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,Participation in another clinical study with an experimental drug within one month of start of the study ,7.0
299,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Participation in another clinical study with an experimental drug within one month of start of the study ,7.0
300,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,"Participation in another clinical study within 30 days preceding Visit V0,",7.0
301,NCT01653756,Phase 2,Asthma,SecuraBio,10-Feb-15,Asthma,Participation in another clinical study within minimum of 30 days prior to study Screening,7.0
302,NCT04170348,Phase 2,"Sickle Cell Disease;Anemia, Sickle Cell;Anemia, Hemolytic, Congenital;Respiratory Tract Diseases;Respiration Disorders;Acute Chest Syndrome;Lung Diseases;Asthma;Respiratory Tract Infections;Nutrition Disorders;Deficiency Diseases Vitamin;Vitamin D Deficiency","Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Lung Diseases;Respiratory Tract Diseases;Acute Chest Syndrome;Respiration Disorders;Anemia;Anemia, Sickle Cell;Anemia, Hemolytic;Anemia, Hemolytic, Congenital;Vitamin D Deficiency;Nutrition Disorders;Deficiency Diseases;Vitamin A Deficiency;Disease",Participation in another clinical trial,7.0
303,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Participation in another clinical trial during the current trial,7.0
304,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,Participation in another clinical trial in the past 3 months. ,7.0
305,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Participation in another clinical trials in the previous 8 weeks,7.0
306,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,participation in another investigational study for the duration of this study,7.0
307,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,Participation in another study at the same time or within a prior 3-month period ,7.0
308,NCT00640016,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Participation in another study within 5 half-lives or 3 months of the start of this study, whichever is the longer",7.0
309,NCT01443728,Phase 2,Sickle Cell Disease;Vitamin D Deficiency;Acute Chest Syndrome;Asthma;Respiratory Infections,"Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Acute Chest Syndrome;Anemia, Sickle Cell;Vitamin D Deficiency",Participation in other therapeutic clinical trial,7.0
310,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,participation in this same study at another study site,7.0
311,NCT01692041,Phase 2,Asthma,Technische Universität Dresden,10-Feb-15,Asthma,Participation of the patient in another clinical trial within the last four weeks before enrollment in this trial,7.0
312,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,Patients that have previously been included in studies evaluating the investigational medicinal product ,7.0
313,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Patients who have been previously enrolled in this study. ,7.0
314,NCT00452400,Phase 2,"Pulmonary Disease, Chronic Obstructive;Asthma",Boehringer Ingelheim,10-Feb-15,"Pulmonary Disease, Chronic Obstructive",Patients who have previously been randomized in this study or are currently participating in another study,7.0
315,NCT00467740,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Patients who have previously been randomized in this study or are currently participating in another study,7.0
316,NCT00181272,Phase 2,Asthma;Chronic Obstructive Pulmonary Disease,Johns Hopkins University,10-Feb-15,"Asthma;Lung Diseases;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive",Previous participation in this study,7.0
317,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Previous participation in this study (receipt of randomized treatment) or active participation in a current interventional study,7.0
318,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Previous randomization in this study or current participation in another study,7.0
319,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,previous randomization into this study,7.0
320,NCT01502371,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Randomization into this study more than once.,7.0
321,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,"Re-entry of patients previously enrolled in this trial,",7.0
322,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of MEDI-528 in any previous clinical study or prior randomization into the trial;,7.0
323,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects who have previously participated in a study of GSK3772847.,7.0
324,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,The participant has previously participated in a study with TEV-53275.,7.0
325,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,Treatment with an investigational drug within 30 days or five half-lives preceding the first dose of study medication or plans to take another investigational drug within 30 days of study completion.,7.0
326,NCT00017693,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Were previously enrolled in a study of soluble IL-4 receptor.,7.0
327,NCT02382510,Phase 2,Asthma,"Theron Pharmaceuticals, Inc.",10-Feb-15,Asthma,"A clinical diagnosis of chronic obstructive pulmonary disease (COPD), chronic bronchitis, bronchiectasis, or other significant pulmonary disease other than asthma",8.0
328,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,A current diagnosis of Chronic Obstructive Pulmonary Disease (COPD,8.0
329,NCT04365556,Phase 2,Asthma,"Children's Hospital Medical Center, Cincinnati",10-Feb-15,Asthma,"Active chronic disease apart from asthma or allergic disease (e.g. Bronchiectasis, pulmonary hypertension, and moderate or severe tracheomalacia)",8.0
330,NCT00512863,Phase 2,Asthma,Abbott,10-Feb-15,Asthma,"Active lung diseases (e.g., bronchitis, chronic obstructive pulmonary disease [COPD], interstitial lung disease, pulmonary fibrosis) other than asthma",8.0
331,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,"Chronic bronchitis, COPD, emphysema and other chronic lung diseases",8.0
332,NCT01591044,Phase 2,Asthma,Rigel Pharmaceuticals,10-Feb-15,Asthma,Chronic obstructive pulmonary disease or bronchiectasis,8.0
333,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Chronic obstructive pulmonary disease or other significant lung disease (e.g. chronic bronchitis, emphysema, bronchiectasis with a need for treatment, cystic fibrosis, or bronchopulmonary dysplasia)",8.0
334,NCT03364608,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)",8.0
335,NCT03371459,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)",8.0
336,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,"Clinically important and significant pulmonary disease other than asthma or COPD (e.g. lung cancer, pulmonary fibrosis, bronchiectasis as primary respiratory problem, active pulmonary tuberculosis, cystic fibrosis, obesity hypoventilation syndrome).",8.0
337,NCT02898662,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Clinically significant lung disease other than asthma (eg, chronic obstructive pulmonary disease, cystic fibrosis, allergic bronchopulmonary aspergillosis, active tuberculosis).",8.0
338,NCT01951222,Phase 2,Asthma,Pierre Fabre Medicament,10-Feb-15,Asthma,"Clinically significant respiratory conditions other than asthma (e.g. pneumonia, pneumothorax, atelectasis, bronchiectasis, chronic bronchitis, COPD, emphysema, pulmonary arterial hypertension, pulmonary fibrosis,etc.).",8.0
339,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Concurrent Respiratory Disease: A subject must not have current evidence or diagnosis of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, emphysema, COPD, or other respiratory abnormalities other than asthma",8.0
340,NCT03393806,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Concurrent respiratory diseases: Presence of a known pre-existing, clinically important respiratory conditions (example pneumonia, pneumothorax, atelectasis segmental or larger, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other respiratory abnormalities) other than asthma or AFAD",8.0
341,NCT02501824,Phase 2,Asthma,University of Bern,10-Feb-15,Asthma,COPD,8.0
342,NCT01484197,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,COPD or other pulmonary disease,8.0
343,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, lung cancer, or other respiratory abnormalities other than asthma.",8.0
344,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Cystic fibrosis or any other chronic lung disease other than asthma.,8.0
345,NCT00207740,Phase 2,Asthma,"Centocor, Inc.",10-Feb-15,Asthma,"Diagnosis of chronic obstructive pulmoanry disease (COPD), cystic fibrosis, or other significant respiratory disorder",8.0
346,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Diagnosis of Chronic Obstructive Pulmonary Disease;,8.0
347,NCT00868023,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Diagnosis of Chronic Obstructive Pulmonary Disease (COPD),8.0
348,NCT02296411,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Diagnosis of Chronic Obstructive Pulmonary Disease (COPD),8.0
349,NCT00116103,Phase 2,Asthma,Astellas Pharma Inc,10-Feb-15,Asthma,Diagnosis of chronic obstructive pulmonary disease (COPD) ,8.0
350,NCT00675649,Phase 2,Asthma,"Centocor, Inc.",10-Feb-15,Asthma,"Diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other significant respiratory disorder",8.0
351,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Diagnosis of chronic obstructive pulmonary disease (COPD) by a healthcare professional,8.0
352,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,"Diagnosis of chronic obstructive pulmonary disease, cystic fibrosis or other significant respiratory disorder (excluding asthma)",8.0
353,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,"Diagnosis of chronic obstructive pulmonary disease or other relevant lung diseases (e.g. history of bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, active tuberculosis, interstitial lung disease)",8.0
354,NCT02127866,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Diagnosis of COPD,8.0
355,NCT00901095,Phase 2,Asthma;Obesity,Palo Alto Medical Foundation,10-Feb-15,Asthma;Weight Loss,Diagnosis of COPD (emphysema or chronic bronchitis) on the current medical problem list or suggested by spirometry at baseline;,8.0
356,NCT01370031,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Diagnosis of COPD as defined by the current GOLD 2009 (Global Initiative for Chronic Obstructive Lung Disease) Guidelines.,8.0
357,NCT02918019,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,"Diagnosis of occupational asthma, aspirin-sensitive asthma, asthma chronic obstructive pulmonary disease overlap syndrome, or bronchiolitis, as determined by the investigator",8.0
358,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,Diagnosis or presence of other pulmonary diseases including chronic obstructive pulmonary disease (COPD) and emphysema,8.0
359,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Evidence of another active pulmonary disorder such as bronchiectasis or chronic obstructive pulmonary disease (COPD),8.0
360,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,evidence of another active pulmonary disorder such as bronchiectasis or COPD;,8.0
361,NCT00404313,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Evidence of another clinically significant, active lung disorder such as bronchiectasis or COPD ",8.0
362,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"evidence of another clinically significant, active pulmonary disorder such as chronic obstructive pulmonary disease (COPD)",8.0
363,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Evidence of concurrent respiratory diseases such as pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other respiratory abnormalities other than asthma",8.0
364,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Evidence of concurrent respiratory diseases such as pneumonia, tuberculosis, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other respiratory abnormalities other than asthma.",8.0
365,NCT01823016,Phase 2,Asthma,"Janssen Research & Development, LLC",10-Feb-15,Asthma,"Has a history of any other chronic respiratory condition including, but not limited to, chronic obstructive pulmonary disease (COPD), bronchiolitis, bronchiectasis, allergic bronchopulmonary aspergillosis (mycosis), occupational asthma, sleep apnea, pulmonary hypertension, or any other obstructive pulmonary disease",8.0
366,NCT00688467,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Has had a diagnosis of chronic obstructive pulmonary disease (COPD) or any other clinically relevant lung disease (eg, cystic fibrosis, pulmonary fibrosis, bronchiectasis) other than mild allergic asthma, or has a history of having been intubated.",8.0
367,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"History of bronchiectasis secondary to respiratory diseases (e.g. cystic fibrosis, Kartagener's syndrome, etc.),",8.0
368,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"History of chronic bronchitis, emphysema, allergic bronchopulmonary aspergillosis or respiratory infection within the 4 preceding weeks of the first morning IMP administration",8.0
369,NCT03650400,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"History of chronic lung disease other than asthma such as and not limited to, sarcoidosis interstitial lung disease, cystic fibrosis, mycobacterial or other infection (including active tuberculosis or atypical mycobacterial disease).",8.0
370,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"History of chronic lung disease other than asthma within 3 months of first treatment visit (Day 1), cystic fibrosis, mycobacterial or other infection (including active SARS-CoV-2, tuberculosis or atypical mycobacterial disease)",8.0
371,NCT00436670,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary condition other than asthma,8.0
372,NCT01018550,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma,8.0
373,NCT01199289,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma,8.0
374,NCT01902290,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma,8.0
375,NCT01225315,Phase 2,Asthma,Idorsia Pharmaceuticals Ltd.,10-Feb-15,Asthma,"History of chronic pulmonary disease (other than asthma), such as chronic obstructive pulmonary disease (COPD), fibrosis, tuberculosis or sarcoidosis",8.0
376,NCT00330070,Phase 2,Asthma,Inflazyme Pharmaceuticals Ltd,10-Feb-15,Asthma,"history of chronic pulmonary diseases other than asthma, including bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, cystic fibrosis, pulmonary tuberculosis, or bronchiectasis",8.0
377,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"History of cystic fibrosis, chronic obstructive pulmonary disease, and/or other clinically significant lung disease other than asthma",8.0
378,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"History of cystic fibrosis, chronic obstructive pulmonary disease, and/or other clinically significant lung disease other than asthma",8.0
379,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,"History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or other clinically significant lung disease other than asthma",8.0
380,NCT02449473,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or other clinically significant lung disease other than asthma",8.0
381,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,"History of interstitial lung disease, chronic obstructive pulmonary disease, or other clinically significant lung disease other than asthma",8.0
382,NCT03296917,Phase 2,Asthma,Hvivo,10-Feb-15,Asthma,"History of life-threatening asthma, Diagnosis of COPD as defined by the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014 guidelines.",8.0
383,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,"History of non-reversible pulmonary disease; chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, or pulmonary fibrosis",8.0
384,NCT04092582,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"History or evidence of significant respiratory disease other than asthma, including occupational asthma, aspirin-sensitive asthma, asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome, bronchiolitis, interstitial lung disease, or COPD",8.0
385,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Lung disease other than asthma (eg, chronic obstructive pulmonary disease [COPD], cystic fibrosis)",8.0
386,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Lung disease other than persistent asthma (for example, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease [COPD], tuberculosis [TB])",8.0
387,NCT01999907,Phase 2,Asthma,St. Justine's Hospital,10-Feb-15,Asthma,other chronic respiratory disease (broncho-pulmonary dysplasia; cystic fibrosis),8.0
388,NCT01478152,Phase 2,Asthma,Bitop AG,10-Feb-15,Asthma,"Other respiratory diseases (e.g. Chronic obstructive pulmonary disease (COPD), cystic fibrosis, alpha-1-Antitrypsin deficiency, sarcoidosis, bronchiectasis, allergic alveolitis, tuberculosis, etc.)",8.0
389,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Other significant pulmonary diseases to include (but not limited to): pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other respiratory abnormalities other than asthma.",8.0
390,NCT00801853,Phase 2,Asthma,"Aerovance, Inc.",10-Feb-15,Asthma,"Patient has a current diagnosis of respiratory disorder other than asthma (e.g., chronic bronchitis, bronchiectasis, emphysema, chronic obstructive pulmonary disease [COPD], etc)",8.0
391,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,Patient with diagnosis of Chronic Obstructive Pulmonary Disease (COPD),8.0
392,NCT00556673,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Patients diagnosed with chronic obstructive pulmonary disease (COPD),8.0
393,NCT00557440,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Patients diagnosed with Chronic Obstructive Pulmonary disease (COPD) as defined by the GOLD guidelines (Global Initiative for Chronic Obstructive Lung Disease 2006).,8.0
394,NCT00605306,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Patients who suffer from chronic obstructive pulmonary disease (COPD),8.0
395,NCT01130064,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients with a diagnosis of chronic obstructive pulmonary disease (COPD),8.0
396,NCT00941798,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients with a previous diagnosis of chronic obstructive pulmonary disease (COPD),8.0
397,NCT01609478,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Patients with chronic lung disease, including COPD, pulmonary tuberculosis, bronchiectasis, sarcoidosis, interstitial lung disease and cystic fibrosis.",8.0
398,NCT03944707,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Patients with chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, clinically significant bronchiectasis, sarcoidosis, interstitial lung disease, cystic fibrosis, Churg-Strauss syndrome, allergic broncho-pulmonary aspergillosis, or clinically significant chronic lung diseases related to a history of tuberculosis or asbestosis.",8.0
399,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,"Patients with history of concomitant chronic or severe pulmonary disease other than asthma (e.g., COPD, bronchiectasis, sarcoidosis, interstitial lung disease, cystic fibrosis, active tuberculosis).",8.0
400,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,Physician diagnosis of chronic obstructive pulmonary disease,8.0
401,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Physician diagnosis of other chronic pulmonary disorders associated with asthma-like symptoms, including, but not limited to, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways",8.0
402,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Presence of a clinically important lung condition other than asthma including current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, Churg-Strauss syndrome, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer.",8.0
403,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Presence of a known pre-existing, clinically important lung condition other than asthma. This includes chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or a history of lung cancer.",8.0
404,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Presence of a known pre-existing, clinically important respiratory conditions (e.g. pneumonia, pneumothorax, atelectasis segmental or larger, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or other respiratory abnormalities) other than asthma.",8.0
405,NCT02740543,Phase 2,Asthma,NYU Langone Health,10-Feb-15,Asthma,Pulmonary diseases such as Chronic Pulmonary Disease (COPD) or Interstitial Lung Disease,8.0
406,NCT00995800,Phase 2,Asthma,Mundipharma Research Limited,10-Feb-15,Asthma;Inflammation,"Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis)",8.0
407,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject had a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.,8.0
408,NCT01006161,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Subject who has been diagnosed with COPD or any other clinically relevant lung disease, other than asthma (eg, cystic fibrosis, pulmonary fibrosis, bronchiectasis). ",8.0
409,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.,8.0
410,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.,8.0
411,NCT02219048,Phase 2,Asthma,Pfizer,10-Feb-15,Asthma,"Subjects diagnosed with chronic pulmonary disease (COPD) and/or other chronic pulmonary diseases (eg, Occupational asthma, pulmonary fibrosis, bronchiectasis, Allergic bronchopulmonary aspergillosis (ABPA), pneumoconiosis, sarcoidosis, tuberculosis).",8.0
412,NCT00640016,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Subjects with a physician-diagnosis of any other significant lung disease, including a primary diagnosis of chronic obstructive pulmonary disease or bronchiectasis, or lung cancer, sarcoidosis, tuberculosis, pulmonary fibrosis and cystic fibrosis",8.0
413,NCT04617171,Phase 2,Asthma Attack;Asthma,Singapore General Hospital,10-Feb-15,Asthma,"Subjects with a physician diagnosis of COPD, bronchiectasis",8.0
414,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Subjects with any other underlying diseases that may compromise safety or may interfere with eﬃcacy outcomes (e.g. tuberculosis, clinically relevant bronchiectasis, diﬀuse lung interstitial disease, pulmonary hypertension, emphysema, chronic bronchitis, alpha-1-antitrypsin deﬁciency, systemic immune-driven disorders).",8.0
415,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Any infirmity, disability or disease of a child or family member likely to impair compliance",9.0
416,NCT01286844,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any medical condition or circumstance making the volunteer unsuitable for participation in the study.,9.0
417,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Individuals who are legally institutionalized,9.0
418,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Individuals who are legally institutionalized ,9.0
419,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Parent/guardian has a history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g. inability to read, comprehend and write) which will limit the validity of consent for their child to participate in this study",9.0
420,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Parent/guardian has a history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g. inability to read, comprehend and write) which will limit the validity of consent to participate in this study.",9.0
421,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Parent/guardian has a history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g. inability to read, comprehend and write) which will limit the validity of consent to participate in this study.",9.0
422,NCT01286844,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Parent/guardian has history of psychiatric disease, intellectual deficiency, substance abuse, or other condition which will limit the validity of consent to participate in this study.",9.0
423,NCT02740868,Phase 2,Cystic Fibrosis;Asthma,The Hospital for Sick Children,10-Feb-15,Cystic Fibrosis;Fibrosis,"Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent/assent from being obtained, or cannot read or understand the written material",9.0
424,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Participant who is mentally or legally incapacitated.,9.0
425,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Participants with any medical condition or circumstance making the volunteer unsuitable for participation in the study.,9.0
426,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,"Subject, who in the opinion of the Investigator, is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments. ",9.0
427,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,subject is mentally or legally incapacitated,9.0
428,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is mentally or legally incapacitated.,9.0
429,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is mentally or legally incapacitated.,9.0
430,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject who is mentally or legally incapacitated.,9.0
431,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.",9.0
432,NCT04617171,Phase 2,Asthma Attack;Asthma,Singapore General Hospital,10-Feb-15,Asthma,Subjects who are deemed by investigators to have with life expectancy of < 12 months (any cause),9.0
433,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects who are kept due to regulatory or juridical order in an institution.,9.0
434,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects who are kept due to regulatory or juridical order in an institution.,9.0
435,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Subjects who are mentally or legally incapacitated, or subjects accommodated in an establishment as a result of an official or judicial order.",9.0
436,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Subjects who are mentally or legally incapacitated or subjects accommodated in an establishment as a result of an official or judicial order.,9.0
437,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.",9.0
438,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study. Randomization exclusion criteria:",9.0
439,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with any medical condition or circumstance making the volunteer unsuitable for participation in the study.,9.0
440,NCT01453296,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The parent or guardian has history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g., inability to read, comprehend or write) which will limit the validity of consent to participate in this study.",9.0
441,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Vulnerable participants (eg, people kept in detention). NOTE- Additional criteria apply, please contact the investigator for more information ",9.0
442,NCT01833390,Phase 2,Asthma;COPD;Healthy,Xemed LLC,10-Feb-15,Asthma,Inability to understand simple instructions or to hold still for approximately 10 seconds.,10.0
443,NCT00901095,Phase 2,Asthma;Obesity,Palo Alto Medical Foundation,10-Feb-15,Asthma;Weight Loss,"Unwilling to attempt weight loss, including unwillingness to perform self-monitoring;",10.0
444,NCT00860418,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Children residing in foster care or where consent cannot be obtained from a legal guardian. ,11.0
445,NCT01006655,Phase 2,Asthma;Bronchial Hyperresponsiveness,Rambam Health Care Campus,10-Feb-15,Bronchial Hyperreactivity,disagreement of the parents or legal tutor ,11.0
446,NCT01443728,Phase 2,Sickle Cell Disease;Vitamin D Deficiency;Acute Chest Syndrome;Asthma;Respiratory Infections,"Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Acute Chest Syndrome;Anemia, Sickle Cell;Vitamin D Deficiency","Patient (or parent or guardian) unwilling or unable to provide written informed consent (and assent, if applicable)",11.0
447,NCT04170348,Phase 2,"Sickle Cell Disease;Anemia, Sickle Cell;Anemia, Hemolytic, Congenital;Respiratory Tract Diseases;Respiration Disorders;Acute Chest Syndrome;Lung Diseases;Asthma;Respiratory Tract Infections;Nutrition Disorders;Deficiency Diseases Vitamin;Vitamin D Deficiency","Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Lung Diseases;Respiratory Tract Diseases;Acute Chest Syndrome;Respiration Disorders;Anemia;Anemia, Sickle Cell;Anemia, Hemolytic;Anemia, Hemolytic, Congenital;Vitamin D Deficiency;Nutrition Disorders;Deficiency Diseases;Vitamin A Deficiency;Disease","Patient unwilling or unable to provide written informed consent (and assent, if applicable)",11.0
448,NCT01445015,Phase 2,Asthma;Psychosocial Stress,Weill Medical College of Cornell University,10-Feb-15,Asthma,Refusal of child assent/parental consent,11.0
449,NCT01225549,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Any clinically significant disease or disorder,12.0
450,NCT02427165,Phase 2,Asthma,Verona Pharma plc,10-Feb-15,Asthma,Any clinically significant disease or disorder or clinically relevant screening result,12.0
451,NCT03296917,Phase 2,Asthma,Hvivo,10-Feb-15,Asthma,Any history or evidence of any clinically significant medical and psychiatric conditions ,12.0
452,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,Any major disability or disease with expected survival less than 6 months,12.0
453,NCT02153541,Phase 2,Asthma,Global United Pharmaceutical Corporation,10-Feb-15,Asthma,Any other significant cardiopulmonary disease,12.0
454,NCT00697801,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,Any other significant childhood illness.,12.0
455,NCT00554970,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,Any other significant illness/abnormality,12.0
456,NCT00150397,Phase 2,Asthma,Pfizer,10-Feb-15,Asthma,"Any significant co-morbid disease, particularly cardiovascular",12.0
457,NCT02609334,Phase 2,Asthma,RSPR Pharma AB,10-Feb-15,Asthma,Clinical significant comorbidities,12.0
458,NCT00318747,Phase 2,"Asthma;Allergy;Allergic Rhinitis;Rhinitis, Allergic, Seasonal",National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Clinically significant acute or chronic illness,12.0
459,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,Clinically significant diseases as assessed by the study doctor,12.0
460,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Clinically significant diseases as assessed by the study doctor,12.0
461,NCT01425801,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Clinically significant respiratory conditions,12.0
462,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Evidence of any systemic disease on physical examination,12.0
463,NCT03364608,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Historical or current evidence of a clinically significant disease,12.0
464,NCT03371459,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Historical or current evidence of a clinically significant disease,12.0
465,NCT01424124,Phase 2,Asthma,Yuhan Corporation,10-Feb-15,Asthma,History of any clinically significant disease,12.0
466,NCT03299686,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"History of ongoing, chronic, or recurrent moderate or severe infectious disease",12.0
467,NCT00758589,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Other clinically relevant disease or disorders,12.0
468,NCT04046939,Phase 2,Eosinophilic Asthma;Asthma,Knopp Biosciences,10-Feb-15,Asthma;Pulmonary Eosinophilia,Other medically significant illness,12.0
469,NCT00166582,Phase 2,Asthma,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),10-Feb-15,Asthma,patient shows evidence of neurological or significant cognitive impairment ,12.0
470,NCT02127866,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Patients who have a clinically significant cardiovascular condition ,12.0
471,NCT03683576,Phase 2,Asthma,"GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.",10-Feb-15,Asthma,Serious co-morbidities,12.0
472,NCT02153541,Phase 2,Asthma,Global United Pharmaceutical Corporation,10-Feb-15,Asthma,Severe psychiatric or cognitive problems,12.0
473,NCT01563029,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,significant abnormality or medical condition,12.0
474,NCT01573767,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,significant abnormality or medical condition,12.0
475,NCT00822861,Phase 2,Asthma,Pharmaxis,10-Feb-15,Asthma,Significant acute or chronic medical or psychiatric illness,12.0
476,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Significant medical history;,12.0
477,NCT00746330,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Significant medication condition or situation.,12.0
478,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,significant neurological disease,12.0
479,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,a current smoker,13.0
480,NCT00930163,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Current smoker,13.0
481,NCT00971035,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Current smoker,13.0
482,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,current smoker,13.0
483,NCT02740543,Phase 2,Asthma,NYU Langone Health,10-Feb-15,Asthma,Current Smoker,13.0
484,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Current smokers,13.0
485,NCT00280683,Phase 2,Asthma,"University of California, Davis",10-Feb-15,Asthma,Current smokers,13.0
486,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,Current smokers,13.0
487,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Current Smokers,13.0
488,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Current smokers,13.0
489,NCT02615080,Phase 2,Asthma,RSPR Pharma AB,10-Feb-15,Asthma,Current smokers,13.0
490,NCT03683576,Phase 2,Asthma,"GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.",10-Feb-15,Asthma,Current smokers (any substance),13.0
491,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Current smokers.,13.0
492,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Current tobacco usage,13.0
493,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,Current tobacco use,13.0
494,NCT00141791,Phase 2,Asthma,Wyeth is now a wholly owned subsidiary of Pfizer,10-Feb-15,Asthma,Current use of cigarettes,13.0
495,NCT00463827,Phase 2,Asthma;COPD;Smoking,NHS Greater Clyde and Glasgow,10-Feb-15,Asthma,Ex-smokers or non-smokers,13.0
496,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Heavy caffeine drinkers,13.0
497,NCT00215397,Phase 2,Asthma,Dey,10-Feb-15,Asthma,History of smoking,13.0
498,NCT00215410,Phase 2,Asthma,Dey,10-Feb-15,Asthma,History of smoking,13.0
499,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,History of smoking,13.0
500,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Ongoing use of tobacco,13.0
501,NCT01563029,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Present use of any tobacco products ,13.0
502,NCT01573767,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Present use of any tobacco products ,13.0
503,NCT02918019,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Recent history of smoking,13.0
504,NCT00896428,Phase 2,Asthma,"University Hospital, Bordeaux",10-Feb-15,Asthma,Smoker or former smoker,13.0
505,NCT00785083,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Smokers,13.0
506,NCT01103037,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Smokers,13.0
507,NCT02153541,Phase 2,Asthma,Global United Pharmaceutical Corporation,10-Feb-15,Asthma,Smokers,13.0
508,NCT01478360,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Smokers ,13.0
509,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Smokers ,13.0
510,NCT02620956,Phase 2,Obese;Asthma,Jacqueline de Melo Barcelar,10-Feb-15,Asthma;Obesity,Smokers and those incapable of performing procedures were excluded. ,13.0
511,NCT02407262,Phase 2,Asthma,"University College, London",10-Feb-15,Asthma;Inflammation,Smoking history,13.0
512,NCT01317563,Phase 2,Asthma,Nemours Children's Clinic,10-Feb-15,Asthma,"smoking history,",13.0
513,NCT00987064,Phase 2,Asthma;Perennial Allergy,Airsonett AB,10-Feb-15,Asthma,Smoking in the family,13.0
514,NCT00583947,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with a history of cigarette smoking or use of any tobacco products. ,13.0
515,NCT02219048,Phase 2,Asthma,Pfizer,10-Feb-15,Asthma,Subjects who are current smokers. ,13.0
516,NCT00400855,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Have a history of milk protein allergy.,14.0
517,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,History of severe allergy to milk protein,14.0
518,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,History of severe allergy to milk protein,14.0
519,NCT00980200,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of severe milk protein allergy,14.0
520,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of severe milk protein allergy,14.0
521,NCT01899144,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,History of severe milk protein allergy,14.0
522,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,History of severe milk protein allergy.,14.0
523,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of severe milk protein allergy.,14.0
524,NCT01317563,Phase 2,Asthma,Nemours Children's Clinic,10-Feb-15,Asthma,"milk allergy,",14.0
525,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Milk Protein Allergy: History of severe milk protein allergy,14.0
526,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Milk Protein Allergy: History of severe milk protein allergy.,14.0
527,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Milk Protein Allergy: History of severe milk protein allergy.,14.0
528,NCT02910401,Phase 2,Asthma;Allergic Rhinitis,University of Virginia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",>5 pack-year smoking history or any smoking within the past 6 mos,15.0
529,NCT02230189,Phase 2,Asthma,Prescott Woodruff,10-Feb-15,Asthma,≥ 10 pack-years smoking or any smoking in the past year,15.0
530,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,1 cigar or pipe per day for 1 year,15.0
531,NCT02210806,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"A smoking history of ≥ 5 pack-years, or having smoked within 6 months prior to Screening",15.0
532,NCT02271334,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"A smoking history of ≥ 5 pack-years, or having smoked within 6 months prior to Screening;",15.0
533,NCT01255709,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"A smoking history of ≥10 pack-years, or having smoked within 6 months prior to Screening;",15.0
534,NCT01581177,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,A smoking history of more than or equal to 10 years or having smoked within 6 months of screening visit,15.0
535,NCT02251379,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Active smoker defined as a positive urine screen for high levels of urine cotinine,15.0
536,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Active smoking of conventional tobacco, inhaling of marijuana or other drugs, or vaping of e-cigarettes or vape pods >1 time per month in the past year",15.0
537,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Active use of any inhalant >1 time per month in the past year,15.0
538,NCT03296917,Phase 2,Asthma,Hvivo,10-Feb-15,Asthma,Any ex-smoker or smoker with a history of more than 10 pack-years.,15.0
539,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Can still be enrolled if ≥30, smoked <10 pack years and none in past year, provided participant demonstrates a normal (negative) urine cotinine",15.0
540,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Can still be enrolled if ≥40 years old, smoked <15 pack years and none in the last year, provided participant demonstrates normal (negative) urine cotinine. Patients with a smoking history of ≥10 to <15 pack years will also need to demonstrate a normal Diffusing Capacity for Carbon Monoxide (DLCO) (>70% predicted) * Smoking equivalent pack years. One pack of cigarettes a day for 1 year is equivalent to:",15.0
541,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Can still be enrolled if <30, smoked <5 5 pack years and none in past year, and normal (negative) urine cotinine",15.0
542,NCT00815347,Phase 2,Asthma,UConn Health,10-Feb-15,Asthma,Cigarette history of >10 pack years.,15.0
543,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,Cigarette smoking > 1 pack per month,15.0
544,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Current cigarette smokers or former smokers with a smoking history of greater than 10 pack years or who stopped smoking within 12 months preceding enrolment in the study.,15.0
545,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Current or ex-smokers who quit <1 year before enrollment. Ex-smokers who quit less than 1 year from enrollment must have a cigarette smoking history of less than 10 pack years. Pack years = Number of cigarettes/day x years of smoking 20,15.0
546,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,current regular use or recent (within past ≤5 years) past abuse of alcohol (>14 drinks/week) or illicit drugs,15.0
547,NCT04092582,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Current smoker, electronic cigarette (e-cigarette) user, former smoker with smoking history of > 10 pack-years, former e-cigarette user with an e-cigarette history of at least daily use for >=10 years, or unwilling to abstain from smoking and/or e-cigarette use from the time of consent through the completion of the study",15.0
548,NCT01402986,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Current smoker or a history of smoking which would be more than 1 pack per day for 10 years,15.0
549,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Current smoker or a smoking history of >=10 pack years (e.g., 20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products within the past 12 months (i.e., cigarettes, e-cigarettes/vaping, cigars or pipe tobacco).",15.0
550,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Current smoker or a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). A subject may not have used tobacco products within the past one year (e.g., cigarettes, cigars, chewing tobacco, or pipe tobacco)",15.0
551,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Current smoker or a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). A subject may not have used tobacco products within the past one year (e.g., cigarettes, cigars, chewing tobacco, or pipe tobacco)",15.0
552,NCT01951222,Phase 2,Asthma,Pierre Fabre Medicament,10-Feb-15,Asthma,Current smoker or former smoker less than 6 months or total lifetime smoking history greater than 10 pack-years.,15.0
553,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Current smoker or former smoker with a history >10 pack years,15.0
554,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Current smoker or former smoker with a history >10 pack years,15.0
555,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Current smoker or former smoker with a smoking history of >15 pack-years,15.0
556,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Current smoker or former smoker with a smoking history of more than 15 pack-years,15.0
557,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,Current smoker or H/O > 15 pack years,15.0
558,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,"Current smoker or history of smoking (greater than [>] 10 pack-years), or unwillingness to abstain from smoking for the duration of the study",15.0
559,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Current smoker or smoking history of 10 pack years or more,15.0
560,NCT01704495,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Current smoker or smoking history of more than 20 pack years ,15.0
561,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Current smokers (any subject who has smoked within the six months prior to screening or has a positive urine cotinine at screening) or subjects with a smoking history of >10 pack years calculated as follows: Number of cigarettes per day X number of years smoked 20,15.0
562,NCT03364608,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana)",15.0
563,NCT03371459,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana)",15.0
564,NCT01425801,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Current smokers, former smokers within the last 6 months, or ex-smokers with a history of more than 10 pack-years",15.0
565,NCT00614874,Phase 2,Asthma,Creighton University,10-Feb-15,Asthma,"Current smokers, greater than 10 pack year history, or patients quitting less than 1 year prior to screening",15.0
566,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,"Current smokers, smokers within six months prior to Visit 1, or subjects with an smoking history greater than 5 pack-years.",15.0
567,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Current smokers, smokers within six months prior to Visit V1, or subjects with an smoking history greater than 10 packs-years",15.0
568,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Current smokers or ex-smokers (tobacco, vapor cigarettes, marijuana) with a smoking history of >10 pack-years or having stopped smoking one year or less prior to screening visit.",15.0
569,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Current smokers or ex-smokers (tobacco, vapor cigarettes, marijuana) with a smoking history of >10 pack-years or having stopped smoking one year or less prior to screening visit.",15.0
570,NCT01123252,Phase 2,Seasonal Affective Rhinitis;Asthma;Grass Allergy,University of East Anglia,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Current smokers or ex-smokers of <1 year or those who have smoked the equivalent of 20 cigarettes/day for 20 years or more.,15.0
571,NCT01437735,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Current smokers or ex-smokers who stopped smoking within 6 months prior to screening or have a smoking history of ≥ 10 pack years. ,15.0
572,NCT00640016,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Current smokers or ex-smokers with greater than 10 pack-years,15.0
573,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Current smokers or former smokers with a smoking history >=10 pack years.,15.0
574,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Current smokers or former smokers with a smoking history more than or equal to 10 pack years.,15.0
575,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,"Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 pack/years;",15.0
576,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Current smokers or regular smokers during last 12 months or more than 10 pack-year history,15.0
577,NCT01841281,Phase 2,Asthma;Inflammation,Nicholas Kenyon,10-Feb-15,Asthma;Inflammation,Current smokers or smoking history > 15 pack years,15.0
578,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Current smokers or smoking history of >=10 pack years,15.0
579,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Current smokers or subjects with a > 10 pack year history of cigarettes, cigars, or pipe smoking",15.0
580,NCT02054130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Current smokers or subjects with a smoking history of ≥ 10 pack years,15.0
581,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,Current smokers or subjects with a smoking history of ≥ 10 pack years. Former smokers with < 10 pack years must have stopped for at least 6 months to be eligible,15.0
582,NCT02382510,Phase 2,Asthma,"Theron Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Current smokers or vapers, or former smokers with > 10 pack-year (self-reported) history of smoking",15.0
583,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,"Current smoking, or former smoking if ≥5 pack-years",15.0
584,NCT03762395,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma,"Current smoking or have former smokers that quit within the previous 1 year, or 10 pack years ",15.0
585,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,Current smoking or smoking history of greater than 10 pack-years,15.0
586,NCT02449473,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Current tobacco smoking or a history of tobacco smoking for >10 pack-years,15.0
587,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Current use of tobacco products or a history of use of tobacco products of more than one cigarette per month or equivalent within 1 year prior to randomization or history of smoking of ≥ 10 pack-years;,15.0
588,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Currently a smoker, or a former smoker with > 10 pack-year history, or a former smoker who stopped smoking <1 year before the Screening Visit",15.0
589,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,Currently smoking or history of smoking ≥ 10 pack years,15.0
590,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,ex smoker who quit <1 year prior to study and pack history >10 pack years,15.0
591,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,"Ex-smokers for less than 1 year, with a tobacco smoking history of >10 pack years",15.0
592,NCT01930461,Phase 2,Asthma;House Dust Mite Allergy,Stallergenes Greer,10-Feb-15,Asthma,Former smoker with > 10 pack year history or current smoker.,15.0
593,NCT01582503,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Former smoker with >10 pack-year history or current smoker; former smokers must have stopped smoking more than 12 months prior to Visit 1,15.0
594,NCT02054130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Former smokers with < 10 pack years must have stopped for at least 1 year to be eligible.,15.0
595,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,Greater than 10 packs per year smoking history and any cigarette smoking within the past 12 months,15.0
596,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,"Greater than 20 pack year smoking history, or smoking within the last 6 months.",15.0
597,NCT00318747,Phase 2,"Asthma;Allergy;Allergic Rhinitis;Rhinitis, Allergic, Seasonal",National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Greater than 5 pack/year history of smoking,15.0
598,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Has a history of smoking within 1 year of Visit 1 and smoking history ≥10 pack years,15.0
599,NCT01823016,Phase 2,Asthma,"Janssen Research & Development, LLC",10-Feb-15,Asthma,Has smoked within 3 years of Screening Visit 1 or has a history of smoking ≥ 10 pack years,15.0
600,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of cigarette smoking >=10 pack years,15.0
601,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of cigarette smoking >20 pack years,15.0
602,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of cigarette smoking more than or equal to (>=) 10 pack-years or smoking within 12 months prior to screening.,15.0
603,NCT00758589,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,History of smoking of more than 10 pack years,15.0
604,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of use of tobacco products of more than one cigarette per month or equivalent within 1 year prior to randomization or history of smoking of ≥ 10 pack-years;,15.0
605,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of use of tobacco products of more than one cigarette per month or equivalent within 1 year prior to screening or history of smoking of ≥ 10 pack-years;,15.0
606,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of use of tobacco products within 2 years of baseline or history of smoking >= 10 pack-years;,15.0
607,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History suggestive of chronic obstructive pulmonary disease (COPD) and of cigarette smoking >=10 pack-years,15.0
608,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History suggestive of COPD or of tobacco smoking ≥ 10 pack-years,15.0
609,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,If ≥40 years old: Smoked ≥15 pack years,15.0
610,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,If <30 years old: Smoked for ≥5 pack-years*,15.0
611,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,If 30-39 years old: Smoked for ≥10 pack years,15.0
612,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Is a current smoker or has a smoking history of 10 or more pack years;,15.0
613,NCT01499446,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Is a current smoker or has a smoking history of 10 pack years or more (e.g., 20 cigarettes/day for 10 years). Note: Current smoker is defined as currently smoking or stopped smoking within 6 months of screening visit. ",15.0
614,NCT00980200,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,No use of inhaled tobacco products within the past three months or historical use of 10 pack years or more,15.0
615,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Past smoker with a history of ≥10 pack per year or current smoker,15.0
616,NCT01609478,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who are current smokers or have a smoking history of greater than 10 pack years (defined as the number of packs of 20 cigarettes smoked per day multiplied by number of years the patient smoked).,15.0
617,NCT04410523,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have a cigarette smoking history of greater than 10 pack years or current smokers.,15.0
618,NCT03944707,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Patients who have smoked or inhaled any substance other than asthma medications within the 6 month period prior to screening, or who have a smoking history of greater than 10 pack years (e.g. 10 pack years = 1 pack/day x 10 years or ½ pack/day x 20 years, etc.).",15.0
619,NCT03299686,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have smoked or inhaled nicotine or tobacco products within the 6 month period prior to Visit 1 or who have a smoking history of greater than 10 pack years,15.0
620,NCT00403754,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have used tobacco products within 6 months prior to the first day of screening or have a smoking history of greater than 10 pack years.,15.0
621,NCT00557440,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,"Patients who have used tobacco products within the 6 months period prior to Visit 1, or who have a smoking history of greater than 10 pack years.",15.0
622,NCT00024544,Phase 2,Asthma,Facet Biotech,10-Feb-15,Asthma,Patients with > 10 pack years of smoking history or smoking within 12 months of study enrollment,15.0
623,NCT00028288,Phase 2,Asthma,Facet Biotech,10-Feb-15,Asthma,Patients with 10 or more pack years of smoking history or smoking within 12 months of study enrollment,15.0
624,NCT00317044,Phase 2,Asthma;GERD,AstraZeneca,10-Feb-15,Asthma,Patients with a smoking history of ≥10 pack-year.,15.0
625,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,Patients with a smoking history of ≥20 pack-years (1 pack year = 20 cigarettes smoked per day for one year),15.0
626,NCT00467740,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Patients with a smoking history of more than 10 pack years,15.0
627,NCT00545272,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Patients with Chronic Obstructive Pulmonary Disease (COPD), or current smokers, or patients who have used tobacco products within the 6 month period prior to Visit 1, or who have a smoking history of greater than 10 pack years.",15.0
628,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Pregnancy and Lactating Females:,15.0
629,NCT00556673,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Recent use of tobacco or history of smoking > 10 pack years,15.0
630,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,"Regular use of tobacco products of any kind or within the previous 6 months, or smoking history > 10 pack-years",15.0
631,NCT00983658,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,"Regular use of tobacco products of any kind or within the previous 6 months, or smoking history > 10 pack-years ",15.0
632,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Self-reported history of greater than 20 pack-yr smoking history;,15.0
633,NCT00394914,Phase 2,Asthma;Common Cold;Picornavirus Infection;Rhinovirus,Merck Sharp & Dohme Corp.,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,Smoker or ex-smoker and has smoked within the previous 5 years of Screening or has had a cumulative smoking history >10 pack years.,15.0
634,NCT01225549,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Smoker or ex-smoker who has stopped smoking < 12 months prior to study start,15.0
635,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Smokers, deﬁned by smoking within the previous 6 months or having a smoking history of more than 10 packs-years, a pack-year being deﬁned as smoking the equivalent of 20 cigarettes (a pack) per day for 1 year.",15.0
636,NCT04617171,Phase 2,Asthma Attack;Asthma,Singapore General Hospital,10-Feb-15,Asthma,Smokers > 20 pack years,15.0
637,NCT01130064,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Smoking history >10 pack-years,15.0
638,NCT01174732,Phase 2,Asthma;Bronchospasm,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma;Bronchial Spasm,"Smoking history of ≥ 10 pack-years, or having smoked within 6 months;",15.0
639,NCT01189396,Phase 2,Asthma;Bronchospasm;Chronic Obstructive Pulmonary Disease (COPD),"Amphastar Pharmaceuticals, Inc.",10-Feb-15,"Asthma;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive;Bronchial Spasm","Smoking history of ≥ 10 pack-years, or having smoked within 6 months prior to Screening;",15.0
640,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,Smoking history of greater than 10 pack-year history of cigarette smoking (number of packs smoked per day times the number of years smoked),15.0
641,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Smoking history of greater than 10 pack-year history of cigarette smoking (number of packs smoked per day times the number of years smoked),15.0
642,NCT02660489,Phase 2,Asthma;Rhinovirus;Picornaviridae Infections;Common Cold,Imperial College London,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,Smoking history over past 12 months,15.0
643,NCT00830102,Phase 2,Asthma,SkyePharma AG,10-Feb-15,Asthma,Smoking history within the last 12 months,15.0
644,NCT00215358,Phase 2,Asthma,Dey,10-Feb-15,Asthma,Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history,15.0
645,NCT00215371,Phase 2,Asthma,Dey,10-Feb-15,Asthma,Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history.,15.0
646,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Smoking History: Current smokers or former smokers who have stopped smoking within 6 months prior to enrollment or with a >10 pack year history of cigarettes, cigars, or pipe smoking. E-cigarettes and inhaled marijuana should be treated in the same manner as tobacco products",15.0
647,NCT03393806,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Smoking history: current smokers or former smokers with a smoking history >= 10 pack years,15.0
648,NCT01225315,Phase 2,Asthma,Idorsia Pharmaceuticals Ltd.,10-Feb-15,Asthma,"Smoking within the last year, or life-time consumption > / = 10 pack-years (e.g., 20 cigarettes/day for 10 years)",15.0
649,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject had a history of cigarette smoking or use of other tobacco products.,15.0
650,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with a history of cigarette smoking or use of any tobacco products.,15.0
651,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Subject with a history of cigarette smoking or use of any tobacco products.,15.0
652,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.,15.0
653,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.,15.0
654,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects with a smoking history of >=10 pack years (pack years = number of cigarettes smoked per day divided by 20 into number of years smoked). Note: Subjects who are current smokers, or ex-smokers (having given up smoking for >=6 months), are eligible for the study if their smoking history is <10 pack years.",15.0
655,NCT00280683,Phase 2,Asthma,"University of California, Davis",10-Feb-15,Asthma,Subjects with more than a 15 pack-year history of smoking ,15.0
656,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"The participant currently smokes or has a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes [20 cigarettes]/day for 1 year), OR the participant used tobacco or marijuana products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco), OR the participant has a history of ""vaping"" tobacco, marijuana, or any other substance within 24 months.",15.0
657,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Tobacco Use : Current smoker or a smoking history of 10 pack years or more (e.g. 20 cigarettes/day for 10 years). A subject may not have used tobacco products within the past one year (i.e., cigarettes, cigars, or pipe tobacco).",15.0
658,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,"Tobacco use within 3 months prior to Screening, or > 5 pack-year lifetime tobacco use",15.0
659,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Tobacco Use: Current smokers or a smoking history of >=10 pack years. A subject may not have used any inhaled tobacco products in 12 weeks preceding the screening visit.,15.0
660,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.,15.0
661,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.,15.0
662,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening (for subjects taking part in the non-smokers group of the study) ,15.0
663,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.,15.0
664,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Use of any nicotine containing products within 12 months prior to Screening or a smoking history > 10 pack years,15.0
665,NCT04046939,Phase 2,Eosinophilic Asthma;Asthma,Knopp Biosciences,10-Feb-15,Asthma;Pulmonary Eosinophilia,Use of any smoke or inhaled nicotine delivery device within 1 year prior to Screening,15.0
666,NCT00232999,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Use of tobacco products within one year starting study or smoking history >10 pack years,15.0
667,NCT04150341,Phase 2,Asthma,Theravance Biopharma,10-Feb-15,Asthma,Uses or have used tobacco or nicotine-containing products within 6 months prior to screening,15.0
668,NCT02388997,Phase 2,Asthma,University of Virginia,10-Feb-15,Infections;Asthma,"Who have a 5 pack/year history of smoking, or any smoking within the last 6 months.",15.0
669,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,"A woman who is pregnant (has a positive serum pregnancy test at Screening Visit), is lactating, or is likely/planning to become pregnant during the study",16.0
670,NCT02293499,Phase 2,Asthma,University of Rochester,10-Feb-15,Asthma,Adolescents who are pregnant or incarcerated at enrollment;,16.0
671,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,"Are pregnant, nursing, or planning a pregnancy within 12 months of enrolment",16.0
672,NCT00017693,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Are pregnant or breast-feeding.,16.0
673,NCT02898662,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Breast feeding, pregnancy or intention to become pregnant during the course of the study",16.0
674,NCT01999907,Phase 2,Asthma,St. Justine's Hospital,10-Feb-15,Asthma,breastfed infants with no vitamin D supplementation,16.0
675,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,"Female participant who is pregnant, lactating or breast-feeding. Additional exclusion criteria on day of exacerbation (Visit 2)",16.0
676,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Female planning to become pregnant during the study period,16.0
677,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Female subject was pregnant or lactating.,16.0
678,NCT00583947,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Female subject who is pregnant or lactating.,16.0
679,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Female subject who is pregnant or lactating.,16.0
680,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Female subject who is pregnant or lactating.,16.0
681,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Female subject who is pregnant or lactating.,16.0
682,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Female subject who is pregnant or lactating.,16.0
683,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,"Female subjects who are pregnant, trying to become pregnant or lactating.",16.0
684,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Female subjects who are pregnant or lactating;,16.0
685,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,female subjects who are pregnant or nursing,16.0
686,NCT00394914,Phase 2,Asthma;Common Cold;Picornavirus Infection;Rhinovirus,Merck Sharp & Dohme Corp.,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,"Female who is breast-feeding, pregnant, or intends to become pregnant.",16.0
687,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,"Female who is breast-feeding, pregnant (verified by urine dipstick pregnancy test) or intends to become pregnant during the study",16.0
688,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Females who are pregnant or are lactating,16.0
689,NCT00512863,Phase 2,Asthma,Abbott,10-Feb-15,Asthma,Females who are pregnant or will not discontinue breast-feeding.,16.0
690,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"If female, is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period",16.0
691,NCT00232999,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"If female, pregnant or lactating or have positive pregnancy test at screening ",16.0
692,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Is a nursing mother at the time of screening;,16.0
693,NCT00688467,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Is pregnant, breast-feeding, or intends to become pregnant during the study.",16.0
694,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Lactating, pregnant, or planning to become pregnant during the study.",16.0
695,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Lactating or breastfeeding woman;,16.0
696,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,Male participants with pregnant female partners.,16.0
697,NCT02740868,Phase 2,Cystic Fibrosis;Asthma,The Hospital for Sick Children,10-Feb-15,Cystic Fibrosis;Fibrosis,Participant is pregnant or lactating,16.0
698,NCT00783601,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Patient is pregnant or breast-feeding ,16.0
699,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,Pregnancy or breastfeeding,16.0
700,NCT01544634,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma;Respiratory Hypersensitivity,Pregnancy or lactation,16.0
701,NCT04353310,Phase 2,Asthma,Loma Linda University,10-Feb-15,Asthma,Pregnancy or lactation,16.0
702,NCT01348139,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Pregnancy or lactation ,16.0
703,NCT00983658,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Pregnancy or lactation or positive serum pregnancy test at screening,16.0
704,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Pregnancy or lactation or positive serum pregnancy test at screening,16.0
705,NCT01074853,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma,Pregnancy or lactation.,16.0
706,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Pregnancy or lactation.,16.0
707,NCT01833390,Phase 2,Asthma;COPD;Healthy,Xemed LLC,10-Feb-15,Asthma,Pregnancy or lactation.,16.0
708,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,Pregnancy or planning to become pregnant over course of study and up to one month after,16.0
709,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,Pregnancy/lactation,16.0
710,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,"Pregnant, breastfeeding or lactating females",16.0
711,NCT00901095,Phase 2,Asthma;Obesity,Palo Alto Medical Foundation,10-Feb-15,Asthma;Weight Loss,"Pregnant, planning to become pregnant, or lactating;",16.0
712,NCT01582503,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Pregnant and lactating women ,16.0
713,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Pregnant and lactating women.,16.0
714,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,Pregnant or breast feeding females,16.0
715,NCT02660489,Phase 2,Asthma;Rhinovirus;Picornaviridae Infections;Common Cold,Imperial College London,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,Pregnant or breast-feeding women (patients should not be enrolled if they plan to become pregnant during the time of study participation),16.0
716,NCT02449473,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Pregnant or breastfeeding,16.0
717,NCT04092582,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the final dose of MTPS9579A",16.0
718,NCT01692041,Phase 2,Asthma,Technische Universität Dresden,10-Feb-15,Asthma,Pregnant or breastfeeding girls - ,16.0
719,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Pregnant or breastfeeding or planning to become pregnant,16.0
720,NCT03683576,Phase 2,Asthma,"GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.",10-Feb-15,Asthma,Pregnant or breastfeeding Other protocol-defined inclusion/exclusion criteria may apply. ,16.0
721,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,Pregnant or breastfeeding woman.,16.0
722,NCT01402986,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Pregnant or breastfeeding women,16.0
723,NCT00634036,Phase 2,Asthma,Fernando Holguin,10-Feb-15,Asthma,Pregnant or lactating,16.0
724,NCT00787644,Phase 2,Asthma;Obesity,University of Vermont,10-Feb-15,Asthma,Pregnant or lactating,16.0
725,NCT02918019,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,"Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A",16.0
726,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,Pregnant or lactating female,16.0
727,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Pregnant or lactating females;,16.0
728,NCT01478152,Phase 2,Asthma,Bitop AG,10-Feb-15,Asthma,Pregnant or lactating females,16.0
729,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Pregnant or lactating females or not able to exclude pregnancy during the study period;,16.0
730,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Pregnant or lactating females; pregnancy as determined by positive pregnancy test at screening or prior to dosing. ,16.0
731,NCT00327808,Phase 2,Asthma,Pharmaxis,10-Feb-15,Asthma,Pregnant or lactating or have positive plasma pregnancy test,16.0
732,NCT01225315,Phase 2,Asthma,Idorsia Pharmaceuticals Ltd.,10-Feb-15,Asthma,Pregnant or lactating women,16.0
733,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Pregnant or lactating women,16.0
734,NCT01516073,Phase 2,Asthma,Dey,10-Feb-15,Asthma,Pregnant or lactating women,16.0
735,NCT01516086,Phase 2,Asthma,Dey,10-Feb-15,Asthma,Pregnant or lactating women,16.0
736,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Pregnant or lactating women,16.0
737,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Pregnant or lactating women,16.0
738,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Pregnant or lactating women,16.0
739,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Pregnant or lactating women,16.0
740,NCT02127866,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Pregnant or lactating women,16.0
741,NCT02296411,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Pregnant or lactating women,16.0
742,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Pregnant or likely to become pregnant during the study,16.0
743,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Pregnant or nursing (lactating) females,16.0
744,NCT01836471,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Pregnant or nursing (lactating) women,16.0
745,NCT04410523,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Pregnant or nursing (lactating) women,16.0
746,NCT00403754,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Pregnant or nursing (lactating) women.,16.0
747,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,Pregnant or nursing (lactating) women.,16.0
748,NCT04946318,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Pregnant or nursing (lactating) women. ,16.0
749,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,Pregnant or nursing (lactating) women. Asthma patients:,16.0
750,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Pregnant or nursing women or women intending to conceive during the course of the study or have a positive serum pregnancy test at Screening or a positive urine pregnancy test during the study.,16.0
751,NCT00501527,Phase 2,"Rhinitis, Allergic, Seasonal;Conjunctivitis, Allergic;Asthma","Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal;Conjunctivitis;Conjunctivitis, Allergic",Pregnant or/ in lactation patients,16.0
752,NCT00280683,Phase 2,Asthma,"University of California, Davis",10-Feb-15,Asthma,"Pregnant women, nursing women, or women actively trying to achieve pregnancy",16.0
753,NCT01930461,Phase 2,Asthma;House Dust Mite Allergy,Stallergenes Greer,10-Feb-15,Asthma,Pregnant women or breast-feeding/lactating.,16.0
754,NCT04046939,Phase 2,Eosinophilic Asthma;Asthma,Knopp Biosciences,10-Feb-15,Asthma;Pulmonary Eosinophilia,Pregnant women or women breastfeeding,16.0
755,NCT01795742,Phase 2,Asthma,Marquette University,10-Feb-15,Asthma,Pregnant women or women who may think they might be pregnant,16.0
756,NCT01902290,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,"Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study",16.0
757,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"The participant is a pregnant or lactating woman, or plans to become pregnant during the study.",16.0
758,NCT04545385,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,The participant is currently pregnant or lactating or is planning to become pregnant during the study.,16.0
759,NCT01393340,Phase 2,Nasal Polyposis;Asthma,"University Hospital, Ghent",10-Feb-15,Colorectal Neoplasms;Nasopharyngeal Neoplasms;Asthma;Nasal Polyps,"Women must not be pregnant, breast feeding, or premenarcheal.",16.0
760,NCT01132781,Phase 2,Rhinosinusitis;Asthma;Allergic Rhinitis,University of East Anglia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",Women who are pregnant or breast feeding,16.0
761,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Women who are pregnant or lactating or are planning to become pregnant during the study.,16.0
762,NCT00556673,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result,17.0
763,NCT00605306,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.,17.0
764,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"A positive hepatitis B surface antigen, or hepatitis C virus antibody",17.0
765,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"A positive hepatitis B surface antigen, or hepatitis C virus antibody, as determined by medical history and/or subject's verbal report",17.0
766,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive Hepatitis B surface antigen or positive Hepatitis C antibody and/or HIV,17.0
767,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,a positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result,17.0
768,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening,17.0
769,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening,17.0
770,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.,17.0
771,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.,17.0
772,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.,17.0
773,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within three months of screening.,17.0
774,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive test for Hepatitis B or Hepatitis C antibody.,17.0
775,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,A positive test for Hepatitis B or Hepatitis C within 3 months of screening.,17.0
776,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,"Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening",17.0
777,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,Chronic hepatitis (either viral (e.g. hepatitis B or C) or autoimmune),17.0
778,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,"Confirmed or suspected current infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)",17.0
779,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Confirmed positive test for HIV or hepatitis B or C,17.0
780,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,Diagnosis of Hepatitis B or C,17.0
781,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active infection with hepatitis A;",17.0
782,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active infection with hepatitis A;",17.0
783,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus-1 or -2 (HIV-1 or HIV-2), or active infection with hepatitis A;",17.0
784,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Evidence of infection with hepatitis B or C virus or HIV-1 or HIV-2, or active infection with hepatitis A; must have negative HIV-1, HIV-2, hepatitis A, B, and C tests at screening;",17.0
785,NCT02449473,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Hepatitis B, C or HIV",17.0
786,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"History of a positive test for HIV, hepatitis B or hepatitis C infection",17.0
787,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"History of a positive test for HIV, hepatitis B or hepatitis C infection",17.0
788,NCT04410523,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients with a history of immunodeficiency disease or hepatitis B or hepatitis C or HIV. ,17.0
789,NCT02479412,Phase 2,Asthma;Efficacy;Safety,AstraZeneca,10-Feb-15,Asthma,"Patients with hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus (HIV)",17.0
790,NCT04150341,Phase 2,Asthma,Theravance Biopharma,10-Feb-15,Asthma,"Positive for hepatitis A, B or C, HIV or tuberculosis",17.0
791,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Positive Hepatitis B surface Ag (active infection) or Hepatitis B core total antibody (marker of past infection that could reactivate),17.0
792,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,"Positive hepatitis B surface antigen, or hepatitis C virus antibody serology",17.0
793,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,"Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to be enrolled.",17.0
794,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,"Positive hepatitis B surface antigen, or positive hepatitis C virus antibody serology or a known medical history of hepatitis B or C.",17.0
795,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Positive Hepatitis B Surface Antigen or positive Hepatitis C antibody at Visit,17.0
796,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Positive hepatitis C (Hep C) test result at screening or within 3 months prior to first dose of study treatment. ,17.0
797,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Positive Hepatitis C RNA test following positive Hepatitis C Antibody,17.0
798,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,Positive hepatitis viral antigens or antibodies,17.0
799,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody within 3 months of screening.",17.0
800,NCT02054130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Positive medical history for hepatitis B or C,17.0
801,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enrol,17.0
802,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,Positive results in any of the virology tests of acute or chronic infectious human immunodeficiency virus (HIV) and hepatitis B/C virus infections,17.0
803,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,"Positive screen on hepatitis B surface antigen, antibodies to the hepatitis C virus or antibodies to the human immunodeficiency virus (HIV 1 and 2).",17.0
804,NCT03745196,Phase 2,Asthma;Respiratory Candidiasis;Respiratory Aspergillosis;COPD;Bronchiectasis,Pulmocide Ltd,10-Feb-15,Candidiasis;Aspergillosis;Asthma;Bronchiectasis;Respiration Disorders;Respiratory Tract Diseases,"Positive test at screening for hepatitis B virus infection, or antibodies to hepatitis C virus",17.0
805,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,"Positive test for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV) at Screening.",17.0
806,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Positive test for hepatitis C antibody or hepatitis B surface antigen.,17.0
807,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,"Positive test for serum hepatitis B surface antigen, hepatitis C antibody, or HIV",17.0
808,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at Screening (Visit 1) or within 3 months prior to first dose of study treatment.",17.0
809,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment",17.0
810,NCT03393806,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.",17.0
811,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Presence of hepatitis B surface antigen (HbsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.",17.0
812,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Presence of hepatitis B surface antigen (HBsAg) or core antigen (HBcAg). Subjects who are HBsAg negative, but hepatitis core antigen positive may be included if they are polymerase chain reaction (PCR) negative for Hepatitis B deoxyribonucleic acid (DNA).",17.0
813,NCT00400855,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Test positive at the screening visit for hepatitis B or C or HIV ,17.0
814,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"The participant has known history of, or a positive test result for, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies (Ab), or human immunodeficiency virus (HIV) Types 1 or 2 Ab (according to 4th generation serology testing).",17.0
815,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen,17.0
816,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.,17.0
817,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.,17.0
818,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Viral hepatitis B surface antigen or Hepatitis C antibody,17.0
819,NCT00404313,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Recent history of heart problems within the past 3 months,18.0
820,NCT00482898,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,You have a history of heart problems in the last 6 months,18.0
821,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,"Acceptable contraception procedures are oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, or use of a condom with spermicide by the sexual partner.",19.0
822,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Career, lifestyle, or sexual orientation precludes intercourse with a male partner",19.0
823,NCT00530166,Phase 2,Asthma,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",10-Feb-15,Asthma,Female of child bearing potential. ,19.0
824,NCT00801853,Phase 2,Asthma,"Aerovance, Inc.",10-Feb-15,Asthma,"Female patient is pregnant, breastfeeding, or not using an adequate method of contraception",19.0
825,NCT01902290,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile,19.0
826,NCT02367313,Phase 2,Asthma,"Biota Pharmaceuticals, Inc.",10-Feb-15,Infections,"Female subjects must not be pregnant or breastfeeding. Females of childbearing potential must be willing to utilize a double barrier method of contraception, as defined in this protocol, regardless of any hormonal contraception they may be concomitantly receiving",19.0
827,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Female subjects of childbearing potential (CBP) who are not using reliable contraception (e.g., abstinence, double barrier method, oral/implantable/transdermal contraception, Depo-Provera, intrauterine device, having one male sexual partner who has undergone vasectomy); a woman is of CBP unless she is premenarchal, is at least 2 years postmenopausal, is without a uterus and/or both ovaries, has had a bilateral tubal ligation, or has undergone the Essure procedure with confirmation of tubal blockage. [Note: If a female is identified as less than 2 years postmenopausal, a serum follicle-stimulating hormone (FSH) determination will be performed as a part of screening laboratory assessments. If an FSH result of < 40 mIU/mL is obtained, the female will be determined to be of CBP and her unwillingness to use reliable contraception as defined above will be exclusionary for the study.]",19.0
828,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Female subjects on hormone replacement therapy or hormonal contraceptives,19.0
829,NCT02388997,Phase 2,Asthma,University of Virginia,10-Feb-15,Infections;Asthma,"Female subjects who are, or who plan to become, pregnant during the study, or who are nursing a baby. Additionally, to be included in this study, a woman of child-bearing potential must have a negative urine pregnancy test at screening, during the run, and prior to viral inoculation and agree to use an effective method of birth control such as, but not limited to, birth control pills, contraceptive foam, diaphragm, intra uterine device (IUD), abstinence, or condoms.",19.0
830,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,Females of child bearing potential unless using birth control,19.0
831,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,"Females of childbearing age who do not agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.",19.0
832,NCT00605306,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,"Females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception (surgical contraception or double barrier methods (to be continued for at least two months following last dose) are acceptable).",19.0
833,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Females of childbearing potential not willing to use acceptable contraceptive methods such as hormonal contraceptives (oral, injection or implant) or intrauterine contraceptive devices or who started such methods less than 2 months prior to screening or who are not willing to use a double barrier method of contraception (diaphragm plus condom)",19.0
834,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"For those in a monogamous relationship that precludes sexual activity with other partners, one of the sexual partners has been sterilized by vasectomy (in males) or hysterectomy and/or bilateral salpingo-oophorectomy (in females)",19.0
835,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,"hormonal contraception (implantable, patch, oral)",19.0
836,NCT03745196,Phase 2,Asthma;Respiratory Candidiasis;Respiratory Aspergillosis;COPD;Bronchiectasis,Pulmocide Ltd,10-Feb-15,Candidiasis;Aspergillosis;Asthma;Bronchiectasis;Respiration Disorders;Respiratory Tract Diseases,"If female, the subject is pregnant (e.g. has a positive serum β human chorionic gonadotropin at screening or a positive urinary pregnancy test pre-dose on Day 1), lactating or breast feeding",19.0
837,NCT02947945,Phase 2,Asthma,National Jewish Health,10-Feb-15,Granulomatosis with Polyangiitis;Systemic Vasculitis;Churg-Strauss Syndrome,"If female and of child-bearing potential, must have negative pregnancy test and must adhere to acceptable method of contraception (with <1% failure rate) during the study and for four months after the study.",19.0
838,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,"If female and of child-bearing potential, must have negative pregnancy test and must adhere to acceptable method of contraception (with <1% failure rate) during the study and for four months after the study.",19.0
839,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,"If of child bearing potential, failure to practice abstinence or use of an acceptable birth control method.",19.0
840,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,"Is currently pregnant or lactating, or plans to become pregnant during the time of study participation --Note: Females of child-bearing potential (post-menarche) must be abstinent or use a medically acceptable birth control method throughout the study (e.g. oral subcutaneous, mechanical, or surgical contraception).",19.0
841,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,"Non-surgically sterile males and males with partners of childbearing potential not willing to use a condom with spermicide for the duration of their participation in the study plus an additional 30 days following study drug administration and to ensure that their partner is using a highly effective method of birth control such as combined oral contraceptives, implants, injectables or an IUD.",19.0
842,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,other forms of effective contraception including placement of an intrauterine device (IUD) or intrauterine system (IUS) or barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal cream/foam/gel/ suppository,19.0
843,NCT00930163,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Patients (men and women) of reproductive potential who are not willing to use contraception,19.0
844,NCT00971035,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Patients (men and women) of reproductive potential who are not willing to use contraception,19.0
845,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,"Pregnancy, breast-feeding, planned pregnancy during the study, or women of child-bearing potential not using adequate contraception. These methods include total abstinence (no sexual intercourse), oral contraceptives, an intrauterine device (IUD), an etonogestrel implant (Implanon), or medroxyprogesterone acetate injections (Depo-Provera shots). If one of these cannot be used, using contraceptive foam and a condom are recommended. Lack of suitability for the study:",19.0
846,NCT00292877,Phase 2,Asthma,St. Joseph's Healthcare Hamilton,10-Feb-15,Asthma,"Pregnancy, breast-feeding or lack of effective contraception in females of childbearing potential or females who are postmenopausal <1 year",19.0
847,NCT00815347,Phase 2,Asthma,UConn Health,10-Feb-15,Asthma,"Pregnancy, breast feeding or the use of hormonal methods of birth control as the only means of birth control during the study.",19.0
848,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Pregnant (as evident by a positive urine hCG or serum β-hCG test) or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS they are willing to use a highly effective birth control method,19.0
849,NCT01650441,Phase 2,Asthma,"University Hospital, Antwerp",10-Feb-15,Asthma,Pregnant or lactating females or females at risk of pregnancy at screening and not willing to use an appropriate contraception method during the study period,19.0
850,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Pregnant or lactating women and all women physiologically capable of becoming pregnant not willing to use at least one acceptable method of contraception.,19.0
851,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Pregnant or lactating women and all women physiologically capable of becoming pregnant UNLESS they are willing to use a highly effective birth control methods,19.0
852,NCT00868023,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they are menopausal or are using effective and acceptable methods of contraception.,19.0
853,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea or are using one or more of the following acceptable methods of contraception.,19.0
854,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,"Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)",19.0
855,NCT01437735,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/mL).",19.0
856,NCT00545272,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Pregnant women, nursing mothers, or females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception.",19.0
857,NCT00557440,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,"Pregnant women, nursing mothers, or females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception.",19.0
858,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"Unwillingness or inability to use a highly effective method of birth control by women of childbearing potential. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner. Barrier methods of contraception are accepted if condom or occlusive cap is used together with spermicides (e.g., foam or gel). Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy, or post-menopausal for at least two years",19.0
859,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Unwillingness to practice medically acceptable birth control or complete abstinence during the study, current pregnancy, or lactation. Medically acceptable birth control/abstinence is defined as:",19.0
860,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,"Unwillingness to use reliable contraception if sexually active (IUD, birth control pills/patch, condoms)",19.0
861,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,"Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during the study treatment and for 5 days (5 half-lives) after treatment",19.0
862,NCT04410523,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using specified methods of contraception during dosing of study drug and one week after last study drug treatment",19.0
863,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,"Women of child-bearing potential, unless they are surgically sterile (i.e. bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), are at least 2 years postmenopausal, practice abstinence, or agree to employ effective contraception from Visit 1 through Visit",19.0
864,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Women of child-bearing potential, unless they are surgically sterile (i.e. bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), are at least 2 years postmenopausal, practice abstinence, or agree to employ effective contraception from Visit 1 through final visit. Acceptable contraception procedures are oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, or use of a condom with spermicide by the sexual partner",19.0
865,NCT01479595,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Women of child-bearing potential must use highly effective methods of contraception during dosing and for at least 18 weeks after last study drug administration ,19.0
866,NCT03299686,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Women of child-bearing potential unless they use highly effective methods of contraception during dosing and for 13 weeks after stopping of investigational drug. ,19.0
867,NCT01478360,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Women of child-bearing potential unwilling to use effective contraception during the study and for 16 weeks after stopping treatment.,19.0
868,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,"Women of childbearing potential (unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years) not using a highly effective method of birth control.",19.0
869,NCT00452400,Phase 2,"Pulmonary Disease, Chronic Obstructive;Asthma",Boehringer Ingelheim,10-Feb-15,"Pulmonary Disease, Chronic Obstructive",Women of childbearing potential not using a highly effective method of birth control,19.0
870,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Women of childbearing potential not using a highly effective method of birth control. ,19.0
871,NCT00467740,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"Women of childbearing potential not using a highly effective method of birth control. Female patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation, or post-menopausal for at least 2 years",19.0
872,NCT00634036,Phase 2,Asthma,Fernando Holguin,10-Feb-15,Asthma,Women of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study ,19.0
873,NCT00787644,Phase 2,Asthma;Obesity,University of Vermont,10-Feb-15,Asthma,Women of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study ,19.0
874,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,Women of childbearing potential who are documented to be pregnant (based on blood beta-human chorionic gonadotropin [HCG] testing) or who are nursing.,19.0
875,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Women of childbearing potential who are unwilling or unable to use an appropriate method of contraception from at least two weeks prior to the first dose of study medication; and to continue until the final pregnancy test has been performed (not less than 150 hours after treatment,19.0
876,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Women of childbearing potential who are unwilling to use an acceptable method of birth control,19.0
877,NCT01930461,Phase 2,Asthma;House Dust Mite Allergy,Stallergenes Greer,10-Feb-15,Asthma,Women with childbearing potential who are not using a medically accepted birth control method.,19.0
878,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,A history of known immunodeficiency disorder (including HIV-1 or HIV-2).,20.0
879,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.,20.0
880,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A known immunodeficiency such as human immunodeficiency virus infection.,20.0
881,NCT03393806,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A known immunodeficiency such as human immunodeficiency virus infection.,20.0
882,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,A positive human immunodeficiency virus (HIV) test,20.0
883,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,A positive human immunodeficiency virus (HIV) test or subject taking antiretroviral medications,20.0
884,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,"A positive human immunodeficiency virus test or is taking anti-retroviral medications, as determined by medical history and/or subject's verbal report.",20.0
885,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"A positive human immunodeficiency virus test or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report",20.0
886,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"A positive human immunodeficiency virus test or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report",20.0
887,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive test for Human Immunodeficiency Virus (HIV) antibody,20.0
888,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,A positive test for Human Immunodeficiency Virus (HIV) antibody.,20.0
889,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive test for human immunodeficiency virus (HIV) antibody. Other Criteria,20.0
890,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Autoimmune disease or immunodeficiency,20.0
891,NCT00318747,Phase 2,"Asthma;Allergy;Allergic Rhinitis;Rhinitis, Allergic, Seasonal",National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Chronic immunodeficiency ,20.0
892,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,"concurrent immunodeficiency (human immunodeficiency [HIV], or acquired immunodeficiency syndrome [AIDS] or congenital immunodeficiency).",20.0
893,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,Diagnosis of immunodeficiency requiring treatment,20.0
894,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Has a known immunodeficiency disease;,20.0
895,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Has severe immunological diseases (eg, multiple sclerosis, systemic lupus erythematosus, progressive multifocal leukoencephalopathy) or known infection with human immunodeficiency virus (HIV)",20.0
896,NCT01402986,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Hepatitis B, C or Human Immuno-deficiency Virus (HIV)",20.0
897,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,"History of, or known significant infection or positivity at screening, including hepatitis B or C, human immunodeficiency virus (HIV), tuberculosis.",20.0
898,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of any known immunodeficiency disorder,20.0
899,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of any known immunodeficiency disorder,20.0
900,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,History of any known immunodeficiency disorder,20.0
901,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,History of any known immunodeficiency disorder.,20.0
902,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of any known primary immunodeficiency disorder,20.0
903,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,History of any known primary immunodeficiency disorder,20.0
904,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,history of human immunodeficiency virus (HIV);,20.0
905,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,History of human immunodeficiency virus (HIV),20.0
906,NCT00605306,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,"History of immunocompromise, including a positive human immunodeficiency virus (HIV)",20.0
907,NCT00556673,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,"History of immunodeficiency diseases, including a positive human immumodeficiency virus (HIV) test result.",20.0
908,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,"History of immunodeficiency diseases, including HIV",20.0
909,NCT00512863,Phase 2,Asthma,Abbott,10-Feb-15,Asthma,"History of listeria, human immunodeficiency virus (HIV), chronic or active Hepatitis B, an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease or active TB",20.0
910,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of primary immunodeficiency;,20.0
911,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of primary immunodeficiency;,20.0
912,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of primary immunodeficiency;,20.0
913,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of primary immunodeficiency,20.0
914,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of primary immunodeficiency,20.0
915,NCT00946569,Phase 2,Asthma,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",10-Feb-15,Asthma,Human Immunodeficiency Virus (HIV) or Hepatitis B or C positive ,20.0
916,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Human Immunodeficiency Virus (HIV) positive or determined to be HIV positive at screening, testing to be conducted in accordance with local practice.",20.0
917,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Infection with human immunodeficiency virus (HIV)-1, HIV-2, or hepatitis A, B, or C virus",20.0
918,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Known history of severe clinically significant immunodeficiency,20.0
919,NCT00995800,Phase 2,Asthma,Mundipharma Research Limited,10-Feb-15,Asthma;Inflammation,Known Human Immunodeficiency Virus (HIV)-positive status,20.0
920,NCT00930163,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Known immunodeficiency,20.0
921,NCT00971035,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Known immunodeficiency,20.0
922,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Known immunodeficiency,20.0
923,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Known immunodeficiency, including, but not limited to, HIV infection",20.0
924,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Known immunodeficiency, including, but not limited to, HIV infection",20.0
925,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,"Known immunodeficiency, including, but not limited to, human immunodeficiency virus (HIV) infection",20.0
926,NCT01582503,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Known immunodeficiency, including but not limited to HIV infection, regardless of treatment status",20.0
927,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Known positive for Human Immunodeficiency Virus (HIV) antibody.,20.0
928,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Positive Human Immunodeficiency Virus, Types 1 & 2 (HIV 1&2) Ab/Ag immunoassay followed by a confirmatory positive test (Geenius™ HIV-1/HIV-2 antibody differentiation immunoassay)",20.0
929,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Positive serology for an infectious disease (including hepatitis B or C) at screening and known case of human immunodeficiency virus [HIV],20.0
930,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Subject is known to be human immunodeficiency virus (HIV) positive.,20.0
931,NCT02054130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Subject with human immunodeficiency virus (HIV) or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report. ",20.0
932,NCT01393340,Phase 2,Nasal Polyposis;Asthma,"University Hospital, Ghent",10-Feb-15,Colorectal Neoplasms;Nasopharyngeal Neoplasms;Asthma;Nasal Polyps,Subjects must not have a medical history of Human Immunodeficiency Virus (HIV) or hepatitis B or C. Testing will not be done at screening.,20.0
933,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with a known immunodeficiency (e.g. human immunodeficiency virus - HIV).,20.0
934,NCT04617171,Phase 2,Asthma Attack;Asthma,Singapore General Hospital,10-Feb-15,Asthma,Subjects with history of primary immunodeficiency,20.0
935,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has tested positive for Human Immunodeficiency Virus ev1(HIV) antibodies.,20.0
936,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,"Administration of any investigational drug or implantation of investigational device, or participation in another trial, within 30 days of screening.",21.0
937,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",An investigational drug within 1 month or six half lives (whichever is greater),21.0
938,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Any investigational drug taken within 30 days or six half-lives (whichever is greater) prior to Visit 2,21.0
939,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Any investigational drug within 30 days or 5 terminal half-lives, whichever is longer",21.0
940,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,"Current participation in another clinical trial or participation in a clinical trial where the patient has received a dose of a test product (IMP) within 12 weeks prior to entry into the study for small molecules and within 12 months prior to entry into the study for biologicals, or 5 times the half-life (whichever is the longest) of the biologic or small molecule IMP",21.0
941,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,Enrolled in any clinical medication trial within the past 30 days,21.0
942,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Exposure to more than 4 investigational medicinal products within 12 months prior to the first dosing day ,21.0
943,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Exposure to more than 4 investigational medicinal products within 12 months prior to the first dosing day.,21.0
944,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Exposure to more than four new chemical entities within 12 months prior to the first dosing day,21.0
945,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Has received any investigational compound within 30 days prior to the start of the clinical trial or has participated in the active treatment phase of another clinical trial where a persisting pharmacodynamic effect of the trial treatment of that clinical trial cannot be excluded (eg, participant is well into a treatment free follow-up phase)",21.0
946,NCT00688467,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Has used any investigational drug within 30 days or 5 half-lives of Screening.,21.0
947,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,"Have been treated with any investigational drug within the previous 3 months or within 5 half-lives, whichever is greater",21.0
948,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Have used any prescription or over-the-counter medication, vitamin or herbal supplement (except as listed in Inclusion Criterion 7 and Exclusion Criterion 7-10) within 7 days of study entry, or the expected need to use any unapproved prescription or over-the-counter medication or supplement seven days prior to the first study visit until completion of the study;",21.0
949,NCT02271334,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Having been on other clinical drug/device studies or donated blood in the last 30 days prior to Screening. ,21.0
950,NCT01255709,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Having been on other investigational drug/device studies, or donated blood, in the last 30 days prior to Screening;",21.0
951,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Having received an investigational drug within 1 month before the screening visit,21.0
952,NCT01584492,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Having received an investigational drug within 2 months before the current study.,21.0
953,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Having received an investigational medicinal drug within 30 days prior to study entry,21.0
954,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Investigational Medications: A subject must not have participated in a study or used any investigational drug within 30 days prior to Visit,21.0
955,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Investigational medications: Participation in a study or used investigational drug within 30 days,21.0
956,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,Participant in an interventional drug study or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study ,21.0
957,NCT02148796,Phase 2,Asthma;Wheezing,University of Arizona,10-Feb-15,Respiratory Sounds,"Participant is currently enrolled in or has completed any other investigational device or drug study <30 days prior to screening, or is receiving other investigational agent(s).",21.0
958,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,Participants who have participated in another research trial involving an investigational product in the past 4 weeks or 5 half-lives prior to visit 2,21.0
959,NCT00697801,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,Participated in any investigational clinical trial within the 30 days prior to screening.,21.0
960,NCT01899144,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Participation (receiving study medication) in any investigational drug trial within the 30 days preceding the screening visit or planned participation in another investigational drug trial at any time during this trial,21.0
961,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,participation in a clinical study involving an investigational drug within past ≤4 weeks,21.0
962,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,participation in a clinical trial involving an investigational drug within 4 weeks prior to Screening Visit;,21.0
963,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Participation in a study with a new molecular entity during the previous 3 months or 5 half-lives (whichever is longer), or participation in a study without a new molecular entity during the previous month or 5 half-lives (whichever is longer), prior to the first dose of study medication.",21.0
964,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Participation in an investigational drug trial during 30 days preceding screening ,21.0
965,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Participation in another clinical study within 1 month prior to or during this study,21.0
966,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,Participation in another clinical trial with an investigational drug or device within the last month or within 10 times the half-life of the respective drug. For biologics the minimum period is at least 6 months or the time of duration of the pharmacodynamic effect or 10 times the half-life of the respective drug before inclusion in this trial,21.0
967,NCT02230189,Phase 2,Asthma,Prescott Woodruff,10-Feb-15,Asthma,Participation in another research study involving a drug or biologic during the past 30 days,21.0
968,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,participation in any investigational drug or device study within 30 days prior to study entry,21.0
969,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Participation in any investigational drug study within the 30 days (starting at the final follow-up visit) preceding the Screening Visit or planned participation in another investigational drug study at any time during this study,21.0
970,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Participation in any investigational drug study within the 30 days (starting at the final follow-up visit) preceding the Screening Visit or planned participation in another investigational drug study at any time during this study,21.0
971,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,"Participation in any other investigational drug study within the preceding 30 days or 5 half-lives of that drug, whichever is longer at the time of Visit 2",21.0
972,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,participation in biologics study within 3 months prior to study entry,21.0
973,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,Participation in research study involving a drug or biologic during the 30 days prior to the study.,21.0
974,NCT01502371,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Participation in this study at another investigational site. Participation in a different investigational study at any site during the same time frame of this study.,21.0
975,NCT00801853,Phase 2,Asthma,"Aerovance, Inc.",10-Feb-15,Asthma,Patient has participated in any clinical trial involving use of an investigational drug within 12 weeks of first dose of study drug. ,21.0
976,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,Patient who received any investigational new drug within the last 4 weeks prior to visit 1 and is participating in any clinical trial,21.0
977,NCT00452400,Phase 2,"Pulmonary Disease, Chronic Obstructive;Asthma",Boehringer Ingelheim,10-Feb-15,"Pulmonary Disease, Chronic Obstructive",Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1),21.0
978,NCT00467740,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1),21.0
979,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Patients who received any investigational drug within the last 8 weeks before the screening;,21.0
980,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Patients who received any investigational new drug within the last 3 months at enrollment;,21.0
981,NCT01650441,Phase 2,Asthma,"University Hospital, Antwerp",10-Feb-15,Asthma,Patients who received any investigational new drug within the last 4 weeks prior to the screening visit,21.0
982,NCT01370031,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Patients who received any investigational new drug within the last 8 weeks before the screening. The patients cannot participate in another clinical study at the same time as the present study.,21.0
983,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Positive for use of investigational drugs within 4 weeks of randomization;,21.0
984,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Previous Participation: Exposure to more than four new chemical entities within 12 months prior to the first dosing day.,21.0
985,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,Receipt of a drug or biologic in an investigational research study within the 30 days prior to the Screening Visit,21.0
986,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Receipt of any investigational drug or biological therapy within 3 months before randomization in this study, or within 5 half-lives of the investigational agent, whichever is longer. Subjects ever treated with omalizumab or other biological therapies for asthma are not eligible",21.0
987,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,"Receipt of any investigational drug therapy or biologicals within 3 months before randomization in this study, or within 5 half-lives of the investigational agent or biologic, whichever is longer.",21.0
988,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Receipt of any investigational drug therapy or use of any biologicals including omalizumab within 6 months before the first dose of investigational product in this study or within 5 half-lives of an investigational agent or biologic, whichever is longer",21.0
989,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to screening;,21.0
990,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to study drug administration through Study Day 126;,21.0
991,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to the first dose of study drug through Study Day 150;,21.0
992,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to the first dose of study drug through Study Day 150;,21.0
993,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of any investigational drug therapy within 30 days prior to randomization into the study or any biologic(s) within 5 half-lives of the agent prior to randomization into the study,21.0
994,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of any investigational drug therapy within 6 months before the first dose of investigational product in this study through Day 168,21.0
995,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,"Receipt of any investigational non biologic within 30 days or 5 half-lives prior to visit 0, whichever is longer.",21.0
996,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to screening, whichever is longer",21.0
997,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Receipt of any marketed or investigational biologic within 4 months or 5 half-lives prior to screening, whichever is longer",21.0
998,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of any non-biological study drugs or interventional therapy (including surgical procedures) within 28 days of the first dose of investigational product in this study,21.0
999,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject participated in an investigational drug study within 30 days prior to screening, or was currently participating in another clinical trial.",21.0
1000,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,"Subject who has participated in an investigational drug study within 30 days of study start, or who is currently participating in another clinical trial.",21.0
1001,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject who has participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another clinical trial.",21.0
1002,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject who has participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another clinical trial.",21.0
1003,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject who has participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another clinical trial.",21.0
1004,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,Subjects dosed with an investigational drug within 30 days prior to the Screening Visit,21.0
1005,NCT04617171,Phase 2,Asthma Attack;Asthma,Singapore General Hospital,10-Feb-15,Asthma,Subjects who are already on investigational drug or has been participating in another clinical study with an investigational product during the last 6 months,21.0
1006,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects who have previously participated in a study of mepolizumab and received study medication within 90 days prior to screening.,21.0
1007,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Subjects who have received an investigational drug within 1 month or 5 half-lives (whichever is greater) prior to screening visit, or have been previously randomized in this trial, or are currently participating in another clinical trial.",21.0
1008,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Subjects who have received an investigational drug within 1 month or 5 half-lives (whichever is greater) prior to screening visit, or have been previously randomized in this trial, or are currently participating in another clinical trial.",21.0
1009,NCT02153541,Phase 2,Asthma,Global United Pharmaceutical Corporation,10-Feb-15,Asthma,Subjects who have received any investigational drug for asthma in the past 60 days ,21.0
1010,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,"Subjects who have received any investigational drug in any clinical trial within 3 months, or who are on extended follow-up.",21.0
1011,NCT03745196,Phase 2,Asthma;Respiratory Candidiasis;Respiratory Aspergillosis;COPD;Bronchiectasis,Pulmocide Ltd,10-Feb-15,Candidiasis;Aspergillosis;Asthma;Bronchiectasis;Respiration Disorders;Respiratory Tract Diseases,"Subjects who have used an experimental medical device or received an experimental drug within 3 months or within a period less than five times the experimental drug's half-life, whichever is longer, before the first dose of the study drug is scheduled",21.0
1012,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Taking any drugs or substances known to be strong inducers of cytochrome P450 enzymes within 28 days of study entry, or the expected need to use such drugs prior to completion of the study;",21.0
1013,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Taking any drugs or substances known to be strong inhibitors of cytochrome P450 enzymes within 10 days of study entry, or the expected need to use such drugs ten days prior to the first study visit until after completion of the study;",21.0
1014,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). ",21.0
1015,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,The participant has participated in another study of an IMP (or a medical device) within the previous 30 days or is currently participating in another study of an IMP (or a medical device).,21.0
1016,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication",21.0
1017,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has participated in a clinical trial and has received an investigational product (IP) within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).",21.0
1018,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has participated in a clinical trial and has received an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).",21.0
1019,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,The subject has participated in a clinical trial and has received an investigational product within 30 days prior to the first dosing day in the current study.,21.0
1020,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).",21.0
1021,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).",21.0
1022,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"the subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)",21.0
1023,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)",21.0
1024,NCT01128569,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months,21.0
1025,NCT01128595,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months,21.0
1026,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months prior to the first dosing day,21.0
1027,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months prior to the first dosing day.,21.0
1028,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months prior to the first dosing day.,21.0
1029,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months prior to the first dosing day.,21.0
1030,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has received an investigational drug within 30 days or 5-half-lives (whichever is longer) prior to the first dose of study drug.,21.0
1031,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has received an investigational medicinal product within 30 days or, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). Use of a biologic (e.g. monoclonal antibodies) agent for the treatment of asthma in the past 6 months.",21.0
1032,NCT00614874,Phase 2,Asthma,Creighton University,10-Feb-15,Asthma,"Treatment with an experimental, non-approved drug, or investigational drug within the past 30 days",21.0
1033,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,"Treatment with an investigational agent within 30 days of informed consent or 5 half-lives of the investigational agent, whichever is longer",21.0
1034,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Treatment with any investigational drug in the last 30 days before enrollment into the study (Visit 1),21.0
1035,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,"Treatment with any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the beginning of dosing (this includes investigational formulations of marketed products, inhaled and topical drugs",21.0
1036,NCT01516086,Phase 2,Asthma,Dey,10-Feb-15,Asthma,Use of an investigational drug or device within 30 days prior to screening ,21.0
1037,NCT01516073,Phase 2,Asthma,Dey,10-Feb-15,Asthma,Use of an investigational drug or device within 30 days prior to screening. ,21.0
1038,NCT00995800,Phase 2,Asthma,Mundipharma Research Limited,10-Feb-15,Asthma;Inflammation,Use of an investigational drug within 30 days prior to the screening visit (12 weeks if an oral or injectable steroid),21.0
1039,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Use of an investigational product or participation in a clinical trial using an investigational product within 30 days before dosing or within 90 days in the case of long-acting products (ex.: Depo-medrol) or biologics with a long-acting half-life (ex.: monoclonal antibodies). ,21.0
1040,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Use of any investigational therapy or participation in another clinical study within 30 days prior to the study drug administration,21.0
1041,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer),21.0
1042,NCT02910401,Phase 2,Asthma;Allergic Rhinitis,University of Virginia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",Use of investigational drugs within 12 weeks of participation,21.0
1043,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,Use of investigational therapies or participation in trials 30 days before or during the study,21.0
1044,NCT01836471,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Use of other investigational drugs at the time of enrollment ,21.0
1045,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,"Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer",21.0
1046,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,"Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer",21.0
1047,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.",21.0
1048,NCT00746330,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,"Use of other investigational drugs at the time of enrolment, or within 30 days or 5 half-lives of enrolment, whichever is longer.",21.0
1049,NCT01478360,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Use of other investigational drugs at the time of screening, or within 30 days of screening.",21.0
1050,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,"Use of other investigational drugs at the time of screening, or within 5 half-lives of experimental drug at the time of screening, or within 30 days of last dose of experimental drug at the time of screening, whichever is longer; or longer if required by local regulations.",21.0
1051,NCT03683576,Phase 2,Asthma,"GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.",10-Feb-15,Asthma,"Use of other investigational drugs within 30 days, or within 5 half-lives, whichever is longer, prior to Screening Visit",21.0
1052,NCT03650400,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Use of other investigational drugs within 5 half-lives of enrollment, or (within 30 days (for small molecules)/until the expected pharmacodynamic effect has returned to baseline (for biologics)), whichever is longer.",21.0
1053,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Use of other investigational drugs within 5 half-lives of enrollment, or [within 30 days (for small molecules) /until the expected PD effect has returned to baseline (for biologics)], whichever is longer",21.0
1054,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,Use of other investigational therapy within 4 weeks or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening,21.0
1055,NCT00394914,Phase 2,Asthma;Common Cold;Picornavirus Infection;Rhinovirus,Merck Sharp & Dohme Corp.,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,Used any investigational drugs within 30 days of Screening.,21.0
1056,NCT00482898,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,You have been in a research study with an investigational drug or vaccine in the last 4 weeks,21.0
1057,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Breast-feeding,22.0
1058,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,Breast-feeding subject,22.0
1059,NCT00896428,Phase 2,Asthma,"University Hospital, Bordeaux",10-Feb-15,Asthma,Breastfeeding,22.0
1060,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,Breastfeeding,22.0
1061,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Breastfeeding or lactating,22.0
1062,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Breastfeeding or lactating woman;,22.0
1063,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Breastfeeding or lactating woman,22.0
1064,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Breastfeeding or lactating women,22.0
1065,NCT00557700,Phase 2,Asthma,"University Hospital, Ghent",10-Feb-15,Asthma,Female subjects who are lactating. ,22.0
1066,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,lactating females,22.0
1067,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Lactating females,22.0
1068,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,Lactating females.,22.0
1069,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Lactating females.,22.0
1070,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Lactating woman,22.0
1071,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Lactation (women),22.0
1072,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,Participant is currently breast feeding an infant,22.0
1073,NCT00318695,Phase 2,Eczema;Asthma;Allergic Rhinitis,"National University Hospital, Singapore",10-Feb-15,"Rhinitis;Rhinitis, Allergic;Eczema",The parents choose to totally breast-feed the child. ,22.0
1074,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,Women supplying lactation,22.0
1075,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,Women supplying lactation.,22.0
1076,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Women who are breastfeeding,22.0
1077,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Is a nursing mother at the time of study enrollment;,23.0
1078,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Pregnancy or nursing,23.0
1079,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,Pregnant females.,23.0
1080,NCT02947945,Phase 2,Asthma,National Jewish Health,10-Feb-15,Granulomatosis with Polyangiitis;Systemic Vasculitis;Churg-Strauss Syndrome,Pregnant or nursing,23.0
1081,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,Pregnant or nursing,23.0
1082,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Pregnant or nursing females,23.0
1083,NCT00320034,Phase 2,Asthma,Hamilton Health Sciences Corporation,10-Feb-15,Asthma;Inflammation,Pregnant or nursing females.,23.0
1084,NCT00526357,Phase 2,Asthma,Firestone Institute for Respiratory Health,10-Feb-15,Asthma;Inflammation,Pregnant or nursing females.,23.0
1085,NCT00452400,Phase 2,"Pulmonary Disease, Chronic Obstructive;Asthma",Boehringer Ingelheim,10-Feb-15,"Pulmonary Disease, Chronic Obstructive",Pregnant or nursing women,23.0
1086,NCT00467740,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Pregnant or nursing women,23.0
1087,NCT00556673,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Pregnant or nursing women,23.0
1088,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Pregnant or nursing women,23.0
1089,NCT01841281,Phase 2,Asthma;Inflammation,Nicholas Kenyon,10-Feb-15,Asthma;Inflammation,Pregnant or nursing women,23.0
1090,NCT00723021,Phase 2,Asthma,Pfizer,10-Feb-15,Asthma,Pregnant/nursing females.,23.0
1091,NCT02479412,Phase 2,Asthma;Efficacy;Safety,AstraZeneca,10-Feb-15,Asthma,Pregnant woman or a nursing mother,23.0
1092,NCT00605306,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Pregnant women or nursing mothers,23.0
1093,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,Pregnant women or nursing mothers,23.0
1094,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,Pregnant women or nursing mothers,23.0
1095,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,Pregnant women or nursing mothers,23.0
1096,NCT01123252,Phase 2,Seasonal Affective Rhinitis;Asthma;Grass Allergy,University of East Anglia,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",A history of hypersensitivity to the milk or its products,24.0
1097,NCT01516073,Phase 2,Asthma,Dey,10-Feb-15,Asthma,"A history of hypersensitivity to the study drug or its components, including albuterol as rescue medication",24.0
1098,NCT01516086,Phase 2,Asthma,Dey,10-Feb-15,Asthma,"A history of hypersensitivity to the study drug or its components, including albuterol as rescue medication",24.0
1099,NCT01650441,Phase 2,Asthma,"University Hospital, Antwerp",10-Feb-15,Asthma,"Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients",24.0
1100,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,"Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients;",24.0
1101,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,"Allergy, sensitivity or intolerance to study drugs or excipients;",24.0
1102,NCT00868023,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Allergy, sensitivity or intolerance to study drugs or excipients.",24.0
1103,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Allergy/intolerance to the excipients in the mepolizumab formulation,24.0
1104,NCT01453296,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any adverse reaction including immediate or delayed hypersensitivity to any betaagonist therapy.,24.0
1105,NCT01286844,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any adverse reaction including immediate or delayed hypersensitivity to any component of study drug,24.0
1106,NCT02947945,Phase 2,Asthma,National Jewish Health,10-Feb-15,Granulomatosis with Polyangiitis;Systemic Vasculitis;Churg-Strauss Syndrome,Any patients with a known hypersensitivity to reslizumab or any of its excipients ,24.0
1107,NCT03108027,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the drugs of a similar class",24.0
1108,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Contraindicated for treatment with, or having a history of reactions/hypersensitivity to any of the following inhaled drugs, drugs of a similar class, or any component there of:",24.0
1109,NCT00995800,Phase 2,Asthma,Mundipharma Research Limited,10-Feb-15,Asthma;Inflammation,"Current evidence or history of hypersensitivity or idiosyncratic reaction to test medications, rescue medication, or components",24.0
1110,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,Drug Allergy: Subjects who have a history of hypersensitivity to any component of the metered-dose inhaler (MDI) ,24.0
1111,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,"Have a history of any clinically significant adverse reaction to murine or chimeric proteins, including but not limited to allergic reactions",24.0
1112,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection,24.0
1113,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,"History of allergic reaction (known hypersensitivity) to albuterol sulfate and/or lactose, in any formulation",24.0
1114,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,History of allergic reactions to any active or inactive ingredients of the nebuliser solution,24.0
1115,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of allergy or adverse reactions to any component of the MEDI-528 formulation;,24.0
1116,NCT00320034,Phase 2,Asthma,Hamilton Health Sciences Corporation,10-Feb-15,Asthma;Inflammation,History of allergy or hypersensitivity to short-acting beta-agonists.,24.0
1117,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of allergy or reaction to any component of the investigational product formulation,24.0
1118,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of allergy or reaction to any component of the MEDI-528 formulation;,24.0
1119,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of allergy or reaction to any component of the study drug formulation;,24.0
1120,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,"History of any immediate or delayed hypersensitivity reaction to inhaled b2-agonists, lactose, milk-protein, or excipients (pMDI inhalers) any component of the formulations",24.0
1121,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,History of cutaneous adverse drug reaction to sulphonamides or signs or symptoms suggestive of anaphylaxis to sulphonamides.,24.0
1122,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,History of documented immune complex disease (Type III hypersensitivity reactions) to mAb administration,24.0
1123,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,"History of hypersensitivity to albuterol, or Xolair, or to drugs with similar chemical structures",24.0
1124,NCT03650400,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.,24.0
1125,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (CRTH2 antagonists),24.0
1126,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,History of hypersensitivity to any of the study treatments or excipients (such as milk or lactose) or to drugs of similar chemical classes (other DP2 antagonists such as timapiprant).,24.0
1127,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,History of hypersensitivity to budesonide or to any of the excipients.,24.0
1128,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of hypersensitivity to investigational medicinal product (IMP) or to drugs of similar chemical class (TLR agonists).,24.0
1129,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,History of hypersensitivity to natural or recombinant Interferon beta-1a or to any of the drug preparation excipients,24.0
1130,NCT00556673,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,History of hypersensitivity to the study drugs or to drugs with similar chemical structures,24.0
1131,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,History of hypersensitivity to the study medication or drugs of similar chemical classes (A1 adenosine receptor antagonists).,24.0
1132,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,History of sensitivity to any component of the investigational product,24.0
1133,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"history of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that contraindicates their participation",24.0
1134,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of sensitivity to any of the study medications.,24.0
1135,NCT00983658,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,History of serious adverse reaction or hypersensitivity to any drug,24.0
1136,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,History of serious adverse reaction or hypersensitivity to any drug,24.0
1137,NCT00327808,Phase 2,Asthma,Pharmaxis,10-Feb-15,Asthma,History of serious adverse reaction or hypersensitivity to corticosteroids,24.0
1138,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,History of severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection,24.0
1139,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,History of severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection,24.0
1140,NCT01348139,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to β2-agonists in general or to AZD3199 and/or excipients",24.0
1141,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,History or current evidence of clinically relevant allergies or idiosyncrasy to drugs,24.0
1142,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Hypersensitivity to any product used in the trial, including excipients",24.0
1143,NCT02479412,Phase 2,Asthma;Efficacy;Safety,AstraZeneca,10-Feb-15,Asthma,"Hypersensitivity to the active substance or to any of the excipients of the Run-in medication (i.e., budesonide) ",24.0
1144,NCT00785083,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Hypersensitivity to the drug,24.0
1145,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Hypersensitivity: Participants with allergy/intolerance to a monoclonal antibody or biologic.,24.0
1146,NCT03393806,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Hypersensitivity: significant allergies to humanized monoclonal antibodies or biologic or to any components of the formulation used in this study,24.0
1147,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,Individuals with known allergy or hypersensitivity to FDG will be excluded. ,24.0
1148,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Intolerance or hypersensitivity to the CXA-10 or it's excipients,24.0
1149,NCT01951222,Phase 2,Asthma,Pierre Fabre Medicament,10-Feb-15,Asthma,Intolerance to one of the ingredients of the study product,24.0
1150,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Known history of allergy or reaction to any component of the investigational product formulation,24.0
1151,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Known history of allergy or reaction to any component of the investigational product formulation,24.0
1152,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Known history of allergy or reaction to any component of the investigational product formulation,24.0
1153,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Known history of allergy or reaction to any component of the investigational product formulation,24.0
1154,NCT02407262,Phase 2,Asthma,"University College, London",10-Feb-15,Asthma;Inflammation,Known history of hypersensitivity to Black seed.,24.0
1155,NCT00672529,Phase 2,Asthma,Canadian Institute of Natural and Integrative Medicine,10-Feb-15,Asthma,Known hypersensitivity to any component of the orthomolecular therapy or placebo.,24.0
1156,NCT00640016,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Known hypersensitivity to CAT-354 or its components, to the challenge agents used in the study or to related drugs. ",24.0
1157,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,"Known hypersensitivity to formoterol, lactose, or methacholine",24.0
1158,NCT00614874,Phase 2,Asthma,Creighton University,10-Feb-15,Asthma,Known hypersensitivity to rosiglitazone,24.0
1159,NCT02787967,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Known hypersensitivity to the active treatmen,24.0
1160,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,Known hypersensitivity to zileuton or components of zileuton injection,24.0
1161,NCT01189396,Phase 2,Asthma;Bronchospasm;Chronic Obstructive Pulmonary Disease (COPD),"Amphastar Pharmaceuticals, Inc.",10-Feb-15,"Asthma;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive;Bronchial Spasm",Known intolerance or hypersensitivity to any of the ingredients of the A006 or Proventil-HFA;,24.0
1162,NCT01174732,Phase 2,Asthma;Bronchospasm,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma;Bronchial Spasm,Known intolerance or hypersensitivity to any of the ingredients of the study drug or Proventil®;,24.0
1163,NCT01255709,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Known intolerance or hypersensitivity to the study MDI ingredients;,24.0
1164,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,"Known or suspected hypersensitivity including anaphylaxis/anaphylactoid reaction following any biologic therapy, or known history of drug hypersensitivity to any component of the study intervention formulation.",24.0
1165,NCT02479412,Phase 2,Asthma;Efficacy;Safety,AstraZeneca,10-Feb-15,Asthma,"Known or suspected hypersensitivity to the IMPs or excipients, including lactose",24.0
1166,NCT01074853,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma,Known or suspected sensitivity to the IMP (Investigational Medicinal Product)(s).,24.0
1167,NCT02918019,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Known sensitivity to any of the active substances or their excipients to be administered during dosing,24.0
1168,NCT01584492,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Known sensitivity to the components of study medication.,24.0
1169,NCT02148796,Phase 2,Asthma;Wheezing,University of Arizona,10-Feb-15,Respiratory Sounds,Participant has known sensitivity to any of the study products and any of the ingredients to be administered.,24.0
1170,NCT00927758,Phase 2,Asthma,Sandoz,10-Feb-15,,past or present history of experiencing allergic reaction to medications used in this study,24.0
1171,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,"Patient with allergy, sensitivity or intolerance to study drugs and/ or study drug formulation ingredients",24.0
1172,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Patients with known hypersensitivity to any component of the investigational treatment (see section,24.0
1173,NCT00961155,Phase 2,Asthma,Medical University of Lodz,10-Feb-15,Asthma;Inflammation,sensitization to allergens other than house dust mites,24.0
1174,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Subject has known hypersensitivity to any of the ingredients,24.0
1175,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with allergy or intolerance to a monoclonal antibody or biologic or to any components of the formulation used in this study.,24.0
1176,NCT01393340,Phase 2,Nasal Polyposis;Asthma,"University Hospital, Ghent",10-Feb-15,Colorectal Neoplasms;Nasopharyngeal Neoplasms;Asthma;Nasal Polyps,Subjects with history of systemic reactions to the study medication.,24.0
1177,NCT04617171,Phase 2,Asthma Attack;Asthma,Singapore General Hospital,10-Feb-15,Asthma,Subjects with known history of allergy or reaction to any component of the investigational product formation,24.0
1178,NCT00896428,Phase 2,Asthma,"University Hospital, Bordeaux",10-Feb-15,Asthma,Pregnancy,25.0
1179,NCT00961155,Phase 2,Asthma,Medical University of Lodz,10-Feb-15,Asthma;Inflammation,pregnancy,25.0
1180,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,Pregnancy,25.0
1181,NCT00930163,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Pregnancy ,25.0
1182,NCT00971035,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Pregnancy ,25.0
1183,NCT01317563,Phase 2,Asthma,Nemours Children's Clinic,10-Feb-15,Asthma,"pregnancy,",25.0
1184,NCT01443728,Phase 2,Sickle Cell Disease;Vitamin D Deficiency;Acute Chest Syndrome;Asthma;Respiratory Infections,"Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Acute Chest Syndrome;Anemia, Sickle Cell;Vitamin D Deficiency",Pregnancy ,25.0
1185,NCT02501824,Phase 2,Asthma,University of Bern,10-Feb-15,Asthma,Pregnancy ,25.0
1186,NCT01058863,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Pregnant,25.0
1187,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,pregnant females at screening or prior to dosing,25.0
1188,NCT02407262,Phase 2,Asthma,"University College, London",10-Feb-15,Asthma;Inflammation,Pregnant women,25.0
1189,NCT00456677,Phase 2,Asthma,State University of New York - Downstate Medical Center,10-Feb-15,Asthma,Pregnant women ,25.0
1190,NCT00536042,Phase 2,Asthma,State University of New York - Downstate Medical Center,10-Feb-15,Asthma,Pregnant women ,25.0
1191,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,A current (or within 5 years) history of solid organ or haematological malignancy.,26.0
1192,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A current malignancy or previous history of cancer in remission for less than five years prior screening (except for localized carcinoma of the skin that has been resected for cure).,26.0
1193,NCT00452400,Phase 2,"Pulmonary Disease, Chronic Obstructive;Asthma",Boehringer Ingelheim,10-Feb-15,"Pulmonary Disease, Chronic Obstructive","a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed)",26.0
1194,NCT00556673,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Active cancer or a history of cancer with less than 5 years disease free survival time,26.0
1195,NCT04092582,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Active malignancy or history of malignancy within 5 years of screening, except for appropriately treated non-melanoma skin carcinoma, cervical carcinoma in situ, breast ductal carcinoma in situ, or Stage I uterine cancer",26.0
1196,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Any evidence of malignancy [active and/or treated] within the previous five years or malignancy that is likely to recur during the period of the study,26.0
1197,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Any malignancy within the previous 5 years,26.0
1198,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Any patient with active cancer or a history of cancer with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases). Localized basal cell carcinoma (without metastases) of the skin is acceptable. ,26.0
1199,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,cancer (except for successfully treated basal and squamous cell carcinomas of the skin) or history of cancer within 5 years prior to Screening Visit;,26.0
1200,NCT03364608,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Cancer not in complete remission for at least 5 years,26.0
1201,NCT03371459,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Cancer not in complete remission for at least 5 years,26.0
1202,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years,26.0
1203,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"current cancer or history (within past ≤5 years) of cancer (except for successfully treated basal and squamous cell carcinomas of the skin); if cancer-free for >5 years, study participation may be allowed",26.0
1204,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Current malignancy excluding basal cell carcinoma; History of malignancy is acceptable only if the subject has been in remission for one year prior to the Screening Visit. (Remission is defined as no current evidence of malignancy and no treatment for the malignancy in the 12 months prior to the Screening Visit),26.0
1205,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Current malignancy excluding basal cell carcinoma; History of malignancy is acceptable only if the subject has been in remission for one year prior to the Screening Visit. (Remission is defined as no current evidence of malignancy and no treatment for the malignancy in the 12 months prior to the Screening Visit),26.0
1206,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,current or history of any cancer (except non-melanomatous skin cancer) diagnosed less than 5 years prior to screening,26.0
1207,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,Currently have any known malignancy or have a history of malignancy within the previous 5 years,26.0
1208,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Evidence of an active or suspected cancer or history of treatment for cancer,26.0
1209,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Has a current malignancy or previous history of cancer in remission for less than 12 months prior to randomization;,26.0
1210,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Has any diagnosis of a malignant disease (other than basal or squamous cell carcinoma) within 5 years prior to Screening Visit 1,26.0
1211,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,"History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin",26.0
1212,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >= 1 year prior to randomization into the study",26.0
1213,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy ≥ 1 year before Day 1 or other malignancies treated with apparent success with curative therapy ≥ 5 years before screening",26.0
1214,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy less than or equal to (<=)1 year prior to Study Day 1 or other malignancies treated with apparent success with curative therapy <=5 years prior to entry",26.0
1215,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"History of cancer, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >=12 months prior to screening or other malignancies treated with apparent success with curative therapy >=5 years prior to screening",26.0
1216,NCT02054130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix treated with apparent success with curative therapy or other malignancies are eligible provided that curative therapy was completed -Known history of active tuberculosis (TB)",26.0
1217,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,History of cancer (except for successfully treated basal and squamous cell carcinomas of the skin) within 5 years of screening visit,26.0
1218,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >1 year prior to entry or other malignancies treated with apparent success with curative therapy >5 years prior to entry,26.0
1219,NCT00512863,Phase 2,Asthma,Abbott,10-Feb-15,Asthma,History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma - in-situ of the cervix.,26.0
1220,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of cancer other than basal cell carcinoma of the skin or cervical carcinoma-in-situ treated with apparent success with curative therapy more than 1 year prior to Study Day 0;,26.0
1221,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of cancer other than basal cell carcinoma or cervical carcinoma-in-situ treated with apparently successful curative therapy (remission for ≥ 1 year prior to screening);,26.0
1222,NCT00614874,Phase 2,Asthma,Creighton University,10-Feb-15,Asthma,History of cancer other than basal cell skin cancer,26.0
1223,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of cancer other than non-melanoma skin cancer or cervical carcinoma-in-situ treated with apparent success with curative therapy (remission for ≥ 1 year prior to screening);,26.0
1224,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of cancer other than nonmelanoma skin cancer or cervical carcinoma-in-situ that have been treated successfully with curative therapy;,26.0
1225,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,"History of cancer within the last 10 years, any history of lymphoma or lung cancer is strictly exclusionary.",26.0
1226,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,History of concurrent malignancy or recurrence of malignancy within 2 years prior to Screening (not including participants with basal cell carcinomas or cervical carcinoma in situ that has been successfully treated surgically).,26.0
1227,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,History of malignancy except non-melanoma skin cancer within the last five years,26.0
1228,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,history of malignancy is acceptable only if subject has been in remission for one year prior to Visit 1 (remission = no current evidence of malignancy and no treatment for the malignancy in the 12 months prior to Visit 1),26.0
1229,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,"History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases",26.0
1230,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,"History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases",26.0
1231,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years.",26.0
1232,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,"History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.",26.0
1233,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"History of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases",26.0
1234,NCT00746330,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,History of malignancy of any organ system within past 5 years.,26.0
1235,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"History of malignancy within the past 5 years, except excised basaliomas",26.0
1236,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"Malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years, with the exception of treated basal cell carcinoma",26.0
1237,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Malignancy within 5 years (except local basal cell carcinoma, or fully excised local dermal, squamous cell carcinoma).",26.0
1238,NCT03393806,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Participants with a diagnosis of malignancy or in the process of investigation for a malignancy. Participants with carcinoma that have not been in complete remission for at least 5 years. Participants who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the participant has been considered cured by treatment.",26.0
1239,NCT00403754,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients with a history of malignancy with the exception of localized basal cell carcinoma of the skin.,26.0
1240,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,Presence of cancer not in remission for at least 5 years prior to the Screening Visit (excludes non-melanomatous skin cancer),26.0
1241,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Presence of glaucoma, cataracts, ocular herpes simplex, or malignancy other than basal cell carcinoma",26.0
1242,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Presence of glaucoma, cataracts, ocular herpes simplex, or malignancy other than basal cell carcinoma",26.0
1243,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with a history of cancer (exception: basal cell carcinoma in remission).,26.0
1244,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with a history of cancer (exception: basal cell carcinoma in remission).,26.0
1245,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Subject with a history of cancer (exception: basal cell carcinoma in remission).,26.0
1246,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,Subjects who have cancer that has not been in complete remission for at least 5 years,26.0
1247,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects with a diagnosis of malignancy or in the process of investigation for a malignancy. Subjects with carcinoma that have not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment.",26.0
1248,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Subjects with a history of malignancy within the past five years, with the exception of localized basal cell carcinoma of the skin",26.0
1249,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,"Subjects with a history of malignancy within the past five years, with the exception of localized basal cell carcinoma of the skin.",26.0
1250,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects with carcinoma that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment.",26.0
1251,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,The participant has a history of malignancy other than fully resected basal cell carcinoma of the skin.,26.0
1252,NCT00407524,Phase 2,Asthma,University of Aberdeen,10-Feb-15,Asthma,"The patient has an active malignancy of any type or history of a malignancy (with the exception of patients with malignancy surgically removed with no evidence of recurrence within five years before enrolment, and patients with history of treated basal cell carcinoma)",26.0
1253,NCT00365560,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"with malignancy for which the patient has undergone resection, radiation ther apy or chemotherapy within the last five years,",26.0
1254,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Diagnosis of malignancy or in the process of investigation,27.0
1255,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,"Diagnosis or history of malignancy, or current investigation for possible malignancy",27.0
1256,NCT01820481,Phase 2,Asthma,Whanin Pharmaceutical Company,10-Feb-15,Asthma,Have malignant tumor ,27.0
1257,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Known current malignancy or current evaluation for a potential malignancy,27.0
1258,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,Known current malignancy or current evaluation for a potential malignancy,27.0
1259,NCT00930163,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Known malignancy,27.0
1260,NCT00971035,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Known malignancy,27.0
1261,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Known malignancy or current evaluation for a potential malignancy,27.0
1262,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Known malignancy or current evaluation for a potential malignancy,27.0
1263,NCT00675649,Phase 2,Asthma,"Centocor, Inc.",10-Feb-15,Asthma,Known malignancy or history of malignancy,27.0
1264,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,malignancy,27.0
1265,NCT02947945,Phase 2,Asthma,National Jewish Health,10-Feb-15,Granulomatosis with Polyangiitis;Systemic Vasculitis;Churg-Strauss Syndrome,Malignancy,27.0
1266,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with a diagnosis of malignancy or in the process of investigation for a malignancy.,27.0
1267,NCT04617171,Phase 2,Asthma Attack;Asthma,Singapore General Hospital,10-Feb-15,Asthma,Anaphylactic/anaphylactoid reaction presenting with bronchospasm,28.0
1268,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Current asthma episode is an anaphylactoid/anaphylactic reaction presenting with acute bronchospasm,28.0
1269,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of anaphylaxis;,28.0
1270,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of anaphylaxis,28.0
1271,NCT01582503,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,History of anaphylaxis,28.0
1272,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of anaphylaxis (defined as immediate life-threatening event requiring medical invention);,28.0
1273,NCT02449473,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,History of anaphylaxis following any biologic therapy,28.0
1274,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of anaphylaxis to any biologic therapy,28.0
1275,NCT02054130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of anaphylaxis to any biologic therapy,28.0
1276,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,History of anaphylaxis to any biologic therapy,28.0
1277,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,History of anaphylaxis to any biologic therapy or vaccine.,28.0
1278,NCT02230189,Phase 2,Asthma,Prescott Woodruff,10-Feb-15,Asthma,History of anaphylaxis to cat allergen,28.0
1279,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of anaphylaxis to other biologic therapy,28.0
1280,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,History of anaphylaxis with omalizumab treatment or history of anaphylaxis to any therapeutic biological agent,28.0
1281,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,History of anaphylaxis.,28.0
1282,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,"History of serious severe hypersensitivity or allergy (e.g., anaphylaxis).",28.0
1283,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,History of severe anaphylactic/anaphylactoid reactions from any cause ,28.0
1284,NCT02061670,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",History of severe drug allergy or anaphylactic reaction to food.,28.0
1285,NCT02161107,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",History of severe drug allergy or anaphylactic reaction to food.,28.0
1286,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,Past episode of anaphylaxis with severe respiratory symptoms,28.0
1287,NCT02340130,Phase 2,Rhinitis;Rhinoconjunctivitis;Asthma,"Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Conjunctivitis",Subjects with a previous history of anaphylaxis,28.0
1288,NCT01370031,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Blood donation (450 mL or more)or significant blood loss less than 12 weeks before the first intake of study drug. ,29.0
1289,NCT00640016,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Blood donation (more than 550 mL) in the previous 2 months,29.0
1290,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Blood donation within 2 weeks of screening visit,29.0
1291,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,Blood donation within 3 months of the study,29.0
1292,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,blood donation within 30 days of screening or plasma donation within 7 days of screening,29.0
1293,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,Blood donation within the last 30 days before screening,29.0
1294,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Blood drawn of at least 250 ml in the previous 45 days,29.0
1295,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Donated blood or has had a blood transfusion within 28 days before screening,29.0
1296,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,donation of a unit of blood within 2 weeks prior to Screening Visit or intention of donating a unit of blood during the study;,29.0
1297,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,donation of a unit of blood within past ≤2 weeks or intention to donate a unit of blood during the study,29.0
1298,NCT02479412,Phase 2,Asthma;Efficacy;Safety,AstraZeneca,10-Feb-15,Asthma,Donation of blood (≥ 450 mL) within 3 months or donation of plasma within 14 days before Visit 1,29.0
1299,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,"Donation of blood, plasma or platelets within 90 days prior to Visit",29.0
1300,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Donation of blood in excess of 500 mL within a 56 day period prior to dosing,29.0
1301,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Donation of blood in excess of 500 mL within a 56-day period prior to dosing,29.0
1302,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,donation of blood or blood products in excess of 500 mL within a 56 day period,29.0
1303,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Donation of blood over 500 mL within 3 months prior to Visit 5,29.0
1304,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Donation or loss of 400 milliliters (mL) or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation or hemoglobin levels below normal range at screening or where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.",29.0
1305,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,Donation or loss of 400 mL or more of blood or donations of plasma within eight (8) weeks prior to initial dosing or longer if required by local regulation. ,29.0
1306,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,Donation or loss of 450 mL or more of blood within eight weeks prior to screening visit or longer if required by local regulation.,29.0
1307,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Have donated (standard donation amount or more) blood or blood products (with the exception of plasma noted below) within 56 days of study entry;,29.0
1308,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Have donated plasma within 7 days of study entry;,29.0
1309,NCT01189396,Phase 2,Asthma;Bronchospasm;Chronic Obstructive Pulmonary Disease (COPD),"Amphastar Pharmaceuticals, Inc.",10-Feb-15,"Asthma;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive;Bronchial Spasm",Having donated blood within the last 30 days prior to Screening. ,29.0
1310,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of blood donation (500 mL) within 2 months of starting the clinical study.,29.0
1311,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of blood donation (500 mL) within 3 months of starting the clinical study,29.0
1312,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of blood donation (500 mL) within 3 months of starting the clinical study.,29.0
1313,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of blood donation (500 mL) within 3 months of starting the clinical study.,29.0
1314,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of blood donation (500 mL) within 3 months of starting the clinical study.,29.0
1315,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"Planned donation of germ cells, blood, organs or bone marrow during the course of the trial or within 6 months thereafter",29.0
1316,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Plans to donate blood during the entire study period,29.0
1317,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of immunoglobulin or blood products within 28 days before randomization,29.0
1318,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of immunoglobulin or blood products within 30 days before randomization into the study,29.0
1319,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of immunoglobulin or blood products within 30 days before randomization into the study,29.0
1320,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Receipt of immunoglobulin or blood products within 30 days prior to screening,29.0
1321,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained.,29.0
1322,NCT04617171,Phase 2,Asthma Attack;Asthma,Singapore General Hospital,10-Feb-15,Asthma,Subjects who receive immunoglobulin or blood products within 30 days before randomization ,29.0
1323,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period,29.0
1324,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.,29.0
1325,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Where participation in the study would result in donation of blood or blood products in excess of 500 ml within a 56 day period.,29.0
1326,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Where participation in the study would result in donation of blood or blood products in excess of 500 ml within a 56 day period.,29.0
1327,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.,29.0
1328,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.,29.0
1329,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Where participation in the study would result in donation of blood or blood products in excess of the lesser of 50 millilitres (mL) or 3mL per kilogram within a 56 day period.,29.0
1330,NCT00482898,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,You have donated blood in the last 4 weeks,29.0
1331,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,BMI >40,30.0
1332,NCT01317563,Phase 2,Asthma,Nemours Children's Clinic,10-Feb-15,Asthma,"BMI<20th percentile,",30.0
1333,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,Body Mass Index (BMI) >,30.0
1334,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Body mass index (BMI) > 38 kg/m2,30.0
1335,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Body mass index (BMI) > 38 kg/m2,30.0
1336,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Body mass index (BMI) >38 kg/m2,30.0
1337,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,Body Mass Index (BMI) <15 and >35,30.0
1338,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,Body mass index (BMI) <18 kg/m2 or ≥ 35 kg/m2 at screening.,30.0
1339,NCT01823016,Phase 2,Asthma,"Janssen Research & Development, LLC",10-Feb-15,Asthma,Body-Mass Index (BMI) greater than or equal to 40 kg/m2 ,30.0
1340,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,Body mass index >38 kilograms per square meter (kg/m^2),30.0
1341,NCT01848769,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Obesity, i.e. > 97% weight percentile by local standards ",30.0
1342,NCT02787967,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,"Obesity, i.e. > 97% weight percentile by local standards ",30.0
1343,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,Patients with a body mass index (BMI) < 17 or > 40 kg/m2. Other protocol-defined inclusion/exclusion criteria may apply. ,30.0
1344,NCT00384813,Phase 2,Asthma,Emory University,10-Feb-15,Asthma,Caregiver is unable to complete study screening process,31.0
1345,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,Deemed unable to adhere to study activities,31.0
1346,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,"expected to be poorly compliant with study drug, procedures, visits",31.0
1347,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,History of medication noncompliance,31.0
1348,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,Inability or unwillingness of a participant to give written informed consent. ,31.0
1349,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Inability to carry out pulmonary function testing, to comply with study procedures or with study drug intake.",31.0
1350,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Inability to carry out pulmonary lung function testing, to comply with study procedures or with study drug intake.",31.0
1351,NCT01584492,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Inability to comply to study procedures or to study treatment intake.,31.0
1352,NCT01074853,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma,Inability to comply with protocol.,31.0
1353,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Inability to comply with the study protocol ,31.0
1354,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,Inability to understand directions for study assessment,31.0
1355,NCT00901095,Phase 2,Asthma;Obesity,Palo Alto Medical Foundation,10-Feb-15,Asthma;Weight Loss,Investigator discretion for clinical safety or protocol adherence reasons. ,31.0
1356,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Is not able or willing to give written informed consent or comply with the study protocol;,31.0
1357,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Lack of ability or willingness to give informed consent,31.0
1358,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,Lack of ability or willingness to give informed consent or inability to cooperate adequately,31.0
1359,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,"May interfere with the participant's ability to comply with study requirements, or",31.0
1360,NCT00980200,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Non-compliance with study medication and other study-related requirements,31.0
1361,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,"Non-cooperative patients, inability to perform outcome measurement correctly",31.0
1362,NCT02501824,Phase 2,Asthma,University of Bern,10-Feb-15,Asthma,Not willing to perform therapy actively,31.0
1363,NCT00801853,Phase 2,Asthma,"Aerovance, Inc.",10-Feb-15,Asthma,Patient cannot communicate reliably with the Investigator or is unlikely to cooperate with the requirements of the study,31.0
1364,NCT01443728,Phase 2,Sickle Cell Disease;Vitamin D Deficiency;Acute Chest Syndrome;Asthma;Respiratory Infections,"Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Acute Chest Syndrome;Anemia, Sickle Cell;Vitamin D Deficiency",Patient unable or unwilling to comply with requirements of the clinical trial,31.0
1365,NCT04170348,Phase 2,"Sickle Cell Disease;Anemia, Sickle Cell;Anemia, Hemolytic, Congenital;Respiratory Tract Diseases;Respiration Disorders;Acute Chest Syndrome;Lung Diseases;Asthma;Respiratory Tract Infections;Nutrition Disorders;Deficiency Diseases Vitamin;Vitamin D Deficiency","Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Lung Diseases;Respiratory Tract Diseases;Acute Chest Syndrome;Respiration Disorders;Anemia;Anemia, Sickle Cell;Anemia, Hemolytic;Anemia, Hemolytic, Congenital;Vitamin D Deficiency;Nutrition Disorders;Deficiency Diseases;Vitamin A Deficiency;Disease",Patient unable or unwilling to comply with requirements of the clinical trial,31.0
1366,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,"Patient unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study",31.0
1367,NCT01650441,Phase 2,Asthma,"University Hospital, Antwerp",10-Feb-15,Asthma,"Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study",31.0
1368,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,"Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study;",31.0
1369,NCT00452400,Phase 2,"Pulmonary Disease, Chronic Obstructive;Asthma",Boehringer Ingelheim,10-Feb-15,"Pulmonary Disease, Chronic Obstructive",Patients who are unable to comply with medication restrictions. ,31.0
1370,NCT00467740,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Patients who are unable to comply with pulmonary medication restrictions prior to randomization ,31.0
1371,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",put the patient at risk because of participation in the study,31.0
1372,NCT00465413,Phase 2,Asthma,Mackay Memorial Hospital,10-Feb-15,,"refusal to participate,",31.0
1373,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject had a schedule that prevented him or her from taking the first daily dose of study medication and/or starting study visits before 9 AM.,31.0
1374,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Subject unable to tolerate or unwilling to take the full dose of the nutritional study formulas,31.0
1375,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Subject whose schedule prevents him or her from starting study visits before 2:30-4:00 PM.,31.0
1376,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject whose schedule prevents him or her from starting study visits before 9 AM.,31.0
1377,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject whose schedule prevents him or her from starting study visits before 9 AM.,31.0
1378,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject whose schedule prevents him or her from taking the first daily dose of study medication and/or starting study visits before 9 AM.,31.0
1379,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects at risk of non-compliance, or unable to comply with the study procedures.",31.0
1380,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Subjects unlikely to comply with the study protocol;,31.0
1381,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,Suspected inability or unwillingness to comply with the study procedures,31.0
1382,NCT00365469,Phase 2,Eczema;Asthma;Allergic Rhinitis,"National University Hospital, Singapore",10-Feb-15,"Rhinitis;Rhinitis, Allergic;Eczema",The parent is unable /unwilling to comply with procedures. ,31.0
1383,NCT00318695,Phase 2,Eczema;Asthma;Allergic Rhinitis,"National University Hospital, Singapore",10-Feb-15,"Rhinitis;Rhinitis, Allergic;Eczema",The parent is unable/unwilling to comply with procedures.,31.0
1384,NCT00407524,Phase 2,Asthma,University of Aberdeen,10-Feb-15,Asthma,"The patient is not able to follow study procedures (e.g., language problems, psychological disorders) or is considered to be non-compliant according to the investigator",31.0
1385,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject is not able to understand or comply with protocol requirements, instructions and protocol stated restrictions.",31.0
1386,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,There is a risk of non-compliance with study procedures,31.0
1387,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,There is a risk of non-compliance with study procedures.,31.0
1388,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,There is a risk of non-compliance with study procedures.,31.0
1389,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,There is a risk of non-compliance with study procedures. ,31.0
1390,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,There is a risk of subject non-compliance with study procedures.,31.0
1391,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Unable or unwilling to follow instructions: Procedures, dosing directions, e-diaries or pMDIs",31.0
1392,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unwillingness or inability of the participant or parent/guardian to follow the procedures outlined in the protocol.,31.0
1393,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unwillingness or inability of the subject or parent/guardian to follow the procedures outlined in the protocol.,31.0
1394,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Unwillingness or inability to comply with the study protocol for any other reason ,31.0
1395,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,unwillingness or inability to follow the procedures outlined in the protocol,31.0
1396,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unwillingness or inability to follow the procedures outlined in the protocol.,31.0
1397,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unwillingness or inability to follow the procedures outlined in the protocol.,31.0
1398,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unwillingness or inability to follow the procedures outlined in the protocol.,31.0
1399,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unwillingness or inability to follow the procedures outlined in the protocol.,31.0
1400,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unwillingness or inability to follow the procedures outlined in the protocol. ,31.0
1401,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,Unwillingness or inability to follow the procedures outlined in the protocol. ,31.0
1402,NCT01174732,Phase 2,Asthma;Bronchospasm,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma;Bronchial Spasm,Use of prohibited drugs or failure to observe the drug washout restrictions;,31.0
1403,NCT01189396,Phase 2,Asthma;Bronchospasm;Chronic Obstructive Pulmonary Disease (COPD),"Amphastar Pharmaceuticals, Inc.",10-Feb-15,"Asthma;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive;Bronchial Spasm",Use of prohibited drugs or failure to observe the drug washout restrictions;,31.0
1404,NCT02210806,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Use of prohibited drugs or failure to observe the drug washout restrictions,31.0
1405,NCT02271334,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Use of prohibited drugs or failure to observe the drug washout restrictions; and,31.0
1406,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A pre-bronchodilator FEV1 less than 50 percent predicted of normal value at Screening (Visit 1).,32.0
1407,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A pre-bronchodilator FEV1 less than 50 percent predicted of normal value at Visit,32.0
1408,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A pre-bronchodilator forced expiratory volume in 1 second (FEV1) < 50 percent predicted of normal value.,32.0
1409,NCT02210806,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Baseline ECG at Screening or Visit 1 with a confirmed (through performing a second ECG) QTc reading greater than 450ms,32.0
1410,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Baseline FEV1 </=39% of predicted,32.0
1411,NCT00292877,Phase 2,Asthma,St. Joseph's Healthcare Hamilton,10-Feb-15,Asthma,Baseline FEV1 before bronchodilator of 40% or less of predicted. This lower FEV1 is acceptable since chronic airflow limitation secondary to the eosinophilic bronchitis or asthma is not an exclusion criteria. Neither is current or ex-cigarette smoking providing that the best FEV1 in these patients has been >60% predicted normal or the best FEV1/VC ratio has been >60% in the past two years,32.0
1412,NCT00280683,Phase 2,Asthma,"University of California, Davis",10-Feb-15,Asthma,Baseline Forced Expiratory Volume in 1 second (FEV1) <40% predicted,32.0
1413,NCT01833390,Phase 2,Asthma;COPD;Healthy,Xemed LLC,10-Feb-15,Asthma,Blood oxygen saturation of 92% less than as measured by pulse oximetry on the day of imaging.,32.0
1414,NCT00635882,Phase 2,Asthma;Airway Inflammation,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma;Inflammation,Decrease in absolute FEV1 >20% between Screening and Baseline Visits.,32.0
1415,NCT01258803,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Demonstrates a decrease in absolute FEV1 of >20% at any time from the Screening Visit up to and including the Baseline Visit,32.0
1416,NCT02271334,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,ECG at Screening and Visit-1 baseline with a QTc reading greater than 450ms;,32.0
1417,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,FEV1 < 1 litre post salbutamol.,32.0
1418,NCT00857779,Phase 2,Rhinitis;Conjunctivitis;Asthma,ALK-Abelló A/S,10-Feb-15,Rhinitis;Conjunctivitis,FEV1 < 70% of predicted value at screening,32.0
1419,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,FEV1 < 70% of predicted values;,32.0
1420,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,FEV1 < 80% of predicted values;,32.0
1421,NCT02740543,Phase 2,Asthma,NYU Langone Health,10-Feb-15,Asthma,FEV1 <60% predicted normal pre-bronchodilator,32.0
1422,NCT00614874,Phase 2,Asthma,Creighton University,10-Feb-15,Asthma,FEV1 <60% predicted value,32.0
1423,NCT02061670,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal","FEV1 of < 70 % of predicted, regardless of the cause.",32.0
1424,NCT02161107,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal","FEV1 of <70 % of predicted, regardless of the cause.",32.0
1425,NCT01833390,Phase 2,Asthma;COPD;Healthy,Xemed LLC,10-Feb-15,Asthma,FEV1 percent predicted less than 25%.,32.0
1426,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Following exercise challenge during the screening visit, the subject experiences a greater than 40% fall in FEV1 compared to baseline.",32.0
1427,NCT01841281,Phase 2,Asthma;Inflammation,Nicholas Kenyon,10-Feb-15,Asthma;Inflammation,Forced expiratory volume 1sec <30% predicted,32.0
1428,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Forced expiratory volume in 1 second (FEV1-subscript) < 70% of predicted values at screening;,32.0
1429,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Pre-bronchodilator FEV1 decrease or increase ≥ 20%.,32.0
1430,NCT00746330,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,"Pre-dose change (increase or decrease) in absolute FEV1 of 15% at Visit 2, compared with value at screening.",32.0
1431,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Subject with FEV1 < 80% predicted at visit 1 or FEV1 < 70% predicted at visit,32.0
1432,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"A participant will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.",33.0
1433,NCT01286844,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.",33.0
1434,NCT01332292,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.",33.0
1435,NCT01453296,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.",33.0
1436,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub investigator, study coordinator, or employee of the participating investigator.",33.0
1437,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator. ",33.0
1438,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Affiliation with investigator or site staff ,33.0
1439,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Affiliation with Investigator's Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.",33.0
1440,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Affiliation with Investigator's Site: Relative or employee ,33.0
1441,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any affiliation with Investigator's site ,33.0
1442,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Any employee of the clinical study site who is involved with the conduct of the study,33.0
1443,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Any employee of the research site who is involved with the conduct of the study. ,33.0
1444,NCT01332292,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Children who are wards of the state or government.,33.0
1445,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Children who are wards of the state or government.,33.0
1446,NCT01502371,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Direct association with either the administration of the this study or the study staff. ,33.0
1447,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,direct association with or family member of one of the investigators or study staff,33.0
1448,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"Employee at the investigational site, relative or spouse of the investigator. ",33.0
1449,NCT01402986,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Employee of the clinical study site or any other individuals directly involved with the conduct of the study, or immediate family members of such individuals",33.0
1450,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Employees of the clinical study site or any other individuals involved with the conduct of the study, or family members of such individuals. ",33.0
1451,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Employees of the clinical study site or any other individuals involved with the conduct of the study, or family members of such individuals. ",33.0
1452,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Employees of the clinical study site or any other individuals involved with the conduct of the study, or first degree family members of such individuals (that is, parents, siblings, or children) ",33.0
1453,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals",33.0
1454,NCT00394914,Phase 2,Asthma;Common Cold;Picornavirus Infection;Rhinovirus,Merck Sharp & Dohme Corp.,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,Family member of the investigational study staff. ,33.0
1455,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Has an affiliation with the Investigative Site. Participation of site personnel, or their spouses or children, is not allowed. ",33.0
1456,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and staff at third party vendors or staff at the study sites),33.0
1457,NCT00688467,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Is a family member of the investigational study staff.,33.0
1458,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.",33.0
1459,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress",33.0
1460,NCT00688467,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Is part of the staff personnel directly involved with this study,33.0
1461,NCT00394914,Phase 2,Asthma;Common Cold;Picornavirus Infection;Rhinovirus,Merck Sharp & Dohme Corp.,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,Part of the staff personnel directly involved with this study.,33.0
1462,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Patient is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator",33.0
1463,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Personnel involved in the planning or conduct of the study,33.0
1464,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,sibling of a participant in this study ,33.0
1465,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Site staff members or their immediate families are not eligible to enroll ,33.0
1466,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Study investigators, sub-investigators, study coordinators, employees of a participating investigator or study site, or immediate family members of the aforementioned that is involved with this study.",33.0
1467,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Study participation by clinical investigator site employees and/or their immediate relatives,33.0
1468,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Study participation by clinical investigator site employees and/or their immediate relatives,33.0
1469,NCT03745196,Phase 2,Asthma;Respiratory Candidiasis;Respiratory Aspergillosis;COPD;Bronchiectasis,Pulmocide Ltd,10-Feb-15,Candidiasis;Aspergillosis;Asthma;Bronchiectasis;Respiration Disorders;Respiratory Tract Diseases,"Subject is an employee or a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study",33.0
1470,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,"Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol",33.0
1471,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject was a staff member or a relative of a staff member at the time of the study. ,33.0
1472,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject who is a staff member or relative of a staff member. ,33.0
1473,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject who is a staff member or relative of a staff member. ,33.0
1474,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject who is a staff member or relative of a staff member. ,33.0
1475,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Subject who is a staff member or relative of a staff member. ,33.0
1476,NCT00603278,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A subject will not be eligible for randomization if he/she has an abnormal visual oropharyngeal exam at the randomization Visit 3 (visual clinical evidence of oral candidiasis),34.0
1477,NCT00603746,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A subject will not be eligible for randomization if he/she has an abnormal visual oropharyngeal exam at the randomization Visit 3 (visual clinical evidence of oral candidiasis),34.0
1478,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A subject will not be eligible for randomization if he/she has an abnormal visual oropharyngeal exam at the randomization Visit 3 (visual clinical evidence of oral candidiasis).,34.0
1479,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,A subject will not be eligible if he/she has clinical visual evidence of oral candidiasis at screening.,34.0
1480,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A subject will not be eligible if he/she has clinical visual evidence of oral candidiasis at screening.,34.0
1481,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinical visual evidence of oral candidiasis at Day,34.0
1482,NCT01332292,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinical visual evidence of oral candidiasis at screening.,34.0
1483,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinical visual evidence of oral candidiasis at screening.,34.0
1484,NCT01453296,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinical visual evidence of oral candidiasis at screening.,34.0
1485,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Clinical visual evidence of oral candidiasis at the Screening Visit,34.0
1486,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,evidence of oropharyngeal candidiasis,34.0
1487,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Oropharyngeal Examination: A subject will not be eligible for the run-in if he/she has clinical visual evidence of oral candidiasis at Visit,34.0
1488,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Oropharyngeal examination: A subject will not be eligible if he/she has clinical visual evidence of oral candidiasis at screening.,34.0
1489,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Subjects with oral candidiasis at screening and at randomization.,34.0
1490,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Subjects with oral candidiasis at screening or at randomization.,34.0
1491,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Untreated oral candidiasis at the Screening Visit. Subjects with clinical visual evidence of oral candidiasis and who agree to receive treatment and comply with appropriate medical monitoring may enter the study,34.0
1492,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Visual clinical evidence of oropharyngeal candidiasis,34.0
1493,NCT00407524,Phase 2,Asthma,University of Aberdeen,10-Feb-15,Asthma,"The patient has difficulty swallowing capsules or tablets, dysphagia or is unable to tolerate oral medication. ",35.0
1494,NCT01006655,Phase 2,Asthma;Bronchial Hyperresponsiveness,Rambam Health Care Campus,10-Feb-15,Bronchial Hyperreactivity,impossibility to perform lung function tests,36.0
1495,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,"Inability to perform acceptable, quality serial spirometry ",36.0
1496,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,Inability to perform acceptable spirometry,36.0
1497,NCT00614874,Phase 2,Asthma,Creighton University,10-Feb-15,Asthma,Inability to perform consistent spirometry or nitric oxide exhalation,36.0
1498,NCT00901095,Phase 2,Asthma;Obesity,Palo Alto Medical Foundation,10-Feb-15,Asthma;Weight Loss,Inability to perform pulmonary function tests by spirometry in a consistent manner;,36.0
1499,NCT02740868,Phase 2,Cystic Fibrosis;Asthma,The Hospital for Sick Children,10-Feb-15,Cystic Fibrosis;Fibrosis,Participant is unable to perform spirometry or plethysmography maneuvers,36.0
1500,NCT01425801,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry,36.0
1501,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,Patients who are unable to demonstrate an acceptable spirometry technique,36.0
1502,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Unable to perform acceptable, repeatable spirometry",36.0
1503,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,A chest radiograph (CXR) done within the last six months of the test that shows no evidence of active TB,37.0
1504,NCT01653756,Phase 2,Asthma,SecuraBio,10-Feb-15,Asthma,A positive screen result for active or latent tuberculosis,37.0
1505,NCT01704495,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Active tuberculosis or latent tuberculosis without completion of an appropriate course of treatment or prophylactic treatment,37.0
1506,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,Active tuberculosis requiring treatment within 12 months prior to Visit 1,37.0
1507,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Active tuberculosis requiring treatment within the 12 months prior to Visit 1,37.0
1508,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Active tuberculosis requiring treatment within the 12 months prior to Visit 1,37.0
1509,NCT01581177,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Any current or recent respiratory tract infections that might affect the response to the study drug as determined by the investigator, including cystic fibrosis, bronchiectasis, tuberculosis, emphysema and other significant respiratory diseases besides asthma",37.0
1510,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Chest X-Ray (CXR) within 6 months of screening showing evidence of active or inactive tuberculosis (TB), or other clinically significant disease other than asthma. If a CXR is not available, it must be performed at screening.",37.0
1511,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Documentation of adequate treatment for latent TB In cases of an indeterminate QuantiFERON-TB test result, a second blood specimen must be drawn. A chest x-ray is not required if the participant has a negative QuantiFERON-TB Gold test. Comorbid Conditions: Comorbidities are commonly present in severe asthma. Specific questionnaires will be used to identify common comorbidities as follows:",37.0
1512,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,EKG with significant clinical findings A positive QuantiFERON-TB (tuberculosis) Gold test requires further screening. A participant may be included in PrecISE if at least one of the following criteria are met:,37.0
1513,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,For adolescents: History of active tuberculosis requiring treatment,37.0
1514,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,"For adults active tuberculosis (TB) requiring treatment within the 12 months before the time of informed consent (patients are also required to have no recurrence of symptoms in the 12 months following completion of TB treatment), or for adolescents history of active TB requiring treatment",37.0
1515,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,For adults: Active tuberculosis requiring treatment within the 12 months prior to Visit 1,37.0
1516,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Has severe acute infectious diseases (eg, tuberculosis, or acute hepatitis)",37.0
1517,NCT01443728,Phase 2,Sickle Cell Disease;Vitamin D Deficiency;Acute Chest Syndrome;Asthma;Respiratory Infections,"Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Acute Chest Syndrome;Anemia, Sickle Cell;Vitamin D Deficiency","History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia",37.0
1518,NCT00452400,Phase 2,"Pulmonary Disease, Chronic Obstructive;Asthma",Boehringer Ingelheim,10-Feb-15,"Pulmonary Disease, Chronic Obstructive",known active tuberculosis,37.0
1519,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"known active tuberculosis,",37.0
1520,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,Known history of active tuberculosis (TB),37.0
1521,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,"Past or present tuberculosis, systemic lupus erythematosis or multiple sclerosis",37.0
1522,NCT00467740,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"Patients with any of the following conditions: a history of myocardial infarction within 1 year of screening visit (Visit 1), a diagnosis of clinically relevant cardiac arrhythmia, a history of cor pulmonale, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed), a history of life-threatening pulmonary obstruction, a history of cystic fibrosis, clinically evident bronchiectasis, a history of significant alcohol or drug abuse",37.0
1523,NCT02407262,Phase 2,Asthma,"University College, London",10-Feb-15,Asthma;Inflammation,"Patients with serious co-morbid conditions such as; cancer, renal, hepatic, cardio-vascular, gastrointestinal diseases, mental health conditions and respiratory disorder such as TB and COPD.",37.0
1524,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Positive for Mycobacterium tuberculosis using QuantiFERON Gold test at screening.,37.0
1525,NCT04092582,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Positive for TB at screening ,37.0
1526,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"Significant disease other than asthma not limited to diagnosis of COPD, such as, active tuberculosis, cystic fibrosis, alpha 1 antitrypsin deficiency, clinically significant bronchiectasis, interstitial lung disease, allergic bronchopulmonary aspergillosis, or constrictive bronchiolitis. A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, or (ii) influence the results of the study, or (iii) cause concern regarding the patient ability to participate in the study",37.0
1527,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,Antihistamines within 7 days of the screening visit.,38.0
1528,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Short-acting or long-acting antihistamines within 48hrs or 7 days, respectively, prior to screening.",38.0
1529,NCT01128569,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unable to abstain from antihistamines,38.0
1530,NCT01128595,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unable to abstain from antihistamines,38.0
1531,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Use of antihistaminic drugs within 3 days preceding the administration of salbutamol during Screening.,38.0
1532,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Use of long-acting antihistamines within 7 days' or short-acting antihistamines within 72 hours prior to the screening skin prick test,38.0
1533,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Use of short-acting or long-acting non-sedatives antihistamines,38.0
1534,NCT01470755,Phase 2,Asthma,Assistance Publique - Hôpitaux de Paris,10-Feb-15,, Any patient aged 2 years 6 months and 6 years 11 months :,39.0
1535,NCT01841281,Phase 2,Asthma;Inflammation,Nicholas Kenyon,10-Feb-15,Asthma;Inflammation,<19 yrs of age,39.0
1536,NCT01999907,Phase 2,Asthma,St. Justine's Hospital,10-Feb-15,Asthma,infants <12 months of age,39.0
1537,NCT01393340,Phase 2,Nasal Polyposis;Asthma,"University Hospital, Ghent",10-Feb-15,Colorectal Neoplasms;Nasopharyngeal Neoplasms;Asthma;Nasal Polyps,Patients younger than 18 years old.,39.0
1538,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,A history of acute heart failure or chronic left sided heart failure,40.0
1539,NCT00322686,Phase 2,Asthma,Forest Laboratories,10-Feb-15,Asthma,Active cardiac disease ,40.0
1540,NCT02061670,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Administration of adrenaline (epinephrine) is contraindicated (e.g. subjects with acute or chronic symptomatic coronary heart disease or severe hypertension).,40.0
1541,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,"Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations within the previous 3 years",40.0
1542,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Any clinically significant abnormalities in haematology.,40.0
1543,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,"arrhythmias, coronary artery disease, congestive heart failure, congenital heart disease or other significant cardiac disease",40.0
1544,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Cardiac Conditions/Disease: Subjects with documented myocardial infarction within a year from the Screening (Visit 1a) are to be excluded. Subjects with a recent history of acute coronary syndrome, or who have undergone percutaneous coronary intervention or coronary artery bypass graft within 3 months of Screening (Visit 1a) are to be excluded. ",40.0
1545,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant coronary heart disease-Clinically significant cardiac arrhythmia,40.0
1546,NCT00207740,Phase 2,Asthma,"Centocor, Inc.",10-Feb-15,Asthma,"Concomitant diagnosis or any history of congestive heart failure (CHF), including medically controlled CHF. ",40.0
1547,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Congestive heart failure-Known aortic aneurysm,40.0
1548,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,"Contraindication to Methacholine challenge testing (heart attack or stroke in last 3 months, uncontrolled hypertension, or known aortic aneurysm).",40.0
1549,NCT02501824,Phase 2,Asthma,University of Bern,10-Feb-15,Asthma,Coronary heart disease,40.0
1550,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,Diagnosis of heart failure or history of hospitalization for congestive heart failure.,40.0
1551,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Has symptomatic ischemic heart disease (angina pectoris),40.0
1552,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"History of clinically significant hypotensive episodes or fainting, dizziness or light-headedness",40.0
1553,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,"History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness",40.0
1554,NCT00292201,Phase 2,Asthma,Queen's University,10-Feb-15,Asthma,"History of coronary artery disease, hyperlipidemia, or other condition requiring statin therapy ",40.0
1555,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,"History of coronary artery disease defined as prior myocardial infarction, prior revascularization procedure, or >50% coronary artery obstruction by angiography.",40.0
1556,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,History of hospitalization within 12 months caused by heart failure or a diagnosis of heart failure higher than New York Heart Association (NYHA) class II,40.0
1557,NCT02427165,Phase 2,Asthma,Verona Pharma plc,10-Feb-15,Asthma,History of ischemic heart disease or heart failure. History of recurrent or current clinically significant arrhythmia or ECG abnormality as judged by the investigator,40.0
1558,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,History of major bleeding or intracranial hemorrhage,40.0
1559,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"History of myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within 3 months of screening visit",40.0
1560,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"history of myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within 3 months prior to Screening Visit;",40.0
1561,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,History or any current clinical evidence suggesting cardiomyopathy or congestive heart failure;,40.0
1562,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,"History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, or cardiac arrhythmias;",40.0
1563,NCT01070524,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,History or current evidence of significant cardiovascular disease,40.0
1564,NCT03944707,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"History or presence of thrombotic or thromboembolic event, or increased risk for thrombotic or thromboembolic event. ",40.0
1565,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,History or symptoms of cardiovascular disease,40.0
1566,NCT00232999,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease",40.0
1567,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within past ≤3 months",40.0
1568,NCT02740868,Phase 2,Cystic Fibrosis;Asthma,The Hospital for Sick Children,10-Feb-15,Cystic Fibrosis;Fibrosis,"Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension",40.0
1569,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,Patients with unstable angina pectoris or stable angina pectoris classified higher than Canadian Cardiovascular Society (CSS) class II or a myocardial infarction or stroke within 6 months,40.0
1570,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous 6 months at enrollment;,40.0
1571,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,"Presence of other known pulmonary disease, coronary disease, congestive heart failure, ventricular arrhythmias, history of a cerebrovascular accident, renal failure (or creatinine >",40.0
1572,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,Prior history of stroke or transient ischemic attack.,40.0
1573,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure.,40.0
1574,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,Subjects with documented myocardial infarction within a year from screening visit,40.0
1575,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,Subjects with symptoms of angina pectoris or with a history of confirmed coronary disease or cardiomyopathy,40.0
1576,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,Subjects with symptoms of angina pectoris or with a history of confirmed coronary disease or cardiomyopathy.,40.0
1577,NCT00407524,Phase 2,Asthma,University of Aberdeen,10-Feb-15,Asthma,"The patient has a recent (less than six months) history of stroke, transient ischemic attack or myocardial infarction",40.0
1578,NCT00365560,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"who have been hospitalized for heart failure (NYHA class III or IV) within the past year,",40.0
1579,NCT00365560,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"with a recent history (i.e., six months or less) of myocardial infarction,",40.0
1580,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,"8° C, Systolic BP > 150mm Hg or < 85 mm Hg; or Diastolic BP > 90 mm Hg or < 50 mm Hg, or pulse oximetry saturation reading less than 93%",41.0
1581,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"As a result of medical interview, physical examination or screening investigations, the principle investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 145 mmHg or a diastolic pressure above 85 mmHg unless the Investigator confirms that it is satisfactory for their age",41.0
1582,NCT02251379,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,"Cardiovascular disease that requires daily medication, excluding hypertension",41.0
1583,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,"Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening",41.0
1584,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Current history of uncontrolled hypertension or uncontrolled diabetes, in the opinion of the Investigator (NOTE: controlled hypertension and/or controlled diabetes are not exclusionary)",41.0
1585,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Current or untreated tuberculosis; History of tuberculosis is acceptable only if a subject has received an approved prophylactic treatment regimen or an approved active treatment regimen and has had no evidence of active disease for a minimum of 2 years • Uncontrolled hypertension (systolic BP ≥160 or diastolic BP >100),41.0
1586,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,Currently being treated for Hypertension or taking any other medications that affect blood pressure significantly.,41.0
1587,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,Diastolic blood pressure <50 mmHg or ≥100 mmHg,41.0
1588,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,evidence of uncontrolled hypertension ,41.0
1589,NCT01833390,Phase 2,Asthma;COPD;Healthy,Xemed LLC,10-Feb-15,Asthma,"History of heart attack, stroke and/or poorly controlled hypertension.",41.0
1590,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,"hypertension which, in the opinion of the Investigator, deems the subject unfit to enter the study; subjects must not have a persistent systolic pressure above 145 mmHg or diastolic pressure above 85 mmHg unless the Investigator confirms that it is satisfactory for their age.",41.0
1591,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,"Hypotension (systolic blood pressure < 110 mmHg) at Screening or Check-in Visit 2, Day 1 or Visit 3, Day 7",41.0
1592,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,"In patients ≥ 60 years old, systolic blood pressure <90 mmHg or ≥160 mmHg",41.0
1593,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,"In patients < 60 years old, systolic blood pressure <90 mmHg or ≥150 mmHg",41.0
1594,NCT01074853,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma,Resting BP (Blood Pressure) <110 systolic or HR (Heart Rate)<60.,41.0
1595,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Stroke within 3 months of Visit 1-Uncontrolled hypertension,41.0
1596,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject has known history of hypertension or is hypertensive at screening. Hypertension at screening is defined as persistent systolic BP >140mmHg or diastolic BP > 90mmHg.,41.0
1597,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject has known history of hypertension or is hypertensive at screening. Hypertension at screening is defined as persistent systolic BP >140mmHg or diastolic BP > 90mmHg.,41.0
1598,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject has known history of hypertension or is hypertensive at screening. Hypertension at screening is defined as persistent systolic BP >150 mmHg or diastolic BP > 90mmHg,41.0
1599,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject has known history of hypertension or is hypertensive at screening. Hypertension at screening is defined as persistent systolic BP >150 mmHg or diastolic BP > 90mmHg.,41.0
1600,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject has uncontrolled hypertension or is hypertensive at screening. Hypertension at screening is defined as persistent systolic BP >150 mmHg or diastolic BP > 90mmHg.,41.0
1601,NCT01128569,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is hypertensive at screening,41.0
1602,NCT01128595,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is hypertensive at screening,41.0
1603,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is hypertensive at screening.,41.0
1604,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"Subjects with a resting heart rate < 45 bpm, systolic blood pressure < 100 mmHg, diastolic blood pressure < 60 mmHg",41.0
1605,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,Subjects with a supine systolic blood pressure ≥160 mmHg or a supine diastolic blood pressure ≥100 mmHg at screening or prior to randomization.,41.0
1606,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,Subjects with current uncontrolled arterial hypertension,41.0
1607,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,Subjects with current uncontrolled arterial hypertension.,41.0
1608,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"systolic blood pressure ≥160, or diastolic blood pressure >100",41.0
1609,NCT00640016,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"systolic blood pressure greater than 200 millimeters of mercury (mmHg), or diastolic blood pressure greater than 100 mmHg, heart disease, psoriasis requiring treatment and subjects who have had a heart attack or stroke within the 3 months preceding Day -28/-14 to Day 0, or who have a known aneurysm",41.0
1610,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Uncontrolled hypertension,41.0
1611,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Uncontrolled hypertension,41.0
1612,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Uncontrolled hypertension, defined as systolic blood pressure >160 mm/Hg, or diastolic blood pressure >100 mm/Hg",41.0
1613,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Uncontrolled hypertension (systolic BP ≥160 or diastolic BP >100),41.0
1614,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Uncontrolled hypertension defined as a blood pressure ≥ 170/100 mm Hg (22.7/13.3 kPa);,41.0
1615,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Uncontrolled hypertension.,41.0
1616,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,uncontrolled hypertension. ,41.0
1617,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Uncontrolled Hypertension: Subjects who, in the opinion of the Investigator, have clinically significant uncontrolled hypertension",41.0
1618,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,Uncontrolled systemic arterial hypertension,41.0
1619,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,3 or more asthma exacerbations requiring treatment with systemic corticosteroids for more than three days in the past year consistent with severe asthma,42.0
1620,NCT00318747,Phase 2,"Asthma;Allergy;Allergic Rhinitis;Rhinitis, Allergic, Seasonal",National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",3 or more courses of oral corticosteroids for asthma within the year prior to study entry,42.0
1621,NCT00635882,Phase 2,Asthma;Airway Inflammation,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma;Inflammation,"A clinical asthma exacerbation defined as a clinical deterioration of asthma that results in emergency treatment, hospitalization for asthma, or treatment with additional, excluded asthma medication (including oral or other systemic corticosteroids but allowing SABA), as per investigator, between Screening and Baseline Visits.",42.0
1622,NCT01499446,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A history of two or more asthma exacerbations requiring treatment with oral corticosteroids or hospitalisation in the 6 months before Visit,42.0
1623,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal","A systemic (intravenous, intramuscular or oral) corticosteroid within 3 months",42.0
1624,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Administration of a parenteral (intravenous or subcutaneous) beta agonist (e. g., albuterol, terbutaline, epinephrine) within 6 hours prior to randomization;",42.0
1625,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Administration of intranasal and/or inhaled steroids within 2 week of the screening visit. Prior to this the subject's maximum daily dose must be less than FP equivalent 250mcg.,42.0
1626,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Administration of oral, injectable or dermal steroids within 4 weeks or intranasal and/or inhaled steroids within 2 week of the screening visit.",42.0
1627,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Administration of oral, injectable or dermal steroids within 8 weeks of screening.",42.0
1628,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Administration of oral or injectable steroids within 5 weeks of screening or intranasal and/or inhaled steroids within 4 weeks of the screening visit,42.0
1629,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Administration of oral or injectable steroids within 5 weeks of screening or intranasal and/or inhaled steroids within 4 weeks of the screening visit.,42.0
1630,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Administration of oral or injectable steroids within 6 weeks of screening.,42.0
1631,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Any asthma exacerbation requiring oral corticosteroids within 1 month of the Screening Visit. A subject must not have had any hospitalization for asthma within 2 month prior to the Screening Visit. Note: An exacerbation of asthma is defined as any worsening of asthma requiring any treatment other than rescue albuterol/salbutamol HFA MDI and/or the subject's regular inhaled corticosteroid maintenance treatment. This includes requiring the use of systemic corticosteroids and/or emergency room visit or hospitalization, a change in the subject's regular inhaled corticosteroid maintenance treatment, or the addition of other asthma medications",42.0
1632,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any asthma exacerbation requiring oral corticosteroids within 8 weeks of screening. A subject must not have had any hospitalisation for asthma within 6 months prior to screening,42.0
1633,NCT01225315,Phase 2,Asthma,Idorsia Pharmaceuticals Ltd.,10-Feb-15,Asthma,Any asthma exacerbation requiring treatment with systemic corticosteroids within the last 3 months,42.0
1634,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Any disease or illness, other than asthma, that is likely to require the use of systemic corticosteroids during the study period;",42.0
1635,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Any disease or illness, other than asthma, that may require the use of systemic corticosteroids during the study period;",42.0
1636,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Any disease or illness, other than asthma, that may require the use of systemic corticosteroids during the study period;",42.0
1637,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Any disease or illness, other than asthma, that may require the use of systemic corticosteroids during the study period.",42.0
1638,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,Any disease or illness other than asthma that may require the use of systemic corticosteroids during the study period.,42.0
1639,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Asthma exacerbation, defined as any worsening of asthma requiring any treatment other than rescue albuterol/salbutamol or regular inhaled corticosteroid use. This includes requiring the use of systemic corticosteroids and / or emergency room visit or hospitalization or a change in subject's regular inhaled corticosteroid dose.",42.0
1640,NCT00603746,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Asthma exacerbation, defined as any worsening of asthma requiring any treatment other than rescue albuterol/salbutamol or regular inhaled corticosteroid use. This includes requiring the use of systemic corticosteroids and / or emergency room visit or hospitalization or a change in subject's regular inhaled corticosteroid dose",42.0
1641,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,Asthma exacerbation requiring systemic corticosteroids within the 4 weeks prior to Visit 0,42.0
1642,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Asthma Exacerbation: Any asthma exacerbation requiring oral corticosteroids within 3 months of Visit,42.0
1643,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Asthma exacerbations requiring treatment with oral corticosteroids: any exacerbations within 4 weeks of the screening visit or two or more exacerbations within 2 months of the screening visit or admittance to hospital for an asthma exacerbation within 6 months of the screening visit.,42.0
1644,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,Asthma necessitating treatment with inhaled corticosteroids for at least one month before the start of the study,42.0
1645,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,"Asthma that is unstable or required emergent/urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids",42.0
1646,NCT00614874,Phase 2,Asthma,Creighton University,10-Feb-15,Asthma,"Chronic intermittent use of inhaled, oral, intra-muscular, topical or intravenous corticosteroids within 4 weeks of visit 1",42.0
1647,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Corticosteroid Use: Administration of systemic, oral or depot corticosteroids within 12 weeks of Visit",42.0
1648,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Corticosteroid Use: ICS used within 6 weeks or OCS/depot corticosteroids within 12 weeks,42.0
1649,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Current use or use of systemic corticosteroids within past 2 months,42.0
1650,NCT00666679,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Has required an oral corticosteroid rescue for worsening asthma during the screening period ,42.0
1651,NCT01136655,Phase 2,Asthma,AstraZeneca,10-Feb-15,,"Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit",42.0
1652,NCT01136382,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit 2 ",42.0
1653,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,History of severe asthma necessitating the use of oral/injectable corticosteroids within the last 2 months and/and or two bursts in the last year,42.0
1654,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Hospitalization for treatment of asthma and/or treatment with oral/injectable corticosteroids within 3 months before the start of the study,42.0
1655,NCT01123252,Phase 2,Seasonal Affective Rhinitis;Asthma;Grass Allergy,University of East Anglia,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal","Inadequate washout periods for the following: Intranasal cromolyn (2 weeks) Intranasal or systemic decongestants (3 days) Intranasal or systemic antihistamines (3 days), except astemizole (6 weeks) or loratadine (10 days).",42.0
1656,NCT00936624,Phase 2,Asthma,"SK Chemicals Co., Ltd.",10-Feb-15,Asthma,"Inhaled, oral or parenteral corticosteroids within 4 weeks before visit 1",42.0
1657,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Inhaled or systemic corticosteroids (oral, intravenous, intramuscular) within 4 weeks prior to screening or prior to randomization.",42.0
1658,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,"Is currently requiring greater than fluticasone 500 mcg administered twice daily plus a long-acting beta agonist (LABA) one puff twice daily or its equivalent, and/or --Individuals using oral corticosteroids daily or every other day for more than 14 days at the time of Visit 0 (Screening).",42.0
1659,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,"Maintenance oral corticosteroid therapy, defined as daily alternate-day oral corticosteroid maintenance therapy within 3 months prior to Visit 1",42.0
1660,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Maintenance oral corticosteroid therapy, defined as daily or alternate day oral corticosteroid maintenance therapy within the 3 months prior to Visit 1",42.0
1661,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Maintenance oral corticosteroid therapy, defined as daily or alternate day oral corticosteroid maintenance therapy within the 3 months prior to Visit 1",42.0
1662,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,More than 12 hours of oral corticosteroid treatment for a current exacerbation,42.0
1663,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,More than four days of albuterol treatment (for symptoms) in the past two weeks,42.0
1664,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,More than one night of albuterol treatment (for symptoms) in the past two weeks,42.0
1665,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,Need for systemic corticosteroids or a hospitalization for respiratory symptoms within four weeks prior to screening,42.0
1666,NCT00980200,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,No use of systemic corticosteroids for any indication within 8 weeks prior to Visit,42.0
1667,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Oral, inhaled, or parenteral corticosteroids for 1 month prior to the first study visit.",42.0
1668,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,"Oral, inhaled or parenteral corticosteroids prior to 4 weeks of visit 1",42.0
1669,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Oral corticosteroid burst or short-acting systemic corticosteroid within 30 days prior to screening or during the screening/run-in period,42.0
1670,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,Oral corticosteroid use at any dose within the 6 weeks prior to the Screening Visit,42.0
1671,NCT00967590,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,oral corticosteroid use within 4 weeks prior to screening,42.0
1672,NCT00961155,Phase 2,Asthma,Medical University of Lodz,10-Feb-15,Asthma;Inflammation,oral corticosteroids for 4 weeks before the study,42.0
1673,NCT00436670,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,Oral or parenteral corticosteroids within 6 weeks before first run-in visit,42.0
1674,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,Oral or systemic corticosteroid burst (for any indication) within the 4 weeks prior to Visit,42.0
1675,NCT02148796,Phase 2,Asthma;Wheezing,University of Arizona,10-Feb-15,Respiratory Sounds,"Participants may not have received inhaled or systemic corticosteroids for respiratory related illness ever, or for other conditions in the month prior to randomization.",42.0
1676,NCT01123252,Phase 2,Seasonal Affective Rhinitis;Asthma;Grass Allergy,University of East Anglia,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Participants receiving any form of corticosteriod from 1 month prior to the study,42.0
1677,NCT00801853,Phase 2,Asthma,"Aerovance, Inc.",10-Feb-15,Asthma,Patient has received oral corticosteroid treatment within 8 weeks of Randomization (Visit 2)or patient has been intubated for ventilation in the past 5 years,42.0
1678,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,Patient who received systemic corticosteroids within the last 4 weeks prior to visit,42.0
1679,NCT01132781,Phase 2,Rhinosinusitis;Asthma;Allergic Rhinitis,University of East Anglia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",Patients consuming more than the recommended amount of alcohol (14 units per week for women and 21 units per week for men) Inhaled corticosteroids at a dose greater than 2mg beclomethasone dipropionate (BDP) equivalent or oral corticosteroids or oral zafirlukast,42.0
1680,NCT02479412,Phase 2,Asthma;Efficacy;Safety,AstraZeneca,10-Feb-15,Asthma,Patients on medium to high-dose ICS (equivalent of budesonide > 400 μg per day) or on inhaled anticholinergic combination within the 6 weeks prior to Visit 1,42.0
1681,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Patients treated with oral or parenteral corticosteroids in the previous 2 months before the screening visit (3 months for parenteral depot corticosteroids),42.0
1682,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Patients treated with oral or parenteral corticosteroids in the previous 8 weeks;,42.0
1683,NCT00868023,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Patients treated with oral or parenteral corticosteroids in the previous 8 weeks (12 weeks for parenteral depot corticosteroids) before screening visit.,42.0
1684,NCT01370031,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Patients treated with oral or parenteral corticosteroids in the previous 8 weeks (12 weeks for parenteral depot corticosteroids) before screening visit.,42.0
1685,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,Patients who have been hospitalized or required high-dose (>10mg prednisolone/day) oral corticosteroid (OCS) therapy within 6 weeks of the screening visit,42.0
1686,NCT01130064,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Patients who have experienced a severe asthma attack/exacerbation requiring systemic corticosteroids or an increase in maintenance doses, within 6 weeks of screening",42.0
1687,NCT03944707,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Patients who have had an asthma exacerbation requiring systemic corticosteroids, hospitalization, or emergency room visit within 6 weeks prior to screening or during the screening period.",42.0
1688,NCT00346398,Phase 2,Asthma;Allergic Sensitization,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Received 10 or more days of systemic steroids in the 3 months prior to study entry,42.0
1689,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,"Regular use of immunosuppressive medication (including but not limited to maintenance daily prednisolone (>10mg per day), hydrocortisone, azathioprine, or weekly methotrexate).",42.0
1690,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Regular use of oral or systemic corticosteroids for diseases other than asthma within 12 months or any intra-articular, short-acting intramuscular corticosteroid within 1 month or intramuscular, long-acting depot corticosteroid within 3 months",42.0
1691,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Regular use of systemic corticosteroids for conditions including asthma within 3 months prior to Screening (Visit 1).,42.0
1692,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Requirement for daily systemic corticosteroids above 10 mg of prednisone (or equivalent) per day for the past 2 months,42.0
1693,NCT00330070,Phase 2,Asthma,Inflazyme Pharmaceuticals Ltd,10-Feb-15,Asthma,requirement for more than 10 inhalations per day of a short-acting beta-2-agonist more than 3 times per week during the baseline period ,42.0
1694,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Significant medical illness other than asthma that could require oral corticosteroids during the study.,42.0
1695,NCT00675649,Phase 2,Asthma,"Centocor, Inc.",10-Feb-15,Asthma,Steroid use at a dose > 20 mg of prednisone at the screening visit,42.0
1696,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,"Subject has received oral, nasal, inhaled, or IM corticosteroids during the preceding month.",42.0
1697,NCT00526357,Phase 2,Asthma,Firestone Institute for Respiratory Health,10-Feb-15,Asthma;Inflammation,Subjects taking >1000 mcg of inhaled steroids daily in those subjects taking inhaled steroids.,42.0
1698,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects who are unable to washout the following protocol defined prohibited medications within the defined times at screening: Oral corticosteroids Inhaled, intranasal and topical steroids Long acting beta agonists Short acting beta agonists",42.0
1699,NCT00526357,Phase 2,Asthma,Firestone Institute for Respiratory Health,10-Feb-15,Asthma;Inflammation,Subjects who have taken oral corticosteroids or a leukotriene receptor antagonist in 4 weeks prior to entry into the study.,42.0
1700,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects who have taken oral steroids within 12 weeks of the screening visit.,42.0
1701,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Subjects with a history of a respiratory tract infection or an asthma exacerbation requiring the use of antibiotics and/or systemic corticosteroids within 4 weeks prior to visit V1, or who develop a respiratory tract infection or asthma exacerbation during the screening period. In the latter case, the subjects can be re-screened 4 weeks after the last dose of systemic corticosteroid (except for depot corticosteroids; see Table",42.0
1702,NCT02479412,Phase 2,Asthma;Efficacy;Safety,AstraZeneca,10-Feb-15,Asthma,Systemic steroid use in the 6 weeks before Visit 1,42.0
1703,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Taking antihistamines, nasal corticosteroids, or decongestants and not on a stable dose for 3 days prior to any dosing day",42.0
1704,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,Taking oral or i.v. corticosteroids for any disease indication other than asthma,42.0
1705,NCT01899144,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,The dosage of any required intranasal corticosteroid and/or cromone has not been stable for at least 2 weeks prior to the screening visit,42.0
1706,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Three or more asthma exacerbations requiring treatment with systemic corticosteroids in the past year consistent with severe asthma,42.0
1707,NCT03762395,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma,Three or more asthma exacerbations requiring treatment with systemic corticosteroids in the past year consistent with severe asthma,42.0
1708,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,Three or more courses of systemic corticosteroids for wheezing illnesses in the last year,42.0
1709,NCT01470755,Phase 2,Asthma,Assistance Publique - Hôpitaux de Paris,10-Feb-15,,treated with oral glucocorticosteroids within 15 days before the test.,42.0
1710,NCT01899144,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Treated with oral or injectable corticosteroids within the 6 weeks before the screening visit,42.0
1711,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Treatment of conditions other than asthma with oral corticosteroids within 1 month of the start of the study,42.0
1712,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,Treatment of conditions other than asthma with oral corticosteroids within one month of the start of the study,42.0
1713,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Treatment with an oral or systemic burst of corticosteroids within 4 weeks prior to randomization into the study,42.0
1714,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,Treatment with immunomodulators (inhaled corticosteroids in two months or oral corticosteroids in six months prior to study),42.0
1715,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,Treatment with oral corticosteroids in the past month,42.0
1716,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Treatment with systemic (oral, intravenous or intramuscular) corticosteroids within the 4 weeks prior to Visit 1",42.0
1717,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,"Treatment with systemic (oral, intravenous or intramuscular) corticosteroids within the 4 weeks prior to Visit 1",42.0
1718,NCT04046939,Phase 2,Eosinophilic Asthma;Asthma,Knopp Biosciences,10-Feb-15,Asthma;Pulmonary Eosinophilia,Treatment with systemic corticosteroids in the 8 weeks prior to Screening,42.0
1719,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,"Treatment with systemic corticosteroids within 4 weeks prior to Visit 1 or during the screening period for any reason, including an acute exacerbation event",42.0
1720,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,"Use of anti-IgE, methotrexate, oral gold, Dapsone, or i.v. gamma globulin within 3 months of Screening",42.0
1721,NCT00697801,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,Use of any corticosteroid within 2 weeks of screening.,42.0
1722,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,"Use of any oral, depot or parental corticosteroids within four weeks of screening visit. The use of topical corticosteroid cream (<1%) to treat skin conditions is allowed",42.0
1723,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Use of immunosuppressive medication (except oral prednisone and inhaled and topical corticosteroids) within 30 days before randomization into the study,42.0
1724,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Use of immunosuppressive medication (except oral prednisone up to 10 milligram/day (mg/day) and inhaled and topical corticosteroids) within 30 days before randomization into the study,42.0
1725,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Use of immunosuppressive medication (except oral prednisone up to a dose of 20 mg every other day or equivalent [eg, 10 mg a day or 5 mg twice a day] and inhaled and topical corticosteroids) within 28 days before randomization",42.0
1726,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Use of immunosuppressive medication within 3 months prior to screening. Chronic oral prednisone or equivalent up to 10 milligram (mg) daily or 20 mg every other day for asthma is allowed,42.0
1727,NCT01057927,Phase 2,Asthma,Oxagen Ltd,10-Feb-15,Asthma,Use of inhaled or local corticosteroids in the period from 28 days prior to screening.,42.0
1728,NCT00822861,Phase 2,Asthma,Pharmaxis,10-Feb-15,Asthma,"Use of inhaled or oral corticosteroids within the last 30 days, or need for antihistamines within 72 hours of each allergen or methacholine challenge, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed). ",42.0
1729,NCT00330070,Phase 2,Asthma,Inflazyme Pharmaceuticals Ltd,10-Feb-15,Asthma,use of injectable or oral corticosteroids within 2 months prior to screening,42.0
1730,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Use of intranasal corticosteroids at a stable dose for at least 4 weeks prior to the Screening Visit and throughout the study is permitted,42.0
1731,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Use of intranasal corticosteroids or ocular corticosteroids at a stable dose for at least 4 weeks prior to the Screening Visit and throughout the study is permitted,42.0
1732,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hr of dosing or aspirin within seven days of dosing and any time during the Treatment Phases,42.0
1733,NCT00697801,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,Use of oral corticosteroid within 30 days of screening or prolonged use of oral corticosteroids within 12 weeks of screening.,42.0
1734,NCT00327808,Phase 2,Asthma,Pharmaxis,10-Feb-15,Asthma,Use of oral/parenteral/inhaled corticosteroids within the last 28 days or injectable depot corticosteroids within the last 6 weeks.,42.0
1735,NCT01006655,Phase 2,Asthma;Bronchial Hyperresponsiveness,Rambam Health Care Campus,10-Feb-15,Bronchial Hyperreactivity,use of oral steroids in the last two months,42.0
1736,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,"Use of oral steroids within the last 1 month, or use of >/= 3 steroid bursts in the last 12 months",42.0
1737,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,"Use of restricted respiratory medication prior to screening within the following time periods: 1) oral or systemic steroids, 1 month; 2) immunosuppressant therapy, 3 months",42.0
1738,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Use of systemic, oral or depot corticosteroids within 12 weeks prior to the Screening Visit",42.0
1739,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,"Use of systemic, oral or depot corticosteroids within 4 weeks prior to the Screening Visit",42.0
1740,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,Use of systemic corticosteroids to treat an asthma exacerbation or any other condition within 4 weeks prior to Visit,42.0
1741,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Use of systemic corticosteroids within 6 weeks of screening. The only exception is subjects who take <=10 mg prednisolone (or equivalent) orally per day for chronic maintenance therapy, and who have been maintained on this regimen for >=12 weeks.",42.0
1742,NCT00635882,Phase 2,Asthma;Airway Inflammation,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma;Inflammation,Use of systemic glucocorticosteroids within 3 months before Screening.,42.0
1743,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Use of topical corticosteroids (≤1% hydrocortisone cream) for dermatological disease is permitted,42.0
1744,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Use of topical corticosteroids (≤1% hydrocortisone cream) for dermatological disease is permitted,42.0
1745,NCT00407524,Phase 2,Asthma,University of Aberdeen,10-Feb-15,Asthma,Use of unlicensed doses of inhaled corticosteroid medication (>2000mcg beclomethasone diproprionate/ day or equivalent),42.0
1746,NCT00096616,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,",42.0
1747,NCT00207740,Phase 2,Asthma,"Centocor, Inc.",10-Feb-15,Asthma,Worsening of asthma symptoms that required treatment with an addition or increase in oral corticosteroids dose (steroid burst) in the 4-week period prior to the screening visit,42.0
1748,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Body weight < 40 kg ,43.0
1749,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Body weight < 40 kg ,43.0
1750,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Body weight <40 kg ,43.0
1751,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,Body weight <40 kilograms (kg),43.0
1752,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients with weight < 17kg at screening,43.0
1753,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,weight > 100 kg or < 50 kg,43.0
1754,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,Weight less than 10 kg,43.0
1755,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Weight: less than 50 kilograms (kg) and more than 150 kg.,43.0
1756,NCT00783601,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Any clinically significant disease of heart, intestinal, kidney, liver, lung or uncontrolled blood pressure",44.0
1757,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,"Any other significant respiratory or cardiac disease, or the presence of clinically important comorbidities, including uncontrolled diabetes, uncontrolled coronary artery disease",44.0
1758,NCT01018550,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,"Any uncontrolled, clinically significant systemic disease",44.0
1759,NCT00436670,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,"Any uncontrolled, clinically significant systemic disease (eg, chronic renal failure, uncontrolled hypertension, liver disease) ",44.0
1760,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,"Any uncontrolled concomitant disease requiring further clinical evaluation (e.g. uncontrolled diabetes, uncontrolled hypertension, etc.) ",44.0
1761,NCT01199289,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,"Any uncontrolled or clinically significant systemic disease (eg, uncontrolled diabetes, liver disease) ",44.0
1762,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Clinically relevant and uncontrolled concomitant diseases,44.0
1763,NCT00936624,Phase 2,Asthma,"SK Chemicals Co., Ltd.",10-Feb-15,Asthma,Clinically significant and uncontrolled psychiatric disease or history of drug or alcohol abuse,44.0
1764,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant disease which is uncontrolled with standard treatment,44.0
1765,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Concurrent disease/abnormalities: Clinically significant uncontrolled disease,44.0
1766,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Evidence of any uncontrolled systemic disease upon physical examination,44.0
1767,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,Previous medical history or evidence of an uncontrolled intercurrent illness,44.0
1768,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,"psychiatric disease requiring daily medication, including controlled or uncontrolled schizophrenia or any other uncontrolled psychiatric condition",44.0
1769,NCT00640016,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Significant, uncontrolled disease including serious psychological disorders, chronic renal failure, uncontrolled hypertension",44.0
1770,NCT02615080,Phase 2,Asthma,RSPR Pharma AB,10-Feb-15,Asthma,"Significant concurrent, uncontrolled medical condition as defined by the protocol",44.0
1771,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,"Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes",44.0
1772,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,"Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, or diabetes at the discretion of the investigator",44.0
1773,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Subjects with any clinically significant, uncontrolled condition",44.0
1774,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Subjects with any clinically significant, uncontrolled condition.",44.0
1775,NCT00930163,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Uncontrolled clinically significant medical disease,44.0
1776,NCT00971035,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Uncontrolled clinically significant medical disease,44.0
1777,NCT01070524,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Uncontrolled concomitant disease ,44.0
1778,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,Uncontrolled systemic disease,44.0
1779,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,unstable or uncontrolled disease in any organ system (including cardiovascular) on present therapy,44.0
1780,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,a positive test for HIV antibody,45.0
1781,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive test for HIV antibody.,45.0
1782,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive test for HIV antibody.,45.0
1783,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,A positive test for HIV antibody.,45.0
1784,NCT00896428,Phase 2,Asthma,"University Hospital, Bordeaux",10-Feb-15,Asthma,"Chronic viral infections (hepatitis, HIV)",45.0
1785,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Diagnosis of HIV,45.0
1786,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,H/O HIV,45.0
1787,NCT00017693,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,"Have serious medical problems (such as heart or lung problems, uncontrolled high blood pressure, are overweight to the extent that ability to breathe is affected, or have cancer other than skin cancer), diabetes, autoimmune diseases, or HIV.",45.0
1788,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,history of HIV,45.0
1789,NCT01445015,Phase 2,Asthma;Psychosocial Stress,Weill Medical College of Cornell University,10-Feb-15,Asthma,"History of psychiatric illness, autoimmune disease, HIV/AIDs, smoking history. ",45.0
1790,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Immune suppression (e.g., Human Immunodeficiency Virus [HIV], Lupus) or other risk factors for pneumonia (e.g., neurological disorders affecting control of the upper airway, such as Parkinson's disease, Myasthenia Gravis). Subjects at potentially high risk (e.g., very low Body Mass Index [BMI], severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator",45.0
1791,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Known HIV-positive history.,45.0
1792,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,Known HIV positivity,45.0
1793,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,"Known systemic infection (HBV, HCV, HIV, TB)",45.0
1794,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,"positive for HIV, or Hep B&C at screening",45.0
1795,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Positive pregnancy test for females.,45.0
1796,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,"Positive results to HIV, HbsAg or anti-HCV tests at Screening",45.0
1797,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Positive test for HIV antibodies.,45.0
1798,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has tested positive for HIV antibodies,45.0
1799,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has tested positive for HIV antibodies (if tested according to site SOPs),45.0
1800,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has tested positive for HIV antibodies.,45.0
1801,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,The subject has tested positive for HIV antibodies.,45.0
1802,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,Positive pregnancy test,46.0
1803,NCT02918019,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Positive pregnancy test ,46.0
1804,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,Positive pregnancy test at screening,46.0
1805,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Positive pregnancy test at screening and at pre-dose,46.0
1806,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Positive pregnancy test at Visit 0, Screening (Visit 1) or Visit",46.0
1807,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Pregnancy (based on positive urine test at screening visit) or lactation,46.0
1808,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,Pregnancy or a positive urinary βHCG,46.0
1809,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Participants with a positive test result for COVID-19.,47.0
1810,NCT00554970,Phase 2,Asthma,Allergan,10-Feb-15,Asthma,A history of upper or lower respiratory tract infection within 2 weeks,48.0
1811,NCT00936624,Phase 2,Asthma,"SK Chemicals Co., Ltd.",10-Feb-15,Asthma,Active upper or lower respiratory tract infection within 3 weeks before visit 1,48.0
1812,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Acute respiratory infection within 6 weeks preceding Visit 2 or any ongoing chronic infection,48.0
1813,NCT01692041,Phase 2,Asthma,Technische Universität Dresden,10-Feb-15,Asthma,Acute respiratory infection within the previous 4 weeks,48.0
1814,NCT00557700,Phase 2,Asthma,"University Hospital, Ghent",10-Feb-15,Asthma,Airway infection within 6 weeks prior to first study visit.,48.0
1815,NCT02910401,Phase 2,Asthma;Allergic Rhinitis,University of Virginia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",An upper or lower respiratory tract infection within 2 months prior to enrollment,48.0
1816,NCT01516073,Phase 2,Asthma,Dey,10-Feb-15,Asthma,An upper or lower respiratory tract infection within 4 weeks of Visit 1 and prior to Visit 2,48.0
1817,NCT01516086,Phase 2,Asthma,Dey,10-Feb-15,Asthma,An upper or lower respiratory tract infection within 4 weeks of Visit 1 and prior to Visit 2,48.0
1818,NCT02388997,Phase 2,Asthma,University of Virginia,10-Feb-15,Infections;Asthma,An upper or lower respiratory tract infection within six weeks prior to enrollment,48.0
1819,NCT04150341,Phase 2,Asthma,Theravance Biopharma,10-Feb-15,Asthma,Any sign of respiratory tract infection within 6 weeks of screening,48.0
1820,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,Clinically relevant acute infections in the last 4 weeks preceding AC,48.0
1821,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Clinically significant lower respiratory tract infection not resolved within 4 weeks prior to Screening and during Run-in.,48.0
1822,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Clinically significant upper respiratory tract infection at Screening and during Run-in.,48.0
1823,NCT01256086,Phase 2,Asthma,MEDA Pharma GmbH & Co. KG,10-Feb-15,Asthma,Evidence of respiratory tract infection within 4 weeks before the study (screening visit 1),48.0
1824,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Had an upper or lower respiratory tract infection within 3 weeks, or sinus infection within 7 days;",48.0
1825,NCT00688467,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Has had a worsening of a respiratory tract infection within 4 weeks before Screening.,48.0
1826,NCT02382510,Phase 2,Asthma,"Theron Pharmaceuticals, Inc.",10-Feb-15,Asthma,History of upper or lower respiratory infection within 4 weeks of screening,48.0
1827,NCT02609334,Phase 2,Asthma,RSPR Pharma AB,10-Feb-15,Asthma,Lower respiratory tract infection <6 weeks prior to Visit 1,48.0
1828,NCT02615080,Phase 2,Asthma,RSPR Pharma AB,10-Feb-15,Asthma,Lower respiratory tract infection <6 weeks prior to Visit 1,48.0
1829,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Lower respiratory tract infection not resolved 4 weeks prior to Visit 1,48.0
1830,NCT01848769,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Lower respiratory tract infection within 1 month prior to inclusion,48.0
1831,NCT02787967,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Lower respiratory tract infection within 1 month prior to screening (Visit 1).,48.0
1832,NCT00640016,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Lower respiratory tract infection within 6 weeks of Day -28/-14 to Day 0,48.0
1833,NCT01370031,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Lower respiratory tract infection within one month prior to screening.,48.0
1834,NCT00830102,Phase 2,Asthma,SkyePharma AG,10-Feb-15,Asthma,No history of respiratory tract infection within 4 weeks,48.0
1835,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Parasitic infestation within previous 6 months,48.0
1836,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,Patient with upper or lower airways infection in the 4 weeks before screening,48.0
1837,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,Recent (within 6 weeks of screening) or current lower respiratory tract infection,48.0
1838,NCT01425801,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Recent Respiratory tract infections within 6 weeks before Screening Visit,48.0
1839,NCT00436670,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,Respiratory illness within 4 weeks of screening,48.0
1840,NCT00815347,Phase 2,Asthma,UConn Health,10-Feb-15,Asthma,Respiratory infection during 30 days preceding screening visit.,48.0
1841,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Respiratory infection within 1 month of screening,48.0
1842,NCT01902290,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,Respiratory infection within 4 weeks of screening or 1 week of baseline visit,48.0
1843,NCT01199289,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,Respiratory infection within 4 weeks of screening visit or 1 week of baseline visit,48.0
1844,NCT00402948,Phase 2,Asthma,Pharmaxis,10-Feb-15,Asthma,Respiratory infection within last 4 weeks,48.0
1845,NCT00292877,Phase 2,Asthma,St. Joseph's Healthcare Hamilton,10-Feb-15,Asthma,Respiratory tract infection in the 4-weeks before the baseline visit,48.0
1846,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection that is not resolved within 2 weeks prior to screening,48.0
1847,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection that is not resolved within 2 weeks prior to screening.,48.0
1848,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Respiratory tract infection within 14 days prior to Visit 1,48.0
1849,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection within 2 weeks prior to the first dose of study medication.,48.0
1850,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,Respiratory tract infection within 6 weeks prior to Visit 1,48.0
1851,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,Respiratory tract infection within the 4 weeks prior to Visit 1,48.0
1852,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,Respiratory tract infection within the last 4 weeks,48.0
1853,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Respiratory tract infection within the last 4 weeks,48.0
1854,NCT03762395,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma,Respiratory tract infection within the last 4 weeks,48.0
1855,NCT00785083,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Respiratory tract infections within 1 month of the study Other protocol-defined inclusion/exclusion criteria may apply ,48.0
1856,NCT01704495,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Significant lower respiratory tract infection not resolved within 30 days prior to enrolment,48.0
1857,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Subject with active upper respiratory tract infection prior to 4 weeks before visit 1,48.0
1858,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects who have suffered an upper or lower respiratory tract infection within 4 weeks of the screening visit,48.0
1859,NCT01478152,Phase 2,Asthma,Bitop AG,10-Feb-15,Asthma,Upper and lower airway respiratory infection within 4 weeks prior to study start ,48.0
1860,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,upper or lower respiratory tract infection (viral or bacterial) within 2 weeks prior to Screening Visit,48.0
1861,NCT01502371,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Upper or lower respiratory tract infection (viral or bacterial) within the 2 weeks prior to Screening and Baseline Visits.,48.0
1862,NCT00635882,Phase 2,Asthma;Airway Inflammation,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma;Inflammation,Upper or lower respiratory tract infection within 4 weeks before Screening.,48.0
1863,NCT00746330,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Upper or lower respiratory tract infection within 4 weeks prior to screening.,48.0
1864,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening,48.0
1865,NCT01951222,Phase 2,Asthma,Pierre Fabre Medicament,10-Feb-15,Asthma,Upper or lower respiratory tract infection within 4 weeks.,48.0
1866,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,Upper or lower respiratory tract infection within the last 2 weeks,48.0
1867,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Upper or lower respiratory tract infections within 8 weeks before screening;,48.0
1868,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Upper respiratory infection (viral or bacterial) within 1 month of screening visit,48.0
1869,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,Upper respiratory tract infection within 4 weeks of Screening,48.0
1870,NCT02740543,Phase 2,Asthma,NYU Langone Health,10-Feb-15,Asthma,Upper respiratory tract infection within the last 4 weeks,48.0
1871,NCT02210806,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Upper respiratory tract infections or lower respiratory tract infection within 6 weeks, prior to Screening",48.0
1872,NCT02271334,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Upper respiratory tract infections within 2 weeks, or lower respiratory tract infection within 4 weeks, prior to Screening;",48.0
1873,NCT01581177,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Upper respiratory tract infections within 2 weeks or lower respiratory tract infection within 4 weeks prior to screening visit,48.0
1874,NCT01189396,Phase 2,Asthma;Bronchospasm;Chronic Obstructive Pulmonary Disease (COPD),"Amphastar Pharmaceuticals, Inc.",10-Feb-15,"Asthma;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive;Bronchial Spasm","Upper respiratory tract infections within 2 wk, or lower respiratory tract infection within 4 wk;",48.0
1875,NCT01255709,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Upper respiratory tract infections within 2 wk, or lower respiratory tract infection within 4 wk, prior to Screening;",48.0
1876,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,Viral upper respiratory tract infection within 4 weeks of challenge,48.0
1877,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,>4 episodes of wheezing in the past year,49.0
1878,NCT00983658,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry,49.0
1879,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry,49.0
1880,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,A worsening of asthma within 6 weeks preceding Visit 1,49.0
1881,NCT01443728,Phase 2,Sickle Cell Disease;Vitamin D Deficiency;Acute Chest Syndrome;Asthma;Respiratory Infections,"Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Acute Chest Syndrome;Anemia, Sickle Cell;Vitamin D Deficiency","Absence of baseline record of respiratory events (respiratory infections, asthma exacerbations, episodes of acute chest syndrome) for the preceding year",49.0
1882,NCT01653756,Phase 2,Asthma,SecuraBio,10-Feb-15,Asthma,Acute asthma exacerbations within 6 weeks prior to Screening,49.0
1883,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,Admission to hospital or ER visit for asthma exacerbation within the last 3 months,49.0
1884,NCT01074853,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma,An asthma exacerbation within the last 6 months. ,49.0
1885,NCT01225315,Phase 2,Asthma,Idorsia Pharmaceuticals Ltd.,10-Feb-15,Asthma,Any hospital admission for asthma within the last 6 months,49.0
1886,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,Any severe asthma exacerbation during the run-in period,49.0
1887,NCT00961155,Phase 2,Asthma,Medical University of Lodz,10-Feb-15,Asthma;Inflammation,asthma exacerbation,49.0
1888,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Asthma exacerbation,49.0
1889,NCT00603278,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Asthma exacerbation, defined as any worsening of asthma requiring any treatment other than rescue albuterol/salbutamol or regular inhaled corticosteroid use. This includes requiring the use of systemic corticosteroids and / or emergency room visit or hospitalization or a change in subject's regular inhaled corticosteroid dose",49.0
1890,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Asthma exacerbation due to acute inhalational exposure. ,49.0
1891,NCT00930163,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Asthma exacerbation during screening,49.0
1892,NCT00971035,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Asthma exacerbation during screening,49.0
1893,NCT02427165,Phase 2,Asthma,Verona Pharma plc,10-Feb-15,Asthma,Asthma exacerbation in the last 3 months,49.0
1894,NCT02660489,Phase 2,Asthma;Rhinovirus;Picornaviridae Infections;Common Cold,Imperial College London,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,Asthma exacerbation or viral illness within the previous 6 weeks,49.0
1895,NCT01582503,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Asthma exacerbation requiring systemic steroids in the 30 days prior to Visit 1,49.0
1896,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Asthma exacerbation within 28 days prior to Visit 1 or during screening (prior to Visit 3),49.0
1897,NCT00322686,Phase 2,Asthma,Forest Laboratories,10-Feb-15,Asthma,Asthma exacerbation within 4 weeks,49.0
1898,NCT02918019,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Asthma exacerbation within 4 weeks prior to screening,49.0
1899,NCT01544634,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma;Respiratory Hypersensitivity,Asthma exacerbation within 6 months of study commencement ,49.0
1900,NCT00096616,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"asthma exacerbation within 6 weeks of trial,",49.0
1901,NCT00292201,Phase 2,Asthma,Queen's University,10-Feb-15,Asthma,Asthma exacerbation within preceding 3 months necessitating any escalation of maintenance medications,49.0
1902,NCT00634036,Phase 2,Asthma,Fernando Holguin,10-Feb-15,Asthma,"Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)",49.0
1903,NCT00787644,Phase 2,Asthma;Obesity,University of Vermont,10-Feb-15,Asthma,"Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)",49.0
1904,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Asthma Exacerbation: Requiring OCS within 3 months or hospitalisation within 6 months,49.0
1905,NCT01174732,Phase 2,Asthma;Bronchospasm,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma;Bronchial Spasm,Asthma exacerbations;,49.0
1906,NCT01484197,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Asthma exacerbations in previous 6 months,49.0
1907,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,Asthma-related hospitalization within the last 2 months,49.0
1908,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Asthma-related hospitalization within the last 2 months,49.0
1909,NCT03762395,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma,Asthma-related hospitalization within the last 6 weeks,49.0
1910,NCT01573624,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Concomitant medications affecting course of asthma,49.0
1911,NCT00215397,Phase 2,Asthma,Dey,10-Feb-15,Asthma,"Current asthma exacerbation or recent asthma exacerbation, requiring hospitalization",49.0
1912,NCT00215410,Phase 2,Asthma,Dey,10-Feb-15,Asthma,"Current or recent asthma exacerbation, requiring hospitalization",49.0
1913,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Currently uncontrolled asthma according to GINA guideline;,49.0
1914,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 3 months at enrollment;,49.0
1915,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,Exacerbation of asthma more than 2x/weeks which would be characteristic of a person with moderate or severe persistent asthma as outlined in the current National Asthma Education and Prevention Program (NAEPP) guidelines for diagnosis and management of asthma,49.0
1916,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,Exacerbation of asthma or lower respiratory tract infection during the 4 weeks before screening or prior to randomization.,49.0
1917,NCT01370031,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Exacerbation of asthma symptoms or hospitalization due to asthma exacerbation within the previous one month before screening until randomisation.,49.0
1918,NCT00278083,Phase 2,Asthma,Imperial College London,10-Feb-15,Asthma,Exacerbation of asthma symptoms requiring hospitalisation within the previous 12 weeks,49.0
1919,NCT02787967,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Exacerbation of asthma symptoms within 4 weeks prior to screening.,49.0
1920,NCT01848769,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Exacerbation of asthma symptoms within the previous 4 weeks,49.0
1921,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Exacerbation of asthma within 4 weeks prior to the first dose of study medication.,49.0
1922,NCT02340130,Phase 2,Rhinitis;Rhinoconjunctivitis;Asthma,"Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Conjunctivitis","Has uncontrolled asthma, according to Global Initiative for Asthma Guidelines (GINA 2010)",49.0
1923,NCT00320034,Phase 2,Asthma,Hamilton Health Sciences Corporation,10-Feb-15,Asthma;Inflammation,"History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks.",49.0
1924,NCT01563029,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,history of asthma exacerbation for asthma within 6 months prior to screening.,49.0
1925,NCT01573767,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,history of asthma exacerbation for asthma within 6 months prior to screening.,49.0
1926,NCT00857779,Phase 2,Rhinitis;Conjunctivitis;Asthma,ALK-Abelló A/S,10-Feb-15,Rhinitis;Conjunctivitis,History of asthma exacerbation or emergency visit or admission for asthma in the previous 12 months,49.0
1927,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of asthma exacerbations or acute intercurrent respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) for a four week period before the screening visit.",49.0
1928,NCT02230189,Phase 2,Asthma,Prescott Woodruff,10-Feb-15,Asthma,History of intubation for asthma exacerbation,49.0
1929,NCT01499446,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of respiratory tract infection and/or exacerbation of asthma within a period of 4 weeks prior to Visit 1,49.0
1930,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of severe asthma or asthma exacerbation requiring intubation;,49.0
1931,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Hospitalization due to asthma exacerbation within 1 month prior to the screening visit or during the run-in period,49.0
1932,NCT01848769,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Hospitalization due to exacerbation of asthma within 1 month prior to inclusion,49.0
1933,NCT02787967,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Hospitalization due to exacerbation of asthma within 1 month prior to screening (Visit 1).,49.0
1934,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Hospitalization for asthma during the past 3 months at enrollment;,49.0
1935,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,Hospitalization for asthma within 3 months of Screening,49.0
1936,NCT00545272,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"hospitalized for an acute asthma attack/asthma exacerbation within 6 months prior to Visit 1,",49.0
1937,NCT01584492,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Occurrence of acute asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening visit.,49.0
1938,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening;,49.0
1939,NCT00868023,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening visit.,49.0
1940,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Part 2 only: History of 3 or more severe asthma exacerbations.,49.0
1941,NCT02296411,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Patients treated for asthma exacerbation in the 4 weeks prior to study entry,49.0
1942,NCT02127866,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Patients treated for asthma exacerbations in the 4 weeks prior to study entry,49.0
1943,NCT03299686,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have had a respiratory tract infection or asthma worsening within 4 weeks prior to Visit 1 or during the screening period,49.0
1944,NCT00557440,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Patients who have had an acute asthma attack/exacerbation requiring hospitalization in the 6 months prior to Visit,49.0
1945,NCT02340130,Phase 2,Rhinitis;Rhinoconjunctivitis;Asthma,"Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Conjunctivitis",Patients with hospital admission due to asthma exacerbations within 1 year prior to V1,49.0
1946,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months,49.0
1947,NCT01536041,Phase 2,Asthma,Ono Pharma USA Inc,10-Feb-15,Asthma,"Previous history of life-threatening asthma, respiratory tract infection and/or exacerbation of asthma within 6 weeks prior to the first screening visit",49.0
1948,NCT01551147,Phase 2,Asthma,Ono Pharma USA Inc,10-Feb-15,Asthma,"Previous history of life-threatening asthma, respiratory tract infection and/or exacerbation of asthma within 6 weeks prior to the first screening visit",49.0
1949,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Recent occurrence of asthma exacerbations,49.0
1950,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,respiratory tract infection and / or exacerbation of asthma within 4 weeks prior the first dose of study drug,49.0
1951,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication,49.0
1952,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication,49.0
1953,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.,49.0
1954,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.,49.0
1955,NCT01128569,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.,49.0
1956,NCT01128595,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.,49.0
1957,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Respiratory tract infection or asthma exacerbation in the 4 weeks prior to Visit 1 or during the screening and baseline period,49.0
1958,NCT01641692,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Severe asthma exacerbation,49.0
1959,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with ongoing asthma exacerbation at the time of Visit,49.0
1960,NCT01730027,Phase 2,Asthma,Pulmagen Therapeutics,10-Feb-15,Asthma,Subjects with severe asthma exacerbation in the 4 weeks prior to consent,49.0
1961,NCT04046939,Phase 2,Eosinophilic Asthma;Asthma,Knopp Biosciences,10-Feb-15,Asthma;Pulmonary Eosinophilia,Treatment for an asthma exacerbation within 8 weeks prior to Baseline visit,49.0
1962,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Treatment or hospitalization for asthma exacerbation within past 2 months,49.0
1963,NCT01087710,Phase 2,Asthma,Abbott Nutrition,10-Feb-15,Asthma,Two or more hospitalizations for asthma in the past year.,49.0
1964,NCT02061670,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Uncontrolled asthma according to GINA,49.0
1965,NCT02161107,Phase 2,Seasonal Allergic Rhinitis;Asthma,Circassia Limited,10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Uncontrolled asthma according to GINA.,49.0
1966,NCT01544634,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma;Respiratory Hypersensitivity,Uncontrolled symptoms of asthma,49.0
1967,NCT01074853,Phase 2,Asthma,University of Dundee,10-Feb-15,Asthma,Uncontrolled symptoms of asthma.,49.0
1968,NCT02227394,Phase 2,Asthma;Asthma Chronic;Asthma Bronchial;Asthmatic,Zambon SpA,10-Feb-15,Asthma,Unstable patient who developed an asthma exacerbation in the 4 weeks before screening,49.0
1969,NCT01225549,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Worsening of asthma or respiratory infection within 6 weeks from visit 1,49.0
1970,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Worsening of asthma or respiratory tract infection prior to study entry,49.0
1971,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia, All Subjects (Asthma patients and healthy volunteers):,50.0
1972,NCT00838591,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,A current or prior diagnosis or suspected diagnosis of COPD or other chronic lung disease other than asthma;,50.0
1973,NCT02479412,Phase 2,Asthma;Efficacy;Safety,AstraZeneca,10-Feb-15,Asthma,Any active disease other than asthma,50.0
1974,NCT00736489,Phase 2,Asthma;Airway Obstruction,AstraZeneca,10-Feb-15,Airway Obstruction,Any clinically significant disease or disorder other than asthma,50.0
1975,NCT01103037,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Any significant disease or illness, other than asthma Other protocol-defined inclusion/exclusion criteria may apply ",50.0
1976,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,Chronic respiratory disorder other than asthma,50.0
1977,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically important lung condition other than asthma,50.0
1978,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Clinically important pulmonary disease other than asthma.,50.0
1979,NCT00557700,Phase 2,Asthma,"University Hospital, Ghent",10-Feb-15,Asthma,"Clinically relevant systemic diseases, other than asthma.",50.0
1980,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Clinically significant conditions or illnesses other than moderate asthma or systemic diseases,50.0
1981,NCT01069991,Phase 2,Asthma,Columbia University,10-Feb-15,Asthma,comorbidity with other diseases that affect lung function,50.0
1982,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,"Has a known, pre-existing clinically important lung condition other than asthma;",50.0
1983,NCT02340130,Phase 2,Rhinitis;Rhinoconjunctivitis;Asthma,"Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Conjunctivitis",Has acute or chronic inflammatory or infectious airways disease,50.0
1984,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,History of chronic pulmonary diseases other than asthma,50.0
1985,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,History of chronic pulmonary diseases other than asthma,50.0
1986,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,History of COPD or any other lung disease,50.0
1987,NCT00785083,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,History of lung disease other than asthma,50.0
1988,NCT02251379,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,"Lung disease, other than asthma, that requires daily medication",50.0
1989,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Lung disease other than allergic asthma (e.g. chronic bronchitis);,50.0
1990,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Lung disease other than allergic asthma (eg, chronic bronchitis);",50.0
1991,NCT00983658,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Lung disease other than mild allergic asthma,50.0
1992,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Lung disease other than mild allergic asthma,50.0
1993,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Lung disease other than mild to moderate allergic asthma,50.0
1994,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Lung disease other than persistent asthma (e.g. chronic bronchitis);,50.0
1995,NCT00232999,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Lung diseases other than mild allergic asthma,50.0
1996,NCT00634036,Phase 2,Asthma,Fernando Holguin,10-Feb-15,Asthma,Lung pathology other than asthma,50.0
1997,NCT00787644,Phase 2,Asthma;Obesity,University of Vermont,10-Feb-15,Asthma,Lung pathology other than asthma,50.0
1998,NCT01225315,Phase 2,Asthma,Idorsia Pharmaceuticals Ltd.,10-Feb-15,Asthma,Ongoing or recent treatment with medication for allergic airway disease,50.0
1999,NCT00330070,Phase 2,Asthma,Inflazyme Pharmaceuticals Ltd,10-Feb-15,Asthma,other asthma therapies:,50.0
2000,NCT00096616,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,"Patients with other significant diseases other than asthma, requiring oxygen,",50.0
2001,NCT00930163,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Pre-existing lung disease other than asthma,50.0
2002,NCT00971035,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Pre-existing lung disease other than asthma,50.0
2003,NCT00112411,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Presence of clinically-significant non-asthmatic acute or chronic disease ,50.0
2004,NCT00843193,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Presence of other respiratory disease or chronic pulmonary condition other than asthma,50.0
2005,NCT00322686,Phase 2,Asthma,Forest Laboratories,10-Feb-15,Asthma,Pulmonary disease other than asthma,50.0
2006,NCT00967590,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,pulmonary disease other than asthma,50.0
2007,NCT02162784,Phase 2,Asthma,Intech Biopharm Ltd.,10-Feb-15,Asthma,Severe asthma associated with reduced lung function;,50.0
2008,NCT00468975,Phase 2,Asthma,Pfizer,10-Feb-15,Asthma,Subjects with a history of pulmonary disease other than asthma. ,50.0
2009,NCT01730027,Phase 2,Asthma,Pulmagen Therapeutics,10-Feb-15,Asthma,Subjects with COPD or other relevant lung diseases,50.0
2010,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects with elevated blood eosinophil levels which is not related to asthma,50.0
2011,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Suffering from relevant lung diseases (other than asthma) causing impairment in lung function,50.0
2012,NCT02620956,Phase 2,Obese;Asthma,Jacqueline de Melo Barcelar,10-Feb-15,Asthma;Obesity,Were women with active pulmonary disease other than asthma,50.0
2013,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Current allergy-vaccination therapy (i.e., desensitization immunotherapy) with less than 3 months of stable maintenance doses prior to the baseline allergen inhalation challenge;",51.0
2014,NCT01479595,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Diagnosed with COPD as defined by the GOLD guidelines,51.0
2015,NCT01955512,Phase 2,Asthma,University of Southampton,10-Feb-15,Asthma,Ongoing allergen desensitisation therapy,51.0
2016,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is undergoing allergen desensitisation therapy,51.0
2017,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is undergoing allergen desensitisation therapy.,51.0
2018,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is undergoing allergen desensitisation therapy.,51.0
2019,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is undergoing allergen desensitisation therapy.,51.0
2020,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subject is undergoing allergen desensitisation therapy.,51.0
2021,NCT01128569,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,undergoing allergen desensitisation therapy ,51.0
2022,NCT01128595,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,undergoing allergen desensitisation therapy ,51.0
2023,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Undergoing allergen desensitisation therapy.,51.0
2024,NCT01499446,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Undergoing allergen desensitisation therapy.,51.0
2025,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"Vulnerable subjects (e.g., persons kept in detention)",51.0
2026,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Allergen or peptide immunotherapy within 6 months prior to study treatment,52.0
2027,NCT01225549,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Allergen-specific immunotherapy within 6 months prior to visit 1 ,52.0
2028,NCT00501527,Phase 2,"Rhinitis, Allergic, Seasonal;Conjunctivitis, Allergic;Asthma","Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal;Conjunctivitis;Conjunctivitis, Allergic",Any contraindication for the use of immunotherapy in accordance with European Allergy and Clinical Immunology Immunotherapy Subcommittee criteria:,52.0
2029,NCT02340130,Phase 2,Rhinitis;Rhinoconjunctivitis;Asthma,"Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Conjunctivitis",Any contraindication for treatment with allergen specific immunotherapy,52.0
2030,NCT00936624,Phase 2,Asthma,"SK Chemicals Co., Ltd.",10-Feb-15,Asthma,Change of Immunotherapy within 6 months before visit 1,52.0
2031,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,"Clinically relevant cardiovascular, hepatic, neurologic, psychiatric, endocrine, or other major systemic disease making the protocol or interpretation of the study results difficult",52.0
2032,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Current allergy vaccination (immunotherapy),52.0
2033,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Current allergy vaccination therapy (desensitization immunotherapy);,52.0
2034,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Current allergy vaccination therapy (desensitization immunotherapy), with less than 3 months of stable maintenance doses prior to screening;",52.0
2035,NCT00967590,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,current escalating immunotherapy,52.0
2036,NCT04353310,Phase 2,Asthma,Loma Linda University,10-Feb-15,Asthma,Current use of biologic therapy/ immunotherapy/ or bronchothermoplasty,52.0
2037,NCT01823016,Phase 2,Asthma,"Janssen Research & Development, LLC",10-Feb-15,Asthma,Has initiated or discontinued allergen immunotherapy within 12 weeks of Screening Visit 1,52.0
2038,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Immunologic compromise,52.0
2039,NCT02230189,Phase 2,Asthma,Prescott Woodruff,10-Feb-15,Asthma,Immunotherapy with cat or dust mite extract now or in the past 5 years,52.0
2040,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Initiation of or change in allergen immunotherapy within three months before the time of informed consent,52.0
2041,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,Initiation of or increase in allergen immunotherapy within 3 months prior to Visit 1 or during screening,52.0
2042,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Initiation or change in allergen immunotherapy within 3 months prior to Visit 1,52.0
2043,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Initiation or change in allergen immunotherapy within 3 months prior to Visit 1,52.0
2044,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Is currently receiving immunotherapy;,52.0
2045,NCT02251379,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,On immunotherapy and has not reached maintenance dose,52.0
2046,NCT02898662,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Ongoing allergen immunotherapy or plans to begin such therapy during the study period,52.0
2047,NCT01930461,Phase 2,Asthma;House Dust Mite Allergy,Stallergenes Greer,10-Feb-15,Asthma,Ongoing immunotherapy for an aeroallergen other than house dust mite.,52.0
2048,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Ongoing or planned specific immunotherapy (SIT) during the whole study period or SIT completed within the last 3 years,52.0
2049,NCT02148796,Phase 2,Asthma;Wheezing,University of Arizona,10-Feb-15,Respiratory Sounds,Participants may not have ever received immunotherapy.,52.0
2050,NCT00346398,Phase 2,Asthma;Allergic Sensitization,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Past or current treatment with allergen-specific immunotherapy,52.0
2051,NCT01930461,Phase 2,Asthma;House Dust Mite Allergy,Stallergenes Greer,10-Feb-15,Asthma,Patient who received allergen immunotherapy for HDM within the past 10 years.,52.0
2052,NCT00857779,Phase 2,Rhinitis;Conjunctivitis;Asthma,ALK-Abelló A/S,10-Feb-15,Rhinitis;Conjunctivitis,Previous treatment by immunotherapy with grass pollen allergen or any other allergen within the previous 5 years,52.0
2053,NCT02570984,Phase 2,Asthma,Boston Children's Hospital,10-Feb-15,Asthma,Prior aeroallergen immunotherapy or use of biologics including anti-IgE,52.0
2054,NCT00318747,Phase 2,"Asthma;Allergy;Allergic Rhinitis;Rhinitis, Allergic, Seasonal",National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Received immunotherapy for ragweed or other allergens within the 5 years prior to study entry,52.0
2055,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Receiving aero allergen immunotherapy and not on at least 3 months of maintenance allergen immunotherapy,52.0
2056,NCT00162773,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Receiving immunotherapy other than maintenance therapy,52.0
2057,NCT01393340,Phase 2,Nasal Polyposis;Asthma,"University Hospital, Ghent",10-Feb-15,Colorectal Neoplasms;Nasopharyngeal Neoplasms;Asthma;Nasal Polyps,Subjects must not have received specific immunotherapy within the previous three months. ,52.0
2058,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"Subjects that are receiving, or have received within the past 5 years, speciﬁc immunotherapy. ",52.0
2059,NCT02388997,Phase 2,Asthma,University of Virginia,10-Feb-15,Infections;Asthma,"Subjects who are currently receiving allergen immunotherapy (IT), or who have received allergen IT within the last 3 years.",52.0
2060,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,"Treatment with allergy immunotherapy, actively or within 90 days prior to Visit",52.0
2061,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,Use of any immunotherapy within 3 months prior to first screening.,52.0
2062,NCT00501527,Phase 2,"Rhinitis, Allergic, Seasonal;Conjunctivitis, Allergic;Asthma","Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal;Conjunctivitis;Conjunctivitis, Allergic",Use of immunotherapy during the last four years.,52.0
2063,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,5 ounces (45 ml) of 80 proof distilled spirits.,53.0
2064,NCT00549744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). 1 unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine),53.0
2065,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,"Alcohol excess (defined as regular consumption above government daily recommend limits; currently defined as 28 units per wk for men, 21 units per week for women)",53.0
2066,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of alcohol abuse or the subject regularly drinks more than 28 units of alcohol in a week if male, or 21 units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of wine, half a pint (250 ml) of beer or one measure (25 ml) of spirits.",53.0
2067,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,"History of drug addiction or excessive use of alcohol (weekly intake in excess of 28 units alcohol; one unit being a glass of beer, wine or a measure of spirits), or excessive consumption of xanthine containing substances (daily intake in excess of 5 cups of coffee, tea, cola, etc) or psychological or other emotional problems likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements;",53.0
2068,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of regular alcohol consumption within 6 months of the study defined as Abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a 285 mL glass of full strength beer or 425 mL schooner of light beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine.,53.0
2069,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 units for males and females. One unit is equivalent to 8 gram (g) of alcohol: a half-pint (~240 mililiter [ml]) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits",53.0
2070,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 units for males and females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.",53.0
2071,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.",53.0
2072,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males). One unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.,53.0
2073,NCT00801853,Phase 2,Asthma,"Aerovance, Inc.",10-Feb-15,Asthma,Patient consumes more than 28 units (male) or 21 units (female) of alcohol a week (unit = 1 glass of wine = 1measure of spirits = ½ pint or 8 fluid ounces of beer),53.0
2074,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,"Significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)",53.0
2075,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,"Subject has current (or within the last six months) evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit)",53.0
2076,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject regularly drinks more than 28 units of alcohol in a week, if male or 21 units per week, if female. One unit of alcohol is defined as a medium (125ml) glass of wine, half a pint (250ml) of beer, or one measure (25ml) of spirits.",53.0
2077,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject regularly drinks more than 28 units of alcohol in a week if male, or 21 units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of wine, half a pint (250 ml) of beer or one measure (25 ml) of spirits",53.0
2078,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject regularly drinks more than 28 units of alcohol in a week if male, or 21 units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of wine, half a pint (250 ml) of beer or one measure (25 ml) of spirits.",53.0
2079,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject regularly drinks more than 28 units of alcohol in a week if male, or 21 units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of wine, half a pint (250 ml) of beer or one measure (25 ml) of spirits.",53.0
2080,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Vaped e-cigarettes =0.5 mLs e-liquid per day for 1 year, or =1 cartridge/tank/pod per day for 1 year",53.0
2081,NCT00482898,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,You are unwilling to limit your alcohol use to less than 5 drinks per week,53.0
2082,NCT00635882,Phase 2,Asthma;Airway Inflammation,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma;Inflammation,Inability to induce sputum after 1 or 2 trys. ,54.0
2083,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects unable to produce a technically acceptable sputum sample.,54.0
2084,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"History of sensitivity to any of the study medications, including Albuterol/Salbutamol or Albuterol components there of or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.",55.0
2085,NCT02497222,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,,"Intolerance to albuterol, atropine, or lidocaine.",55.0
2086,NCT01951222,Phase 2,Asthma,Pierre Fabre Medicament,10-Feb-15,Asthma,Intolerance to salbutamol.,55.0
2087,NCT01833390,Phase 2,Asthma;COPD;Healthy,Xemed LLC,10-Feb-15,Asthma,"Known hypersensitivity to albuterol or any of its components, or levalbuterol. ",55.0
2088,NCT01470755,Phase 2,Asthma,Assistance Publique - Hôpitaux de Paris,10-Feb-15,,known intolerant to Salbutamol ,55.0
2089,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Patient known to be intolerant to salbutamol or albuterol,55.0
2090,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject had a known sensitivity to levalbuterol or racemic albuterol, including Ventolin or any of the excipients contained in any of these formulations.",55.0
2091,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.",55.0
2092,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.",55.0
2093,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.",55.0
2094,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,"Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.",55.0
2095,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject using any prescription drug with which albuterol sulfate administration is contraindicated.,56.0
2096,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject using any prescription drug with which albuterol sulfate administration is contraindicated.,56.0
2097,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Subject using any prescription drug with which albuterol sulfate administration is contraindicated.,56.0
2098,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject was using any prescription drug with which albuterol sulfate administration was contraindicated,56.0
2099,NCT00024544,Phase 2,Asthma,Facet Biotech,10-Feb-15,Asthma,No significant disease other than asthma ,57.0
2100,NCT00028288,Phase 2,Asthma,Facet Biotech,10-Feb-15,Asthma,No significant disease other than asthma ,57.0
2101,NCT00783601,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Patient is intending to move or vacation for more than 5 days during the study,58.0
2102,NCT02687815,Phase 2,Asthma,"Juan Celedon, MD",10-Feb-15,Asthma,Plans to move out of the study site area in the next year Additional exclusion criteria applied after the run-in period:,58.0
2103,NCT02251379,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Sleeping in another home 4 or more nights/week,58.0
2104,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Major surgery within 3 months prior to signing the ICF or anticipated during study,59.0
2105,NCT03299686,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Previous use of biologics or other concomitant medications within the time periods specified in the SOM/protocol,60.0
2106,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,The use of prescription or over-the-counter medications is subjected to protocol- established restrictions (non-permitted medications),60.0
2107,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,Unable to abstain from protocol-defined prohibited medications during the study,60.0
2108,NCT03364608,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Unable to abstain from protocol-defined prohibited medications during the study ,60.0
2109,NCT03371459,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Unable to abstain from protocol-defined prohibited medications during the study ,60.0
2110,NCT00181272,Phase 2,Asthma;Chronic Obstructive Pulmonary Disease,Johns Hopkins University,10-Feb-15,"Asthma;Lung Diseases;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive",Patients prescribed warfarin (azithromycin may increase INR in patients on warfarin),61.0
2111,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal","Patients taking CYP2C8 substrates such as -but not restricted to- amiodarone, amodiaquine, paclitaxel, rosiglitazone, pioglitazone, and repaglinide and CYP2C9 substrates such as -but not restricted to- warfarin, tolbutamide, phenytoin, losartan and acenocoumarol",61.0
2112,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,"Patients taking Xolair, theophylline, montelukast, zafirlukast, nedocromil, cromolyn sodium, Zyflo (within the past 7 days), warfarin, propranolol, inhaled anti-cholinergics, or LABA",61.0
2113,NCT01097694,Phase 2,Asthma,Brigham and Women's Hospital,10-Feb-15,Asthma,"Regular use of anticoagulants (eg: Warfarin Sodium, Coumadin), amiodarone, carbamazepine, Cyclosporine, Rifampicin, or reverse transcriptase inhibitors ",61.0
2114,NCT03944707,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,"Requirement for anti-platelet or anticoagulant medication (e.g., warfarin, or clopidogrel or Novel Oral Anti-Coagulant (NOAC)) other than acetylsalicylic acid (up to 100 mg/d).",61.0
2115,NCT00526357,Phase 2,Asthma,Firestone Institute for Respiratory Health,10-Feb-15,Asthma;Inflammation,"Subjects using anti-coagulants (warfarin, heparin)",61.0
2116,NCT00815347,Phase 2,Asthma,UConn Health,10-Feb-15,Asthma,"Use of potent CYP3A4 and CYP2C9 inhibitors, including, but not limited to azole antifungals, amiodarone, glyburide, warfarin, cyclosporine, ritonavir, other medications potentially toxic to the liver or bone marrow.",61.0
2117,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,"Use of warfarin, current or last 30 days",61.0
2118,NCT00136305,Phase 2,Asthma,Children's Mercy Hospital Kansas City,10-Feb-15,Asthma,Not English or Spanish speaking ,62.0
2119,NCT02340130,Phase 2,Rhinitis;Rhinoconjunctivitis;Asthma,"Laboratorios Leti, S.L.",10-Feb-15,"Rhinitis;Asthma;Rhinitis, Allergic;Conjunctivitis",Acute or chronic infectious conjunctivitis,63.0
2120,NCT01424124,Phase 2,Asthma,Yuhan Corporation,10-Feb-15,Asthma,"Active upper respiratory tract infection within 3 weeks, emergency room treatment for asthma within 1 month, or hospitalization for asthma within 3 months of the prestudy visit ",64.0
2121,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"An asthma exacerbation or respiratory tract infection within six weeks prior to screening (an exacerbation is defined as worsening asthma requiring the use of systemic corticosteroids and/or emergency department visit, hospitalisation).",64.0
2122,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,An asthma exacerbation requiring oral corticosteroids within 3 months or hospitalization within 6 months prior to screening.,64.0
2123,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"An asthma exacerbation requiring oral/intravenous corticosteroids ≤ 30 days, intramuscular depot corticosteroid ≤3 months or hospitalization within 6 months prior to screening.",64.0
2124,NCT01287065,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Respiratory Aspiration,Any asthma exacerbation requiring oral corticosteroids within 12 weeks of screening or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to screening.,64.0
2125,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any asthma exacerbation requiring oral corticosteroids within 12 weeks of screening or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to screening.,64.0
2126,NCT01899144,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Any asthma exacerbation requiring oral corticosteroids within 3 months of the screening visit. A patient must not have had any hospitalization for asthma within 6 months prior to the screening visit,64.0
2127,NCT01772368,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV.,64.0
2128,NCT01332292,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Any clinically relevant abnormality identified on the screening medical assessment, including asthma exacerbation requiring systemic corticosteroids (oral, intramuscular, intravenous) or emergency room attendance within 3 months or asthma exacerbation requiring hospitalization within 6 months prior to screening.",64.0
2129,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Any severe asthma exacerbation, defined as deterioration of asthma requiring the use of systemic corticosteroids (oral, parenteral or depot) within 12 weeks of Visit 1, or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids within 12 weeks of Visit",64.0
2130,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Asthma exacerbation (as defined by protocol) within 28 days before the time of informed consent or during Screening,64.0
2131,NCT01453296,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Asthma exacerbation requiring systemic corticosteroids (oral, intramuscular, intravenous) or Emergency Room attendance within 3 months or asthma exacerbation requiring hospitalization within 6 months prior to the screening visit.",64.0
2132,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Asthma exacerbation requiring treatment with oral corticosteroids or hospitalization within 3 months prior to screening,64.0
2133,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Asthma exacerbation requiring treatment with systemic corticosteroids or hospitalization within 3 months prior to screening.,64.0
2134,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Asthma Exacerbation: Any asthma exacerbation requiring oral corticosteroids within 12 weeks of screening or that resulted in overnight hospitalization requiring additional treatment for asthma within 6 months prior to screening.,64.0
2135,NCT01581177,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,Asthma exacerbations that required emergency care or a hospital stay within 4 weeks prior to screening visit,64.0
2136,NCT02210806,Phase 2,Asthma,"Amphastar Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Asthma exacerbations that required emergency care or hospitalized treatment, within 4 weeks prior to Screening",64.0
2137,NCT01189396,Phase 2,Asthma;Bronchospasm;Chronic Obstructive Pulmonary Disease (COPD),"Amphastar Pharmaceuticals, Inc.",10-Feb-15,"Asthma;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive;Bronchial Spasm","Asthma exacerbations that required emergency care or hospitalized treatment, within 4 wk prior;",64.0
2138,NCT02433977,Phase 2,Asthma,"Gladwin, Mark, MD",10-Feb-15,Asthma,Asthma-related ER visit within the previous 4 weeks,64.0
2139,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,Asthma-related ER visit within the previous 4 weeks,64.0
2140,NCT03762395,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma,Asthma-related ER visit within the previous 4 weeks,64.0
2141,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,Asthma-related ER visit within the previous 4 weeks of Visit 0,64.0
2142,NCT00936624,Phase 2,Asthma,"SK Chemicals Co., Ltd.",10-Feb-15,Asthma,Emergency room treatment for asthma within 1 month or hospitalization for asthma within 3 months before visit 1,64.0
2143,NCT01656395,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,emergency room treatment for asthma within past ≤4 weeks or hospitalization for asthma within past ≤8 weeks,64.0
2144,NCT01200108,Phase 2,Asthma,Activaero GmbH,10-Feb-15,Asthma,Emergency room visit for treatment of asthma exacerbation within 4 weeks of Screening,64.0
2145,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Evidence of a moderate asthma exacerbation leading to a change in therapy or severe exacerbation during screening or the run-in period, defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.",64.0
2146,NCT01808339,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Evidence of a severe exacerbation, defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids between screening and Day",64.0
2147,NCT01951222,Phase 2,Asthma,Pierre Fabre Medicament,10-Feb-15,Asthma,Exacerbation (requiring oral corticosteroids or hospitalization) within 3 months.,64.0
2148,NCT01258803,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Experiences a clinical deterioration in asthma that results in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication (including oral or other systemic corticosteroids, but allowing SABA) as judged by the investigator, at any time from the Screening Visit up to and including the Baseline Visit ",64.0
2149,NCT00017693,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Had a breathing tube inserted for asthma treatment within 15 years of beginning study treatment.,64.0
2150,NCT00017693,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Had asthma requiring emergency room treatment within 12 months of beginning study treatment.,64.0
2151,NCT00017693,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,Had asthma requiring hospitalization within 6 weeks of beginning study treatment.,64.0
2152,NCT01136382,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Has been hospitalized at least once or required emergency treatment (was seen in the emergency room or had an urgent care visit) more than once for an asthma-related condition during the 6 months prior to Visit 2,64.0
2153,NCT01136655,Phase 2,Asthma,AstraZeneca,10-Feb-15,,Has been hospitalized for >24 hours at least once or required emergency treatment or urgent care visit more than once for an asthma-related condition during the 6 months prior to Visit 1,64.0
2154,NCT01993329,Phase 2,Asthma,"Afferent Pharmaceuticals, Inc.",10-Feb-15,Asthma,Has been hospitalized or attended the emergency department for an asthma attack in the 12 months prior to screening.,64.0
2155,NCT01258803,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Has been treated in the emergency room for a severe asthma exacerbation requiring systemic glucocorticosteroid treatment, or hospitalized for management of airway obstruction within 3 months prior to the Screening Visit",64.0
2156,NCT01820481,Phase 2,Asthma,Whanin Pharmaceutical Company,10-Feb-15,Asthma,Have been hospitalized due to an acute worsening of asthma within 3 months before the screening,64.0
2157,NCT01820481,Phase 2,Asthma,Whanin Pharmaceutical Company,10-Feb-15,Asthma,"Have visited emergency room due to the worsening asthma symptoms, within 4 weeks before the screening",64.0
2158,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,History of an upper or lower respiratory tract infection requiring antibiotics; emergency room treatment in the preceding four weeks; or hospitalization in the previous three months; or a history of multiple hospital visits for treatment of their respiratory disease,64.0
2159,NCT02382510,Phase 2,Asthma,"Theron Pharmaceuticals, Inc.",10-Feb-15,Asthma,History of asthma exacerbation requiring oral or systemic corticosteroids or hospital admission within 6 months of screening,64.0
2160,NCT00946569,Phase 2,Asthma,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",10-Feb-15,Asthma,"History of life-threatening asthma attack requiring hospitalization for asthma within 5 years of screening, or emergency department treatment of asthma within the last month",64.0
2161,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,History of life-threatening asthma or hospitalization for asthma prior to the study entry,64.0
2162,NCT00868023,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in Intensive Care Unit) within 1 year before screening.",64.0
2163,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,"hospital admission for asthma (including treatment in an emergency room),",64.0
2164,NCT00995800,Phase 2,Asthma,Mundipharma Research Limited,10-Feb-15,Asthma;Inflammation,Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit,64.0
2165,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"Hospitalisation or emergency room treatment for acute asthma in the 6 months prior to screening, between screening and the start of the treatment period",64.0
2166,NCT01650441,Phase 2,Asthma,"University Hospital, Antwerp",10-Feb-15,Asthma,Hospitalization due to asthma or symptomatic infection of the airways in the previous 8 weeks,64.0
2167,NCT00746330,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,"Hospitalized or had an emergency room treatment for an acute asthma exacerbation in the 1 month prior to Visit 1, or who had a clinical deterioration of asthma between Visits 1 and 2 that resulted in emergency treatment, hospitalization, or treatment with excluded asthma medication.",64.0
2168,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,Intubation (ever) or hospitalisation for longer than 24 hours for the management of an asthma exacerbation within the preceding 6 months of the screening visit,64.0
2169,NCT01425801,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Intubation (ever) or hospitalization for longer than 24 hours for the management of an asthma exacerbation within the preceding 6 weeks of the screening visit,64.0
2170,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Lower respiratory tract infection (LRTI) or asthma exacerbation requiring antibiotics or systemic corticosteroids within 6 weeks of screening.,64.0
2171,NCT00941798,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who had an asthma attack/exacerbation requiring hospitalization/emergency room visit or respiratory tract infection within 1 month prior to randomization,64.0
2172,NCT00605306,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Patients who have been hospitalized or had emergency treatment for an asthma attack in the 6 months prior to study start,64.0
2173,NCT03299686,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have had an asthma attack/exacerbation requiring systemic corticosteroids for at least 3 continuous days within 4 weeks prior to screening,64.0
2174,NCT02892019,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have had an asthma attack/exacerbation requiring systemic steroids (SCS) or hospitalization or emergency room visit within 3 months prior to Visit 1 (Screening) or more than 3 separate exacerbations in the 12 months preceding Visit,64.0
2175,NCT03108027,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 1 year of Screening.,64.0
2176,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of first treatment visit (Day 1),64.0
2177,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Received emergency treatment for asthma within 1 month, or hospitalized for asthma within 3 months;",64.0
2178,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Severe asthma exacerbation not resolved 4 weeks prior to Visit 1, (defined by the need for oral or parenteral glucocorticosteroid intake for at least 3 days and/or hospitalization or emergency room visit with the need for oral or parenteral corticosteroid use)",64.0
2179,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial",64.0
2180,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial",64.0
2181,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial",64.0
2182,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,"Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.",64.0
2183,NCT00583947,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject who has a history of hospitalization for asthma within one year, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.",64.0
2184,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,"Subjects with a history of a respiratory tract infection or an asthma crisis requiring the use of antibiotics and/or systemic corticosteroids within 4 weeks prior to Visit 1, or who develop a respiratory tract infection or asthma crisis during the screening period. In the latter case, the subjects can be re-screened four weeks after the last dose of systemic corticosteroid or antibiotic.",64.0
2185,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects with a history of life-threatening asthma, an asthma exacerbation requiring systemic corticosteroids or Emergency Room attendance (within 3 months) or requiring hospitalization (within 6 months) prior to screening.",64.0
2186,NCT01502371,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,"Treated in the emergency room for a severe asthma exacerbation requiring systemic glucocorticosteroid treatment, or hospitalization for management of airway obstruction within 3 months prior to the Screening Visit.",64.0
2187,NCT02720081,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,Treatment in an emergency room for asthma (within 4 weeks) or hospitalization for asthma or respiratory condition within 2 months of screening visit,64.0
2188,NCT01624974,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,treatment in an emergency room for asthma within 4 weeks prior to Screening Visit or hospitalization for asthma within 2 months prior to Screening Visit;,64.0
2189,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,treatment in the emergency room (for a severe asthma exacerbation requiring systemic corticosteroid treatment) or hospitalization for management of airway obstruction within 3 months prior to Screening Visit,64.0
2190,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,Treatment with oral corticosteroids and/or hospitalisation for an exacerbation of asthma and/or COPD in the previous 4 weeks prior to randomisation.,64.0
2191,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Worsening Asthma: A subject must not have experienced a worsening of asthma that involved an emergency department visit, hospitalization, or use of oral/parenteral corticosteroids within 6 weeks of Screening (Visit 1a)",64.0
2192,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,"Worsening of asthma in the 4 weeks preceding the screening visit (requiring daily use of nebulised β2-agonists or any use of long acting β agonists [LABA], or requiring inpatient hospitalisation for asthma control, or requiring emergency room treatment, or requiring systemic corticosteroids for asthma control) or respiratory infection in the 4 weeks preceding the first screening visit or prior to randomization (Day 1).",64.0
2193,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Worsening of Asthma: A subject must not have experienced a worsening of asthma which involved an emergency department visit, hospitalization or use of oral/parenteral corticosteroids within 6 weeks of screening",64.0
2194,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Asthma considered unstable within 2 months prioir to screening.,65.0
2195,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Significant seasonal variation in asthma occurring or expected to occur during study participation;,65.0
2196,NCT00684827,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.,65.0
2197,NCT00684866,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.,65.0
2198,NCT00685022,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.,65.0
2199,NCT00685347,Phase 2,Asthma;Bronchoconstriction,Sunovion,10-Feb-15,Asthma,Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.,65.0
2200,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,Unstable asthma; defined as the presence of 1 or more of the following events in the month prior to study [Emergency/'out of hours' visit to GP for asthma exacerbation; GP visit to patient at home for asthma exacerbation or A & E/hospital admission for asthma exacerbation],65.0
2201,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Recent change in the patient's usual asthma treatment,66.0
2202,NCT00815347,Phase 2,Asthma,UConn Health,10-Feb-15,Asthma,"Requirement for change in scheduled asthma medication use, including oral steroid dose change, or acute medical care for asthma during the 30 days preceding screening visit.",66.0
2203,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Respiratory tract infections or worsening of asthma or changes in asthma medications within 6 weeks before Screening/Baseline.,66.0
2204,NCT01286844,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects who have changed their asthma medication, dose or regime within 4 weeks of screening",66.0
2205,NCT01453296,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Subjects who have changed their asthma medication within 4 weeks of screening.,66.0
2206,NCT01930461,Phase 2,Asthma;House Dust Mite Allergy,Stallergenes Greer,10-Feb-15,Asthma,Patient with a urine level of cotinine ≥ 500 ng/mL.,67.0
2207,NCT00812929,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Positive pre-study urine cotinine/ breath carbon monoxide test and or urine drug/urine alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.",67.0
2208,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,Positive urine cotinine or THC test on the day of the bronchoscopy visit,67.0
2209,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,positive urine cotinine test,67.0
2210,NCT01190826,Phase 2,Asthma,Asmacure Ltée,10-Feb-15,Asthma,Positive urine cotinine test at Screening.,67.0
2211,NCT02334553,Phase 2,Asthma,SolAeroMed Inc.,10-Feb-15,Asthma,Positive urine drug screen or urine cotinine test at screening,67.0
2212,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has a positive pre-study urine cotinine/ breath carbon monoxide test or urine drug or urine or breath alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbituates, Cocaine, Opiates, Cannabinoids and Benzodiazepines. ",67.0
2213,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"The subject has a positive pre-study urine cotinine/ breath carbon monoxide test or urine drug or urine or breath alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine, Opiates, Cannabinoids and Benzodiazepines. ",67.0
2214,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Urinary cotinine levels indicative of smoking or history within 6 months prior to screening.,67.0
2215,NCT01296087,Phase 2,Asthma,Targacept Inc.,10-Feb-15,Asthma,Urine cotinine level > 50 ng/ml,67.0
2216,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,hemoglobin,68.0
2217,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Hemoglobin <10 g/dL,68.0
2218,NCT02388997,Phase 2,Asthma,University of Virginia,10-Feb-15,Infections;Asthma,Hemoglobin <11.5 g/dL for non-African American subjects or hemoglobin <,68.0
2219,NCT02910401,Phase 2,Asthma;Allergic Rhinitis,University of Virginia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",Hemoglobin <11.5 g/dL for non-African American subjects or hemoglobin <,68.0
2220,NCT03944707,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Hemoglobin: < 10 g/dl,68.0
2221,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Laboratory abnormalities: Neutrophils <1.95 multiplied by 10 raise to 9 per liter; Platelet count <140 multiplied by 10 raise to 9 per liter; Hemoglobin <8.5 grams per decilitre (g/dL); WBC count <3.5 × multiplied by 10 raise to 9 per liter.,68.0
2222,NCT02910401,Phase 2,Asthma;Allergic Rhinitis,University of Virginia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",Laboratory values (other than hemoglobin and absolute neutrophil count (ANC)) measured at Visit 1 that are considered to be of clinical relevance by the Investigator,68.0
2223,NCT03989635,Phase 2,"Asthma;Asthma, Bronchial;Bronchial Asthma;Eosinophilia;Physiological Effects of Drugs",Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,0 X ULN or total bilirubin >,69.0
2224,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35 percent).,69.0
2225,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,5xULN (isolated bilirubin <1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin ≥35%).,69.0
2226,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,Abnormal liver enzymes (alanine aminotransferase >1.5x upper limit of normal [ULN] or total bilirubin >1.5x ULN).,69.0
2227,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Abnormal liver function tests defined as aspartate aminotransferase (AST), alanine aminotransferace (ALT), alkaline phosphatase or total bilirubin ≥",69.0
2228,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Alanine aminotransferase (ALT), and bilirubin >2x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) at Visit",69.0
2229,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.5 times the upper limit of normal (ULN) confirmed during screening period.,69.0
2230,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,"Alanine aminotransferase or AST level ≥ 3 times the upper limit of normal (ULN), confirmed by repeated testing during Screening Period.",69.0
2231,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Alanine transaminase (ALT) >1.5 times upper limit of normal (ULN) and bilirubin >ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).,69.0
2232,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Alanine transaminase (ALT) >2xUpper Limit of Normal (ULN) and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%),69.0
2233,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Alanine transaminase (ALT) >2xupper limit of normal (ULN) and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent).,69.0
2234,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Alanine Transaminase (ALT)/Aspartate Aminotransferase (AST) >2x upper limits of normal (ULN),69.0
2235,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,alkaline phosphatase,69.0
2236,NCT00534625,Phase 2,Asthma,Critical Therapeutics,10-Feb-15,Asthma,ALT > 3 x ULN,69.0
2237,NCT04098718,Phase 2,Asthma;COPD,University of Oxford,10-Feb-15,,An alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level that is persistently ≥1.5 times the upper limit of normal.,69.0
2238,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Aspartarte aminotransferase, Alanine aminotransferase, alkaline phosphatase and bilirubin more than",69.0
2239,NCT03680976,Phase 2,Asthma,Sally E. Wenzel MD,10-Feb-15,Asthma,"Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3.0X upper limit of normal (ULN), gamma-glutamyl transferase (GGT) >3X ULN, and total bilirubin >2X ULN. If all liver function tests (LFTs) are within normal limits (WNL) and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted. Subjects with indirect total bilirubin up to 3X ULN are presumed to have Gilbert's syndrome and may be enrolled if all other LFTs are WNL",69.0
2240,NCT01366521,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"AST, ALT, alkaline phosphatase and bilirubin ≥",69.0
2241,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,"Bilirubin, alanine aminotransferase (ALT) or asparate aminotransferase (AST) greater than the upper limit of normal at screening",69.0
2242,NCT04129931,Phase 2,Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Asthma,Bilirubin ≥2x ULN,69.0
2243,NCT00815347,Phase 2,Asthma,UConn Health,10-Feb-15,Asthma,"History of liver disease, clinically significant cardiac disease, renal disease or pulmonary disease other than asthma. Patients with clinically significant laboratory abnormalities of LFTs/bilirubin (AST/ALT, TBili, alkaline phosphatase) and clinically significant anemia will be excluded. Clinically significant anemia will be defined as any anemia resulting in serum Hgb more than 1 gm/dl below the LLN, Patients with isolated minimal elevations of bilirubin (eg. as occurs in Gilbert's disease) or minimal elevations in transaminases (less than",69.0
2244,NCT01653756,Phase 2,Asthma,SecuraBio,10-Feb-15,Asthma,Inadequate hepatic function defined by Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) greater than,69.0
2245,NCT02433834,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,"Liver Function: Subjects with abnormal liver function tests defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or total bilirubin ≥1.5 times the upper limit of normal on repeat testing",69.0
2246,NCT02491684,Phase 2,Asthma,AstraZeneca,10-Feb-15,Infections;Respiratory Tract Infections;Asthma,Patients who have hepatic serum enzyme levels ≥2.5 times the normal range,69.0
2247,NCT00512863,Phase 2,Asthma,Abbott,10-Feb-15,Asthma,"Abnormal, clinically significant screening laboratory and other analyses (including ECG).",70.0
2248,NCT00327808,Phase 2,Asthma,Pharmaxis,10-Feb-15,Asthma,Abnormal chest X-ray that is judged clinically significant,70.0
2249,NCT01225549,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Any clinically relevant abnormal finding at screening examinations,70.0
2250,NCT00736489,Phase 2,Asthma;Airway Obstruction,AstraZeneca,10-Feb-15,Airway Obstruction,Any clinically relevant abnormal findings at screening examinations,70.0
2251,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Any clinically relevant abnormal findings in physical examination,70.0
2252,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Any clinically relevant abnormal value or physical finding at screening;,70.0
2253,NCT01453296,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any clinically relevant abnormality identified on the screening medical assessment,70.0
2254,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination, or ECG.",70.0
2255,NCT01286844,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Any clinically relevant abnormality identified on the screening medical assessment.,70.0
2256,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,any clinically significant (per the investigator) lab abnormalities,70.0
2257,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,any fever or other clinically significant physical exam abnormalities,70.0
2258,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,clinical significant abnormalities in safety laboratory analysis at screening,70.0
2259,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,Clinically relevant abnormal findings in hematology or clinical chemistry,70.0
2260,NCT00818454,Phase 2,Asthma,Boehringer Ingelheim,10-Feb-15,Asthma,Clinically relevant abnormal hematology or blood chemistry at screening if the abnormality defines a significant disease as defined in exclusion criterion 1,70.0
2261,NCT01743768,Phase 2,Asthma,Sterna Biologicals GmbH & Co. KG,10-Feb-15,Asthma,"Clinically relevant abnormalities in clinical chemical, haematological or in any other laboratory variables as judged by the investigator",70.0
2262,NCT00556673,Phase 2,Asthma,Novartis,10-Feb-15,Asthma,Clinically relevant laboratory abnormality or a clinically significant condition,70.0
2263,NCT01951222,Phase 2,Asthma,Pierre Fabre Medicament,10-Feb-15,Asthma,Clinically relevant physical examination abnormality. ,70.0
2264,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Clinically significant abnormal laboratory result (Chemistry, Hematology and Urinalysis) at SV1.",70.0
2265,NCT01615874,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,clinically significant abnormal vital sign,70.0
2266,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,"Clinically significant abnormalities in physical examination or in laboratory test results (including serum biochemistry, hematology and urinalysis) as assessed by the Investigator.",70.0
2267,NCT00748306,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant abnormalities in safety laboratory analysis at screening,70.0
2268,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Clinically significant abnormalities in safety laboratory analysis at screening, as determined by the investigator.",70.0
2269,NCT01516073,Phase 2,Asthma,Dey,10-Feb-15,Asthma,Clinically significant abnormalities in safety laboratory analysis at screening (Visit 1) and deemed exclusionary by the Investigator,70.0
2270,NCT00812773,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant abnormalities in safety laboratory analysis at screening.,70.0
2271,NCT00850642,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant abnormalities in safety laboratory analysis at screening.,70.0
2272,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant abnormalities in safety laboratory analysis at screening.,70.0
2273,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant abnormalities in safety laboratory analysis at screening.,70.0
2274,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant abnormalities in vital signs or safety laboratory analysis at screening.,70.0
2275,NCT04150341,Phase 2,Asthma,Theravance Biopharma,10-Feb-15,Asthma,Clinically significant abnormalities of laboratory evaluations,70.0
2276,NCT00686335,Phase 2,Asthma,"Horizon Pharma Ireland, Ltd., Dublin Ireland",10-Feb-15,Asthma,Clinically significant abnormalities of the hematological or biochemical constants,70.0
2277,NCT00557700,Phase 2,Asthma,"University Hospital, Ghent",10-Feb-15,Asthma,Clinically significant laboratory deviations.,70.0
2278,NCT00768079,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Evidence of any clinically significant systemic disease on physical examination,70.0
2279,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Evidence of clinically significant abnormal ECG findings at Visit,70.0
2280,NCT01765192,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,"Has, in the judgment of the investigator, clinically significant abnormal laboratory values (hematology or biochemistry) at screening suggesting an undiagnosed disease requiring further clinical evaluation",70.0
2281,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,"Have any abnormal vital signs (B/P, respiratory rate, heart rate) considered to be clinically significant;",70.0
2282,NCT00679263,Phase 2,Asthma,MediciNova,10-Feb-15,Asthma,Have any laboratory value outside the laboratory reference range that is considered to be clinically significant;,70.0
2283,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,Laboratory value exceeding the limit of normal and determined to be clinically relevant by the Investigator,70.0
2284,NCT04589663,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients who have a clinically significant ECG abnormality or clinically significant abnormal lab values reported at Screening Visit,70.0
2285,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal","Patients with a clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis at screening, if the abnormality defines a significant disease as defined in exclusion criterion No",70.0
2286,NCT00317044,Phase 2,Asthma;GERD,AstraZeneca,10-Feb-15,Asthma,Patients with clinically relevant abnormalities.,70.0
2287,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,Patients with clinically significant laboratory abnormalities (not associated with the study indication) at screening,70.0
2288,NCT01836471,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients with clinically significant laboratory abnormalities at screening,70.0
2289,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,"Subject had clinically significant abnormal laboratory values (hematology, blood chemistry, or urinalysis).",70.0
2290,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,Subjects who have a clinically significant laboratory abnormality at screening (Visit 2).,70.0
2291,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,Subjects who have a clinically significant laboratory abnormality at screening blood analysis on visit V2+24h,70.0
2292,NCT00830102,Phase 2,Asthma,SkyePharma AG,10-Feb-15,Asthma,No history or evidence of any clinically significant disease or abnormality ,71.0
2293,NCT00526357,Phase 2,Asthma,Firestone Institute for Respiratory Health,10-Feb-15,Asthma;Inflammation,Subjects who use medications to lower LDL cholesterol levels,72.0
2294,NCT02660489,Phase 2,Asthma;Rhinovirus;Picornaviridae Infections;Common Cold,Imperial College London,10-Feb-15,Common Cold;Picornaviridae Infections;Asthma,"Current or concomitant use of oral steroids, anti--leukotrienes or monoclonal antibodies",73.0
2295,NCT01470755,Phase 2,Asthma,Assistance Publique - Hôpitaux de Paris,10-Feb-15,,taking regular treatment including leukotrienes receptor antagonist during the week before the test.,73.0
2296,NCT01689571,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Use of leukotrienes modifiers, roflumilast or cromoglycate",73.0
2297,NCT02087644,Phase 2,Asthma,Cytos Biotechnology AG,10-Feb-15,Asthma,Presence of suspicious lymphadenopathy or splenomegaly on physical examination,74.0
2298,NCT01007721,Phase 2,"Rhinitis, Allergic, Seasonal;Asthma",Boehringer Ingelheim,10-Feb-15,"Rhinitis;Rhinitis, Allergic;Rhinitis, Allergic, Seasonal",Any immunomodulatory therapy since specific positive skin prick test.,75.0
2299,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Current use of an immunomodulatory/ immunosuppressive therapy or past use within 3 months or 5 drug half-lives (whichever is longer) prior to Visit 1,75.0
2300,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Current use of an immunomodulatory/immunosuppressive therapy or past use within three months or five drug half-lives (whichever is longer) before the time of informed consent,75.0
2301,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Immunomodulatory/suppressive agents including but not limited to cyclophosphamide, a cytotoxic agent, cyclosporine A, azathioprine, tacrolimus, mycophenolate mofetil, oral or parenteral gold, or D-penicillamine within 3 months of screening.",75.0
2302,NCT02099656,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma;Inflammation,Use of a systemic immunomodulatory or immunosuppressive therapy within 3 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening,75.0
2303,NCT02947945,Phase 2,Asthma,National Jewish Health,10-Feb-15,Granulomatosis with Polyangiitis;Systemic Vasculitis;Churg-Strauss Syndrome,Taking cyclophosphamide,76.0
2304,NCT03010436,Phase 2,Asthma,National Jewish Health,10-Feb-15,Systemic Vasculitis,Taking cyclophosphamide ,76.0
2305,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,"cirrhosis, alcoholism, biliary obstruction or other hepatic disease",77.0
2306,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant hepatic impairment or current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones),77.0
2307,NCT01128569,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities",77.0
2308,NCT01128595,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities",77.0
2309,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities",77.0
2310,NCT02833974,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)",77.0
2311,NCT01471665,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).",77.0
2312,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).",77.0
2313,NCT01617746,Phase 2,Asthma,University of Glasgow,10-Feb-15,Asthma,Current or known history of liver disease (with the exception of Gilberts disease and gallstones),77.0
2314,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,Evidence of active liver disease,77.0
2315,NCT02054130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Evidence of active liver disease.,77.0
2316,NCT01545440,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Evidence of acute or chronic hepatitis or known liver cirrhosis,77.0
2317,NCT01545453,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma,Evidence of acute or chronic hepatitis or known liver cirrhosis,77.0
2318,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Evidence of acute or chronic hepatitis or known liver cirrhosis,77.0
2319,NCT01987492,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Evidence of acute or chronic hepatitis or known liver cirrhosis,77.0
2320,NCT03292588,Phase 2,Asthma,National Institute of Allergy and Infectious Diseases (NIAID),10-Feb-15,Asthma,"Has known, pre-existing, unstable liver disease;",77.0
2321,NCT01948401,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Inadequate liver function,77.0
2322,NCT03532490,Phase 2,Asthma;Obesity,Johns Hopkins University,10-Feb-15,Asthma,Liver cirrhosis,77.0
2323,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Liver disease: Current or chronic history,77.0
2324,NCT01000506,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Unstable liver disease,77.0
2325,NCT03885245,Phase 2,Asthma;Obesity,"University of Colorado, Denver",10-Feb-15,Asthma;Overweight,Chronic renal failure,78.0
2326,NCT00946569,Phase 2,Asthma,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",10-Feb-15,Asthma,Moderate or severe renal insufficiency,78.0
2327,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,History of significant hepatic or renal impairment,79.0
2328,NCT01443728,Phase 2,Sickle Cell Disease;Vitamin D Deficiency;Acute Chest Syndrome;Asthma;Respiratory Infections,"Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Acute Chest Syndrome;Anemia, Sickle Cell;Vitamin D Deficiency",Known liver or renal disease,79.0
2329,NCT04170348,Phase 2,"Sickle Cell Disease;Anemia, Sickle Cell;Anemia, Hemolytic, Congenital;Respiratory Tract Diseases;Respiration Disorders;Acute Chest Syndrome;Lung Diseases;Asthma;Respiratory Tract Infections;Nutrition Disorders;Deficiency Diseases Vitamin;Vitamin D Deficiency","Gary M Brittenham, MD",10-Feb-15,"Respiratory Tract Infections;Lung Diseases;Respiratory Tract Diseases;Acute Chest Syndrome;Respiration Disorders;Anemia;Anemia, Sickle Cell;Anemia, Hemolytic;Anemia, Hemolytic, Congenital;Vitamin D Deficiency;Nutrition Disorders;Deficiency Diseases;Vitamin A Deficiency;Disease",Known liver or renal disease,79.0
2330,NCT02712047,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Recent or poorly controlled peptic ulcer-Haematologic, hepatic, or renal disease",79.0
2331,NCT01833390,Phase 2,Asthma;COPD;Healthy,Xemed LLC,10-Feb-15,Asthma,"History of congenital cardiac disease, chronic renal failure, or cirrhosis.",80.0
2332,NCT01848769,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Past or present diagnoses of cardiovascular, renal or liver disease",80.0
2333,NCT02787967,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,"Past or present diagnosis of cardiovascular, renal or liver disease.",80.0
2334,NCT01132781,Phase 2,Rhinosinusitis;Asthma;Allergic Rhinitis,University of East Anglia,10-Feb-15,"Rhinitis;Rhinitis, Allergic",Patients with previous cardiac problems or significant renal or hepatic impairment,80.0
2335,NCT00048022,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,Asthma,Undergoing allergy shots unless on a stable maintenance dose for 3 months before the start of the study,81.0
2336,NCT00048009,Phase 2,Asthma,Hoffmann-La Roche,10-Feb-15,,Undergoing allergy shots unless on a stable maintenance dose for three months before the start of the study,81.0
2337,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,0°C (100.5°F) at screening and through the time of the study drug administration on Study Day 0;,82.0
2338,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,0°C (100.5°F) at screening and through the time of the study drug administration on Study Day 0;,82.0
2339,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,0°C (100.5°F) at screening and up through time of the first dose of study drug;,82.0
2340,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,0°C (100.5°F) from screening through Study Day 0;,82.0
2341,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,A live attenuated vaccination received within 28 days before screening,83.0
2342,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,A live or attenuated vaccination received within 4 weeks prior to Screening,83.0
2343,NCT00436670,Phase 2,Asthma,Amgen,10-Feb-15,Asthma,Live/attenuated vaccinations within 4 weeks of screening or during the study,83.0
2344,NCT02794519,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Live virus or bacterial vaccine from 30 days before screening.,83.0
2345,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,Receipt of any live or attenuated vaccines. ,83.0
2346,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,received attenuated live attenuated vaccines within three months prior to study entry,83.0
2347,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,Received live or attenuated vaccine within 30 days prior to Visit 5,83.0
2348,NCT01453023,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Consumption of red wine, seville oranges, grapefruit or grapefruit juice, and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.",84.0
2349,NCT00857857,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication. ",84.0
2350,NCT00945932,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication. ",84.0
2351,NCT01245426,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication. ",84.0
2352,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication",84.0
2353,NCT01160224,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Consumption of seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.",84.0
2354,NCT00526357,Phase 2,Asthma,Firestone Institute for Respiratory Health,10-Feb-15,Asthma;Inflammation,Regular consumption of fish consisting more than 1 meal of fish per week or regular fish oil supplements during the trial and for at least 2 weeks prior to the first study visit.,84.0
2355,NCT00482898,Phase 2,Asthma,Merck Sharp & Dohme Corp.,10-Feb-15,Asthma,You are unwilling to avoid grapefruit juice throughout the study ,84.0
2356,NCT03774290,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,"A history of clinically signiﬁcant ECG abnormalities or a recent history of autonomic dysfunction (e.g. recurrent episodes of fainting, arrhythmia, etc.).",85.0
2357,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Abnormal and clinically significant 12-lead electrocardiogram;,85.0
2358,NCT03108534,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Abnormal clinically relevant ECG,85.0
2359,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Any clinically important ECG abnormalities.,85.0
2360,NCT02105012,Phase 2,Asthma,"Pearl Therapeutics, Inc.",10-Feb-15,Asthma,Clinically significant abnormal ECG,85.0
2361,NCT04046939,Phase 2,Eosinophilic Asthma;Asthma,Knopp Biosciences,10-Feb-15,Asthma;Pulmonary Eosinophilia,Clinically significant abnormal laboratory or ECG values,85.0
2362,NCT00634036,Phase 2,Asthma,Fernando Holguin,10-Feb-15,Asthma,Clinically significant abnormalities present on screening 12-lead electrocardiogram,85.0
2363,NCT00787644,Phase 2,Asthma;Obesity,University of Vermont,10-Feb-15,Asthma,Clinically significant abnormalities present on screening 12-lead electrocardiogram,85.0
2364,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Clinically significant abnormality, as determined by the investigator, on 12-lead ECG or chest radiograph at screening;",85.0
2365,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Clinically significant abnormality, as determined by the investigator, on 12-lead ECG or chest radiograph at the time of screening;",85.0
2366,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Clinically significant abnormality, as determined by the investigator, on 12-lead ECG or chest radiograph at the time of screening;",85.0
2367,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Clinically significant and abnormal electrocardiogram (ECG) at screening visit,85.0
2368,NCT01252758,Phase 2,Asthma,Acerus Pharmaceuticals Corporation,10-Feb-15,Asthma,Clinically significant ECG abnormalities,85.0
2369,NCT01436890,Phase 2,Asthma,Glenmark Pharmaceuticals Ltd. India,10-Feb-15,Asthma,Clinically significant ECG Abnormality at baseline,85.0
2370,NCT01304628,Phase 2,Asthma,Palatin Technologies,10-Feb-15,Asthma,clinically significant electrocardiogram (ECG) at screening,85.0
2371,NCT03643874,Phase 2,Asthma,"Concentrx Pharmaceuticals, Inc.",10-Feb-15,Asthma,"Electrocardiogram obtained at Screening Visit that shows (in the Investigator's medical opinion) medically significant abnormalities (e.g., left bundle branch block, frequent premature ventricular contractions, chronic atrial fibrillation, or QTcB interval prolongation > 450 msec for males and > 470 msec for females)",85.0
2372,NCT01453296,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Evidence of clinically significant abnormality in the 12-lead ECG (electrocardiogram) at Screening ,85.0
2373,NCT01332292,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Evidence of clinically significant abnormality in the 12-lead ECG (electrocardiogram) at screening. ,85.0
2374,NCT00873860,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of clinically significant abnormality on electrocardiogram (ECG) in the opinion of the investigator,85.0
2375,NCT00968669,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,History of clinically significant abnormality on electrocardiogram (ECG) in the opinion of the investigator,85.0
2376,NCT01238861,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Past history of clinically significant cardiac disease or any electrocardiogram (ECG) abnormality,85.0
2377,NCT01545726,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma;Eosinophilia,Patients who have a clinically significant abnormality on a 12-lead ECG recorded within one month prior to or at screening,85.0
2378,NCT01400906,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,significant abnormality on 12-lead ECG at screening,85.0
2379,NCT01656811,Phase 2,Asthma,Sunovion,10-Feb-15,Asthma,Subject had a clinically significant abnormal 12-lead ECG that would have put the subject at risk for experiencing adverse cardiac events.,85.0
2380,NCT01551147,Phase 2,Asthma,Ono Pharma USA Inc,10-Feb-15,Asthma,History of clinically significant multiple drug or food allergy ,86.0
2381,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,Presence of a transplanted tissue or organ,87.0
2382,NCT01939587,Phase 2,Asthma,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,10-Feb-15,Respiratory Hypersensitivity,"Asthmatics in treatment Step 5 as per GINA guidelines, including oral corticosteroids and/or omalizumab, or any immunosuppressive medication whether asthma-related or indicated for any concomitant morbidities.",88.0
2383,NCT00394654,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Current use of any systemic or inhaled immunosuppressive drugs, including systemic and inhaled corticosteroids (topical corticosteroids are permitted), long-acting β2 agonists, leukotriene antagonists, cromolyn sodium, nedocromil sodium, theophylline or any inhaled or systemic medication for asthma other than short-acting β2 agonists, for at least 4 weeks prior to study drug administration on Study Day",88.0
2384,NCT00603382,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Immunosuppressive Medications: A subject must not be using, or require use, of immunosuppressive medications during the study. NOTE: Immunotherapy for the treatment of allergies is allowed during the study provided that the treatment was initiated prior to Visit 1 and the subject is maintained on a stable regimen throughout the study period.",88.0
2385,NCT01147744,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Immunosuppressive medications: Either using or required during the study,88.0
2386,NCT02377427,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Participants with any history of life threatening asthma (e.g. requiring intubation), immunosuppressive medications intake or immunodeficiency disorder.",88.0
2387,NCT02635945,Phase 2,Asthma,Palobiofarma SL,10-Feb-15,Asthma,Patients under any immunosuppressive medication whether asthma-related or indicated for any concomitant morbidities,88.0
2388,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,"Prior/Concomitant Therapy: Systemic corticosteroid use, AZD1402, marketed or investigational biologicals such as monoclonal antibodies or chimeric biomolecules, investigational nonbiologic drug within 60 days prior to Screening and during Run-in, any immunosuppressive therapy, Live or attenuated vaccine within 4 weeks of Screening and during Run-in, Receipt of COVID-19 vaccine (vaccine or booster dose) within 30 days prior to randomisation, Immunoglobulin or blood products within 4 weeks of Screening and during Run-in, Any immunotherapy within 3 months of Screening and during Run-in.",88.0
2389,NCT03683576,Phase 2,Asthma,"GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.",10-Feb-15,Asthma,Regular use of systemic corticosteroids or immunosuppressive treatments or monoclonal antibodies for asthma,88.0
2390,NCT03707678,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"Subjects who have received treatment with allergen immunotherapy (in the last 2 years), anti-immunoglobulin E (IgE) or anti interleukin 5 (IL5) or anti IL13 antibodies or immunosuppressive agents (example given [e.g.] methotrexate, azothioprine, cyclosporine) within the past 6 months.",88.0
2391,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Subjects with concomitant immunosuppressive therapy, use of oral or injected corticosteroids, anti- Immunoglobulin E (IgE), anti-Interleukin 5 (IL5) or other monoclonal or polyclonal antibodies within 12 weeks prior to screening.",88.0
2392,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,"Subjects with concomitant immunosuppressive therapy, use of oral or injected corticosteroids, anti-IgE, anti-IL5 or other monoclonal or polycolonal antibodies within 12 weeks prior to screening.",88.0
2393,NCT01501942,Phase 2,Asthma,AIM Therapeutics Inc.,10-Feb-15,Asthma,"Systemic immunosuppressive or cytotoxic drug therapy (systemic corticosteroids, cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.) taken within two months prior to the study treatment administration. Corticosteroid nasal spray (e.g. for allergic rhinitis) or inhaled corticosteroid must have a 30 day washout prior to randomization (Visit 6)",88.0
2394,NCT04847674,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,The participant has been treated with a monoclonal antibody or is currently using or has used a systemic immunosuppressive medication within the last 6 months.,88.0
2395,NCT00783289,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Use of any chronic systemic immunosuppressive drugs, including oral corticosteroids within 4 weeks prior to randomization into the study",88.0
2396,NCT01196039,Phase 2,Asthma,"Genentech, Inc.",10-Feb-15,Asthma;Airway Obstruction,"Use of corticosteroids, immunosuppressives, anticoagulants, or any medications that may interact with study drug within 4 weeks prior to Visit 2",88.0
2397,NCT02698501,Phase 2,Asthma,Celeste Porsbjerg,10-Feb-15,Asthma,Use of immunosuppressive medication,88.0
2398,NCT01479621,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Use of immunosuppressive medications within 4 weeks prior to the Screening Visit and during the study,88.0
2399,NCT01576718,Phase 2,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",10-Feb-15,Asthma,Use of immunosuppressive medications within 4 weeks prior to the Screening Visit and during the study,88.0
2400,NCT03444298,Phase 2,Airway Inflammation;Asthma,"University of North Carolina, Chapel Hill",10-Feb-15,Inflammation,"Use of immunosuppressive or anticoagulant medications including routine use of NSAIDS. Oral contraceptives are acceptable, as are Antidepressants and other medications may be permitted if, in the opinion of the investigator, the medication will not interfere with the study procedures or compromise safety and if the dosage has been stable for 1 month",88.0
2401,NCT00587288,Phase 2,Asthma,Ception Therapeutics,10-Feb-15,Asthma,use of systemic immunosuppressive agents within 6 months of study,88.0
2402,NCT00590720,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Use of systemic immunosuppressive drugs including systemic corticosteroids, ICS with doses > 800 μg/day budesonide (or another ICS of equivalent dose), long-acting β2 agonists, cromolyn sodium, nedocromil sodium, leukotriene receptor antagonists, theophylline, or omalizumab from screening through Study Day 150;",88.0
2403,NCT00483041,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,"Use of systemic immunosuppressive drugs including systemic corticosteroids (topical corticosteroids are permitted), ICS at doses > 800 μg/day budesonide or equivalent, long-acting β2 agonists (eg, salmeterol), leukotriene antagonists, cromolyn sodium, nedocromil sodium, theophylline, omalizumab, or any other medication for asthma except short-acting β2 agonist (as needed) within the 4 weeks prior to screening up through administration of study drug;",88.0
2404,NCT00507130,Phase 2,Asthma,MedImmune LLC,10-Feb-15,Asthma,Use of systemic immunosuppressive drugs including systemic corticosteroids or ICS with doses > 264 μg/day fluticasone or equivalent within 4 weeks prior to Study Day 0;,88.0
2405,NCT01349257,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Diagnosis of restrictive lung disease,89.0
2406,NCT01651650,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Diagnosis of restrictive lung disease,89.0
2407,NCT02148120,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,,Diagnosis of restrictive lung disease;,89.0
2408,NCT01584492,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Diagnosis of restrictive lung disease.,89.0
2409,NCT03207243,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"In the opinion of the investigator, any subject who is unable to read and/or would not be able to complete a diary card/questionnaire.",101.0
2410,NCT03012061,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,"In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete study related materials.",101.0
2411,NCT00901095,Phase 2,Asthma;Obesity,Palo Alto Medical Foundation,10-Feb-15,Asthma;Weight Loss,"Inability to speak, read or understand English;",101.0
2412,NCT00860418,Phase 2,Asthma,Johns Hopkins University,10-Feb-15,Asthma,Inability to speak and understand English,101.0
2413,NCT00181272,Phase 2,Asthma;Chronic Obstructive Pulmonary Disease,Johns Hopkins University,10-Feb-15,"Asthma;Lung Diseases;Lung Diseases, Obstructive;Pulmonary Disease, Chronic Obstructive","Patient unable to provide consent (e.g., language difficulty or history of dementia)",101.0
2414,NCT02422121,Phase 2,Asthma,Revalesio Corporation,10-Feb-15,Asthma,Subjects who cannot communicate reliably with the Investigator.,101.0
2415,NCT00936624,Phase 2,Asthma,"SK Chemicals Co., Ltd.",10-Feb-15,Asthma,Other ineligible subject in the opinion of the investigator ,102.0
2416,NCT02388997,Phase 2,Asthma,University of Virginia,10-Feb-15,Infections;Asthma,Inability or unwillingness of a participant or subject's legal representative to give written informed consent and HIPPA authorization,103.0
2417,NCT01653756,Phase 2,Asthma,SecuraBio,10-Feb-15,Asthma,A history of cardiovascular disease,104.0
2418,NCT04643158,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma;Respiratory Aspiration,Any clinically significant cardiac disease.,104.0
2419,NCT02517099,Phase 2,Asthma,Imperial College London,10-Feb-15,,Any known cardiac disease,104.0
2420,NCT03393806,Phase 2,Asthma,GlaxoSmithKline,10-Feb-15,Asthma,Cardiovascular disease: Clinically significant organic heart disease,104.0
2421,NCT01425801,Phase 2,Asthma,AstraZeneca,10-Feb-15,Asthma,Clinically significant cardiovascular conditions,104.0
2422,NCT02296411,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Patients who have a clinically significant cardiovascular condition ,104.0
2423,NCT00941798,Phase 2,Asthma,Novartis Pharmaceuticals,10-Feb-15,Asthma,Patients with certain cardiovascular co-morbid conditions,104.0
2424,NCT03084718,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Subjects who have clinically significant cardiovascular condition,104.0
2425,NCT03086460,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Subjects who have clinically significant cardiovascular condition.,104.0
2426,NCT00868023,Phase 2,Asthma,Chiesi Farmaceutici S.p.A.,10-Feb-15,Asthma,Diagnosis of restrictive lung disease.,89.0
